Nitrogen-containing macrocyclic compound, and preparation method therefor and use thereof
By providing a nitrogen-containing macrocyclic compound, the problem of limited types of small molecule inhibitors for DNA polymerase θ is solved, and efficient inhibition of DNA polymerase θ is achieved, and a new method for treating cancers related to DNA repair defects is provided.
Patent Information
- Application Number
- PCT/CN2024/081244
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-08
- Filing Date
- 2024-03-12
- Publication Date
- 2024-12-05
AI Technical Summary
In the prior art, there are limited types of DNA polymerase theta small molecule inhibitors, which are difficult to effectively inhibit cancers related to DNA repair defects.
A nitrogen-containing macrocyclic compound is provided with a structure specific to efficiently inhibit DNA polymerase theta activity, for the preparation of DNA polymerase theta inhibitors for the treatment of cancers associated with DNA repair defects.
This compound has better inhibitory activity on DNA polymerase θ, providing a new targeted therapeutic strategy, and has therapeutic potential for breast cancer, lung cancer and ovarian cancer.
Smart Images

Figure CN2024081244_05122024_PF_FP_ABST
Abstract
Description
Nitrogen-containing macrocyclic compounds and their preparation methods and applications
[0001] This application claims priority to Chinese Patent Application No. 2023102372953, filed on March 13, 2023, and Chinese Patent Application No. 2023106771702, filed on June 8, 2023. This application incorporates the entirety of the aforementioned Chinese patent applications. Technical Field
[0002] The present invention relates to a nitrogen-containing macrocyclic compound and a preparation method and application thereof. Background Art
[0003] Mammalian cells have evolved multiple pathways to repair DNA double-strand breaks (DSBs) to ensure genomic stability. The most studied DSB repair mechanisms include non-homologous end joining (NHEJ) and homologous recombination (HR). NHEJ does not require a homologous template or only requires a small amount of homologous template, and connects the DNA ends by inserting and deleting a few bases at the break site (Chang HHY, Pannunzio NR, Adachi N, Lieber MR. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol. 2017, 18(8): 495-506); HR uses sister chromatids as templates to promote error-free repair (Ranjha L, Howard SM, Cejka P. Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes. Chromosoma. 2018, 127(2): 187-214). In addition to the well-characterized NHEJ and HR, mammalian cells also use a third pathway: microhomology-mediated end joining (MMEJ), originally named alternative non-homologous end joining (alt-EJ), as a backup pathway to repair DNA double-strand breaks when NHEJ or HR is impaired (Sfeir A, Symington LS. Microhomology-Mediated End Joining: A Back-up Survival Mechanism or Dedicated Pathway? Trends Biochem Sci. 2015, 40(11): 701-714).
[0004] DNA polymerase θ (Polθ, encoded by POLQ) is a multifunctional DNA polymerase of the A family that has been identified as a key protein in the MMEJ pathway (Kent T et al. Mechanism of microhomology-mediated end-joining promoted by human DNA polymeraseθ. Nat Struct Mol Biol. 2015, 22(3): 230-7; Mateos-Gomez PA et al. Mammalian polymeraseθ promotes alternative NHEJ and suppresses recombination. Nature. 2015, 518(7538): 254-257). POLθ contains three domains and is structurally and functionally distinct from other polymerases (Ozdemir AY et al. Polymeraseθ-helicase efficiently unwinds DNA and RNA-DNA hybrids. J Biol Chem. 2018, 293(14): 5259-5269).The N-terminus contains a helicase-like ATPase domain that can unwind several types of DNA structures (Ozdemir AY et al. Polymeraseθ-helicase efficiently unwinds DNA and RNA-DNA hybrids. J Biol Chem. 2018, 293(14): 5259-5269); and an unstructured central domain that can bind to RAD51, displace replication protein A (RPA) from the resected DSB, and antagonize HR repair in an ATP hydrolysis-dependent manner (Ceccaldi R et al. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature. 2015, 518(7538): 258-62; Mateos-Gomez PA et al. Mammalian polymeraseθ promotes alternative NHEJ and suppresses recombination. Nature. 2015, 518(7538): 254-7; Mateos-Gomez PA et al. The The helicase domain of Polθ counteracts RPA to promote alt-NHEJ. Nat Struct Mol Biol. 2017, 24(12): 1116-1123). Finally, the C-terminus contains a nuclease domain that trims the DNA end and an error-prone polymerase domain that fills in nucleotides in MMEJ repair (Zahn KE, Jensen RB, Wood RD, Doublié S. Human DNA polymeraseθ harbors DNA end-trimming activity critical for DNA repair. Mol Cell. 2021, 81(7): 1534-1547).Both the ATPase domain and the polymerase domain are required for MMEJ repair (Beagan K et al. Drosophila DNA polymerase theta utilizes both helicase-like and polymerase domains during microhomology-mediated end joining and interstrand crosslink repair. PLoS Genet. 2017, 13(5): e1006813). Therefore, inhibiting Polθ activity and thereby depriving cells of MMEJ repair ability provides a new targeted strategy for treating certain specific tumors.
[0005] DNA polymerase θ (Polθ) is not essential in healthy cells, but its expression is upregulated in breast cancer, lung cancer, and ovarian cancer. Its overexpression is associated with HR repair defects and poor clinical outcomes (Ceccaldi R et al. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature. 2015, 518(7538):258-62).In the context of HR deficiency, loss of POLQ has been shown to impair cell viability, revealing a synthetic lethal relationship between POLQ and HR factors (e.g., POLQ and FA / BRCA deficiency are synthetically lethal) (Shima N, Munroe RJ, Schimenti JC. The mouse genomic instability mutation chaos1 is an allele of Polq that exhibits genetic interaction with Atm. Mol Cell Biol. 2004, 24(23): 10381-9; Wang Z et al., DNA polymeraseθ(POLQ)is important for repair of DNA double-strand breaks caused by fork collapse. J Biol Chem. 2019, 294(11): 3909-3919; Ceccaldi R et al. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature. 2015, 518(7538): 258-62; Mateos-Gomez PA et al. al.Mammalian polymeraseθpromotes alternative NHEJ and suppresses recombination.Nature.2015,518(7538):254-7; Dai CH et al.Co-inhibition of polθand HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival.Oncotarget.2016,7(40):65157-65170; Zhou,J.et al.Polymerase theta inhibition kills homologous recombination deficient tumors.bioRxiv.Published online,May 26,2020).In addition, POLQ deficiency and PARP inhibitors show synergistic effects in killing HR-deficient tumor cells (Ceccaldi R et al. Homologous-recombination-deficient tumors are dependent on Polθ-mediated repair. Nature. 2015, 518(7538):258-62; Mateos-Gomez PA et al. Nature. 2015, 518(7538):254-7.).
[0006] Therefore, for cancer types with DNA repair defects, Polθ is an attractive new target for synthetic lethal therapy, and the development of small molecule inhibitors of DNA polymerase θ is of great significance.
[0007] Summary of the Invention
[0008] To overcome the limitations of existing small molecule inhibitors of DNA polymerase θ, the present invention provides a nitrogen-containing macrocyclic compound, a preparation method, and applications thereof. The compounds of the present invention exhibit excellent inhibitory activity against DNA polymerase θ.
[0009] The present invention provides a compound as shown in Formula I, a pharmaceutically acceptable salt thereof, an isotope-labeled substance thereof, a solvate thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof:
[0010] Wherein, -L- is -(CH2) n -, n is 1, 2, 3, 4, 5 or 6; -(CH2) n Any one, two or three -CH2- in - may be optionally replaced by -CL 1a L 1b -、-CL 2a =CL 2b -、-NL 3 -, -O-, -S(=O)-, -S(=O)2-, -C(=O)- and -S-;
[0011] L 1a 、L 1b 、L 2a and L 2b are independently H, deuterium, halogen, cyano, hydroxyl, -NL 1a-1 L 1a-2 、C 1-6 Alkyl, C 1-6 Alkoxy or C 3-6 cycloalkyl, and L 1a and L1b Not at the same time H;
[0012] Or, any adjacent L 1a Together with the atoms it is connected to form C 3-6 cycloalkyl or 3-6 membered heterocyclic group, or L 1a and L 1b Together with its common atoms, it forms C 3-6 cycloalkane or 3-6 membered heterocycle; the heteroatoms in the 3-6 membered heterocyclic group and the 3-6 membered heterocycle are independently selected from 1, 2 or 3 of N, O and S;
[0013] L 1a-1 、L 1a-2 and L 3 Independently H, C 1-6 Alkyl, 1 or more deuterated C 1-6 Alkyl or C 3-6 Cycloalkyl;
[0014] R 1 H, C 1-6 Alkyl, C 3-6 Cycloalkyl, one or more R 1-1 Substituted C 1-6 Alkyl, or one or more R 1-2 Substituted C 3-6 Cycloalkyl;
[0015] Each R 1-1 and each R 1-2 are independently deuterium, halogen, hydroxyl, -COOH, -NR 1-1-1 R 1-1-2 、-C(=O)NR 1-1-3 R 1-1-4 、-S(=O)2R 1- 1-5 or -S(=O)2NR 1-1-6 R 1-1-7 ;
[0016] R 1-1-1 、R 1-1-2 、R 1-1-3 、R 1-1-4 、R 1-1-5 、R 1-1-6 and R 1-1-7 Independently H, C 1-6 Alkyl or C 3-6 Cycloalkyl;
[0017] R 2 、R 3a and R 3b are independently H or C 1-6The alkyl group,
[0018] Or, R 2 and R 3a Together with the atoms to which it is attached, it forms a 5-6 membered heterocyclic group or is replaced by one or more R 2-1 substituted 5-6 membered heterocyclic group; said 5-6 membered heterocyclic group and said substituted 5-6 membered heterocyclic group 2-1 The heteroatoms in the substituted 5-6 membered heterocyclic group are independently selected from 1, 2 or 3 of N, O and S, and contain at least 1 N;
[0019] Each R 2-1 are independently halogen, cyano, hydroxy, oxo (=O), C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl or -NR 2-1-1 R 2-1-2 ,
[0020] Or, any two adjacent R 2-1 Together with the atoms to which it is attached, it forms a ring A, wherein the ring A is C 6-18 aryl, 5-10 membered heteroaryl, C 3-6 Cycloalkyl, 5-10 membered heterocyclic group, 1 or more R 2-1-3 Substituted C 6-18 aryl, 1 or more R 2-1-4 Substituted 5-10 membered heteroaryl, substituted by one or more R 2-1-5 Substituted C 3-6 Cycloalkyl, or one or more R 2-1-6 substituted 5-10 membered heterocyclic group;
[0021] The 5-10 membered heteroaryl, the 5-10 membered heterocyclic group, the one or more R 2-1-4 The 5-10 membered heteroaryl substituted with one or more R 2-1-6 The heteroatoms in the substituted 5-10 membered heterocyclic group are independently selected from 1, 2 or 3 of N, O and S;
[0022] R 2-1-1 and R 2-1-2 Independently H, C 1-6 Alkyl or C 3-6 Cycloalkyl;
[0023] Each R 2-1-3 , each R 2-1-4 , each R 2-1-5 and each R 2-1-6 are independently deuterium, halogen, cyano, hydroxyl, -NR 2-1-3-1 R 2-1-3-2、C 1-6 Alkyl, -C 1-6 Alkyl-C(=O)OH, C 1-6 Alkoxy or C 3-6 Cycloalkyl;
[0024] R 2-1-1-1 and R 2-1-1-2 Independently H, C 1-6 Alkyl or C 3-6 Cycloalkyl;
[0025] Ar 1 and Ar 2 Independently C 6-18 aryl, 5-10 membered heteroaryl, 1 or more R 4-1 Substituted C 6-18 aryl, 1 or more R 4-2 Substituted 5-10 membered heteroaryl, 5-10 membered heteroaryl and 3-8 membered heterocyclic group, substituted by one or more R 4-2 Substituted 5-10 membered heteroaryl and 3-8 membered heterocyclic group (preferably, Ar 1 and Ar 2 Independently C 6-18 aryl, 5-10 membered heteroaryl, 1 or more R 4-1 Substituted C 6-18 aryl, or one or more R 4-2 substituted 5-10 membered heteroaryl);
[0026] The 5-10 membered heteroaryl, the one or more R 4-2 substituted 5-10 membered heteroaryl, the 5-10 membered heteroaryl and 3-8 membered heterocyclic group and the substituted ... 4-2 The heteroatoms in the substituted 5-10 membered heteroaryl and 3-8 membered heterocyclic group are independently selected from 1, 2 or 3 of N, O and S;
[0027] Each R 4-1 and each R 4-2 are independently deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-6 Alkyl, C 1-6 Alkoxy, -NR 4-1-1 R 4- 1-2 、-C(=O)NR 4-1-3 R 4-1-4 、-S(=O)2R 4-1-5 、-S(=O)2NR 4-1-6 R 4-1-7 , by one or more R 4-1-8 Substituted C 1-6Alkyl, or one or more R 4-1-9 Substituted C 1-6 Alkoxy;
[0028] Or, any two adjacent R 4-1 Together with the atoms to which it is attached, it forms a 5-10 heteroaryl, C 3-6 Cycloalkyl, 5-10 membered heterocycloalkyl, 1 or more R 4-1-10 Substituted 5-10 membered heteroaryl, substituted by one or more R 4-1-11 Substituted C 3-6 Cycloalkyl, or one or more R 4-1-12 substituted 5-10 membered heterocycloalkyl;
[0029] The 5-10 heteroaryl, 5-10 membered heterocycloalkyl, the one or more R 4-1-10 The 5-10 membered heteroaryl substituted with one or more R 4-1-12 The heteroatoms in the substituted 5-10 membered heterocycloalkyl are independently selected from 1, 2 or 3 of N, O and S;
[0030] R 4-1-1 、R 4-1-2 、R 4-1-3 、R 4-1-4 、R 4-1-5 、R 4-1-6 and R 4-1-7 Independently H, C 1-6 Alkyl or C 3-6 Cycloalkyl;
[0031] Each R 4-1-8 , each R 4-1-9 , each R 4-1-10 and each R 4-1-11 are independently deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-6 Alkyl, C1-6 alkoxy, -NR 4-1-8-1 R 4-1-8-2 、-C(=O)NR 4-1-8-3 R 4-1-8-4 、-S(=O)2R 4-1-8-5 or -S(=O)2NR 4-1-8-6 R 4-1-8-7 ;
[0032] R 4-1-8-1 、R 4-1-8-2 、R 4-1-8-3 、R 4-1-8-4 、R 4-1-8-5 、R 4-1-8-6 and R 4-1-8-7 Independently H, C 1-6 Alkyl or C 3-6of a cycloalkyl group.
[0033] In the above general formula I Indicates a connection key.
[0034] In the compound of Formula I, its pharmaceutically acceptable salt, its isotope-labeled substance, its solvate, its solvate of a pharmaceutically acceptable salt, or its prodrug, some of the groups are defined as follows, and the remaining groups are defined as described in any other embodiment.
[0035] In a certain embodiment, in the compound shown in Formula I:
[0036] -L- is -(CH2) n -, n is 1, 2, 3, 4, 5 or 6; -(CH2) n Any one, two or three -CH2- in - may be optionally replaced by -CL 1a L 1b -、-CL 2a =CL 2b -、-NL 3 -, -O-, -S(=O)-, -S(=O)2- and -S-;
[0037] L 1a 、L 1b 、L 2a and L 2b are independently H, deuterium, halogen, cyano, hydroxyl, -NL 1a-1 L 1a-2 、C 1-6 Alkyl, C 1-6 Alkoxy or C 3-6 cycloalkyl, and L 1a and L 1b Not at the same time H;
[0038] Or, any adjacent L 1a Together with the atoms it is connected to form C 3-6 cycloalkyl or 3-6 membered heterocyclic group, or L 1a and L 1b Together with its common atoms, it forms C 3-6 cycloalkane or 3-6 membered heterocycle; the heteroatoms in the 3-6 membered heterocyclic group and the 3-6 membered heterocycle are independently selected from 1, 2 or 3 of N, O and S;
[0039] L 1a-1 、L 1a-2 and L 3 Independently H, C 1-6 Alkyl or C 3-6 Cycloalkyl;
[0040] R 1 H, C 1-6 Alkyl, C 3-6 Cycloalkyl, one or more R 1-1 Substituted C 1-6 Alkyl, or one or more R 1-2 Substituted C 3-6 Cycloalkyl;
[0041] Each R 1-1 and each R 1-2 are independently deuterium, halogen, hydroxyl, -COOH, -NR 1-1-1 R 1-1-2 、-C(=O)NR 1-1-3 R 1-1-4 、-S(=O)2R 1- 1-5 or -S(=O)2NR 1-1-6 R 1-1-7 ;
[0042] R 1-1-1 、R 1-1-2 、R 1-1-3 、R 1-1-4 、R 1-1-5 、R 1-1-6 and R 1-1-7 Independently H, C 1-6 Alkyl or C 3-6 Cycloalkyl;
[0043] R 2 、R 3a and R 3b are independently H or C 1-6 The alkyl group,
[0044] Or, R 2 and R 3a Together with the atoms to which it is attached, it forms a 5-6 membered heterocyclic group or is replaced by one or more R 2-1 substituted 5-6 membered heterocyclic group; said 5-6 membered heterocyclic group and said substituted 5-6 membered heterocyclic group 2-1 The heteroatoms in the substituted 5-6 membered heterocyclic group are independently selected from 1, 2 or 3 of N, O and S, and contain at least 1 N;
[0045] Each R 2-1 are independently halogen, cyano, hydroxy, oxo (=O), C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl or -NR 2-1-1 R 2-1-2 ,
[0046] Or, any two adjacent R 2-1 Together with the atoms to which it is attached, it forms a ring A, wherein the ring A is C 6-18 aryl, 5-10 membered heteroaryl, C 3-6 Cycloalkyl, 5-10 membered heterocyclic group, 1 or more R 2-1-3 Substituted C 6-18 aryl, 1 or more R 2-1-4 Substituted 5-10 membered heteroaryl, substituted by one or more R 2-1-5 Substituted C 3-6 Cycloalkyl, or one or more R 2-1-6 substituted 5-10 membered heterocyclic group;
[0047] The 5-10 membered heteroaryl, the 5-10 membered heterocyclic group, the one or more R 2-1-4 The 5-10 membered heteroaryl substituted with one or more R 2-1-6 The heteroatoms in the substituted 5-10 membered heterocyclic group are independently selected from 1, 2 or 3 of N, O and S;
[0048] R 2-1-1 and R 2-1-2 Independently H, C 1-6 Alkyl or C 3-6 Cycloalkyl;
[0049] Each R 2-1-3 , each R 2-1-4 , each R 2-1-5 and each R 2-1-6 are independently deuterium, halogen, cyano, hydroxyl, -NR 2-1-3-1 R 2-1-3-2 、C 1-6 Alkyl, C 1-6 Alkoxy or C 3-6 Cycloalkyl;
[0050] R 2-1-1-1 and R 2-1-1-2 Independently H, C 1-6 Alkyl or C 3-6 Cycloalkyl;
[0051] Ar 1 and Ar 2 Independently C 6-18 aryl, 5-10 membered heteroaryl, 1 or more R 4-1 Substituted C 6-18 aryl, or one or more R 4-2 substituted 5-10 membered heteroaryl;
[0052] The 5-10 membered heteroaryl and the4-2 The heteroatoms in the substituted 5-10 membered heteroaryl are independently selected from 1, 2 or 3 of N, O and S;
[0053] Each R 4-1 and each R 4-2 are independently deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-6 Alkyl, C 1-6 Alkoxy, -NR 4-1-1 R 4- 1-2 、-C(=O)NR 4-1-3 R 4-1-4 、-S(=O)2R 4-1-5 、-S(=O)2NR 4-1-6 R 4-1-7 , by one or more R 4-1-8 Substituted C 1-6 Alkyl, or one or more R 4-1-9 Substituted C 1-6 Alkoxy;
[0054] Or, any two adjacent R 4-1 Together with the atoms to which it is attached, it forms a 5-10 heteroaryl, C 3-6 Cycloalkyl, 5-10 membered heterocycloalkyl, 1 or more R 4-1-10 Substituted 5-10 membered heteroaryl, substituted by one or more R 4-1-11 Substituted C 3-6 Cycloalkyl, or one or more R 4-1-12 substituted 5-10 membered heterocycloalkyl;
[0055] The 5-10 heteroaryl, 5-10 membered heterocycloalkyl, the one or more R 4-1-10 The 5-10 membered heteroaryl substituted with one or more R 4-1-12 The heteroatoms in the substituted 5-10 membered heterocycloalkyl are independently selected from 1, 2 or 3 of N, O and S;
[0056] R 4-1-1 、R 4-1-2 、R 4-1-3 、R 4-1-4 、R 4-1-5 、R 4-1-6 and R 4-1-7 Independently H, C 1-6 Alkyl or C 3-6 Cycloalkyl;
[0057] Each R 4-1-8 , each R 4-1-9 , each R 4-1-10 and each R 4-1-11are independently deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-6 Alkyl, C1-6 alkoxy, -NR 4-1-8-1 R 4-1-8-2 、-C(=O)NR 4-1-8-3 R 4-1-8-4 、-S(=O)2R 4-1-8-5 or -S(=O)2NR 4-1-8-6 R 4-1-8-7 ;
[0058] R 4-1-8-1 、R 4-1-8-2 、R 4-1-8-3 、R 4-1-8-4 、R 4-1-8-5 、R 4-1-8-6 and R 4-1-8-7 Independently H, C 1-6 Alkyl or C 3-6 of a cycloalkyl group.
[0059] In one scenario, L 1a 、L 1b 、L 2a and L 2b In the above, the halogen can independently be fluorine, chlorine or bromine, for example fluorine.
[0060] In one scenario, L 1a 、L 1b 、L 2a 、L 2b 、L 1a-1 、L 1a-2 and L 3 In the C 1-6 The alkyl groups are independently and the deuterated C 1-6 The C in the alkyl group 1-6 The alkyl group may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example methyl.
[0061] In one scenario, L 1a 、L 1b 、L 2a and L 2b In the C 1-6 The alkoxy groups independently may be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.
[0062] In one scenario, L 1a 、L 1b 、L 2a 、L 2b 、L 1a-1 、L 1a-2 and L 3In the C 3-6 The cycloalkyl groups of EMI14.1 and EMI15.1 are independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0063] In one scenario, L 1a and L 1b Together with its common atoms, it forms C 3-6 The cycloalkane may be cyclopropane, cyclobutane, cyclopentane or cyclohexane, for example cyclopropane ( # indicates that a spiro ring is formed through this carbon atom).
[0064] In one scenario, L 3 wherein the C 1-6 The alkyl group may be -CD3.
[0065] In one scenario, R 1 In the C 1-6 The alkyl group and the one or more R 1-1 Substituted C 1-6 The C1-6 alkyl group in the alkyl group can independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example, methyl.
[0066] In one scenario, R 1 In the above, one or more R 1-1 Substituted C 1-6 The alkyl group may be a C1-6 alkyl group substituted with 1, 2 or 3 deuterium atoms, such as -CD3.
[0067] In one scenario, R 2 、R 3a and R 3b In the C 1-6 The alkyl groups of independently may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example methyl.
[0068] In one scenario, R 2 and R 3a Together with the atoms to which it is connected, the 5-6 membered heterocyclic group and the one or more R 2-1 The substituted 5-6 membered heterocyclic group may independently be pyrrolidinyl, for example Through N and Ar 1 Connected to the carbonyl group through C.
[0069] In a certain scheme, each R 2-1 , each R 2-1-3 , each R 2-1-4 , each R 2-1-5 and each R 2-1-6 In the C 1-6The alkoxy groups independently may be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.
[0070] In a certain scheme, each R 2-1 、R 2-1-1 、R 2-1-2 , each R 2-1-3 , each R 2-1-4 , each R 2-1-5 , each R 2-1-6 、R 2-1-1-1 and R 2-1-1-2 , the C 1-6 The alkyl groups of independently may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example methyl.
[0071] In a certain scheme, each R 2-1 、R 2-1-1 、R 2-1-2 Each R 2-1-3 , each R 2-1-4 , each R 2-1-5 , each R 2-1-6 、R 2-1-1-1 and R 2-1-1-2 In the C 3-6 Cycloalkyl, any two adjacent R 2-1 Together with the atoms to which it is attached, it forms the C 3-6 The cycloalkyl group and the one or more R 2-1-5 Substituted C 3-6 The C in the cycloalkyl 3-6 The cycloalkyl groups independently may be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0072] In a certain scheme, any two adjacent R 2-1 Together with the atoms to which it is attached, it forms the C 6-18 The aryl group and the one or more R 2-1-3 Substituted C 6-18 The aryl groups of α- ...
[0073] In a certain scheme, any two adjacent R 2-1 Together with the atoms to which it is attached, the 5-10 membered heteroaryl and the one or more R 2-1-4 The 5-10 membered heteroaryl in the substituted 5-10 membered heteroaryl can be independently a 5-6 membered heteroaryl, wherein the heteroatom is selected from N, and the number is 1 or 2, for example, pyridyl Pyrazolyl or pyrimidinyl This indicates that a cyclic structure is formed with a 5- to 6-membered heterocyclic group through the bond therein.
[0074] In a certain scheme, when any two adjacent R 2-1 Together with the atoms to which it is attached, it forms a 2-1-4 When the 5-10 membered heteroaryl is substituted; the one or more R 2-1-4 The substituted 5-10 membered heteroaryl may be substituted by one R 2-1-4 Substituted 5-6 membered heteroaryl, R 2-1-4 C 1-6 Alkyl or -C 1-6 Alkyl-C(=O)OH, for example (Preferably ), This indicates that a cyclic structure is formed with a 5- to 6-membered heterocyclic group through the bond therein.
[0075] In one scheme, Ar 1 and Ar 2 In the C 6-18 The aryl group and the one or more R 4-1 Substituted C 6-18 The C in the aryl group 6-18 The aryl groups of independently may be phenyl or naphthyl, for example phenyl.
[0076] In one scheme, Ar 1 and Ar 2 wherein the 5-10 membered heteroaryl and the 1 or more R 4-2 The 5-10 membered heteroaryl in the substituted 5-10 membered heteroaryl can be independently a 5-10 membered heteroaryl, wherein the heteroatom is selected from N, and the number is 1 or 2, and can also be a 5-6 membered monocyclic heteroaryl or an 8-10 membered cyclic heteroaryl, such as pyridyl or (Preferably pyridyl).
[0077] In one scheme, Ar 1 and Ar 2 wherein the 5-10 membered heteroaryl and 3-8 membered heterocyclic group and the one or more R 4- 2 The 5-10-membered heteroaryl and 3-8-membered heterocyclic group in the substituted 5-10-membered heteroaryl and 3-8-membered heterocyclic group can independently be a 5-6-membered heteroaryl and 3-6-membered heterocyclic group, wherein the heteroatom is selected from N, and the number of the heteroatom is 1 or 2, and can also be pyridyl and pyrrolidinyl, for example
[0078] In a certain scheme, each R 4-1 and each R 4-2 In the C 1-6 The alkyl group and the one or more R 4-1-8Substituted C 1-6 The C in the alkyl group 1-6 The alkyl groups of independently may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example methyl.
[0079] In a certain scheme, each R 4-1 , each R 4-2 , each R 4-1-8 , each R 4-1-9 , each R 4-1-10 and each R 4-1-11 In the C 1-6 The alkoxy group and the one or more R 4-1-9 Substituted C 1-6 The alkoxy groups independently may be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.
[0080] In a certain scheme, any two adjacent R 4-1 Together with the atoms to which they are attached, they form the 5-10 heteroaryl group and the one or more R 4-1-10 The 5-10 membered heteroaryl in the substituted 5-10 membered heteroaryl may be a 5-6 membered heteroaryl, wherein the heteroatom is selected from N and the number of the heteroatom is 1 or 2, for example, pyrazolyl ( Indicates that the key here is connected to C 6-18 The aromatic groups form a ring structure).
[0081] In one scenario, R 4-1-1 、R 4-1-2 、R 4-1-3 、R 4-1-4 、R 4-1-5 、R 4-1-6 、R 4-1-7 , each R 4-1-8 , each R 4-1-9 , each R 4-1-10 , each R 4-1-11 、R 4-1-8-1 、R 4-1-8-2 、R 4-1-8-3 、R 4-1-8-4 、R 4-1-8-5 、R 4-1-8-6 and R 4-1-8-7 In the C 1-6 The alkyl groups of independently may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example methyl.
[0082] In one scenario, R 4-1-1 、R 4-1-2 、R 4-1-3 、R 4-1-4 、R 4-1-5 、R4-1-6 、R 4-1-7 、R 4-1-8-1 、R 4-1-8-2 、R 4-1-8-3 、R 4-1-8- 4 、R 4-1-8-5 、R 4-1-8-6 and R 4-1-8-7 In the C 3-6 The cycloalkyl groups of EMI14.1 and EMI15.1 are independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0083] In a certain scheme, each R 4-1 , each R 4-2 , each R 4-1-8 , each R 4-1-9 , each R 4-1-10 and each R 4-1-11 In the above, the halogen may independently be fluorine, chlorine or bromine, for example fluorine or chlorine.
[0084] In a certain scheme, each R 4-1 , each R 4-2 , each R 4-1-8 , each R 4-1-9 , each R 4-1-10 and each R 4-1-11 In the above, the halogen may independently be fluorine, chlorine or bromine, for example fluorine or chlorine.
[0085] In a certain scheme, each R 4-1 and each R 4-2 In the above, one or more R 4-1-8 Substituted C 1-6 The alkyl group may be substituted by 1, 2 or 3 halogens. 1-6 Alkyl, such as -CF3.
[0086] In one scenario, -CL 1a L 1b -Middle, L 1a and L 1b One of the groups is H and the other is halogen, hydroxyl or C 1-6 Alkyl, or L 1a and L 1b Together with its common atoms, it forms C 3-6 cycloalkane or 3-6 membered heterocycle.
[0087] In one scenario, -NL 3 -Middle, L 3 H, C 1-6 Alkyl or one or more deuterated C 1-6 of alkyl.
[0088] In one embodiment, in L, when the -(CH2)n Any one, two or three -CH2- in - are replaced by -CL 1a L 1b -(e.g. -CH(CH3)-, -CH(OH)-, -CHF2- or ),-CL 2a =CL 2b -(e.g. -CH=H-), -NL 3 -(e.g. -N(CH3)- or -N(CD3)-), -O-, -S(=O)-, -S(=O)2-, -C(=O)- and -S- when one or two of them are substituted, the -(CH2) n - may be -(CH2) n Any one or two -CH2- in - are replaced by -CL 1a L 1b -、-CL 2a =CL 2b -、-NL 3 -, -O-, -S(=O)2- and -C(=O)- are substituted by one or two thereof, and n is 2, 3, 4 or 5;
[0089] It can also be -(CH2) n Any one or two -CH2- in - are replaced by -CL 1a L 1b -、-CL 2a =CL 2b -、-NL 3 -, -C(=O)-, -OC(=O)-, -S(=O)2- and -O-, n is 2, 3 or 4 or 5;
[0090] It can also be -(CH2) n Any one or two -CH2- in - are replaced by -CL 1a L 1b -、-CL 2a =CL 2b - and -O-, and n is 2, 3, 4 or 5.
[0091] Preferably, when -(CH2) n When any one -CH2- in - is replaced, -(CH2) n Any one -CH2- in - is replaced by -CL 1a L 1b -、-NL 3 -, -O- and -S(=O)2-; when -(CH2) n When any two -CH2- in - are replaced, -(CH2) nAny two -CH2- in - are replaced by --CL 2a =CL 2b - or "-NL 3 - and C(=O)-"; for example -(CH2) n - in which any one -CH2- is replaced by -CH(CH3)-, -CH(OH)-, -CHF2-, N(CH3)-, -N(CD3)- or -S(=O)2-, or -(CH2) n - is replaced by any two -CH2- by "-NH- and C(=O)-", "-N(CH3)- and C(=O)-", "-N(CD3)- and C(=O)-" or "-C(=O)- and -O-".
[0092] Preferably, the main chain of -L- contains 3, 4 or 5 atoms, such as 3-4 atoms, for example 3 atoms.
[0093] In one embodiment, in L, -(CH2) n -Can be For example (In the above structural fragment, the left end can be connected to Ar 1 Connected, the right end and Ar 2 Connected (with fragments For example, according to the reading habit from left to right, the mark 1 position is the left end and the mark 2 position is the right end), such as the alkyl or alkenyl on the left end and Ar 1 connected, the right end of the alkyl, NH, C (= O) or O and Ar 2 connected).
[0094] In one scenario, R 1 Can be H or C 1-6 Alkyl (such as methyl) or one or more R 1-1 Substituted C 1-6 of an alkyl group (e.g., -CD3).
[0095] In one plan, In, R 2 、R 3a and R 3b Defined as case 1 or 2:
[0096] Scenario 1:
[0097] R 2 、R 3a and R 3b H or C1-6 Alkyl, or R 2 and R 3a Together with the atoms to which it is attached, it forms a 5-6 membered heterocyclic group or is replaced by one or more R 2-1 substituted 5-6 membered heterocyclic group;
[0098] Each R 2-1 are independently hydroxyl, C 1-6 an alkyl (methyl) or oxo (=O) group (preferably a hydroxyl or oxo group),
[0099] Or, any two adjacent R 2-1 Together with the atoms to which it is connected, it forms a ring A, wherein the ring A is a 5-10 membered heteroaryl, or, is supported by one or more R 2-1-4 substituted 5-10 membered heteroaryl;
[0100] Each R 2-1-4 Independently C 1-6 Alkyl (such as methyl) or C 1-6 Alkyl-C(=O)OH (e.g. )(preferably a C1-6 alkyl group).
[0101] Scenario 2:
[0102] R 2 、R 3a and R 3b H or C 1-6 Alkyl, or R 2 and R 3a Together with the atoms to which it is attached, it forms a 5-6 membered heterocyclic group or is replaced by one or more R 2-1 substituted 5-6 membered heterocyclic group;
[0103] Each R 2-1 are independently hydroxy or oxo (=O),
[0104] Or, any two adjacent R 2-1 Together with the atoms to which it is connected, it forms a ring A, wherein the ring A is a 5-10 membered heteroaryl, or, is supported by one or more R 2-1-4 substituted 5-10 membered heteroaryl;
[0105] Each R 2-1-4 Independently C 1-6 of alkyl.
[0106] Preferably, in case 1, when R 2 and R 3a Together with the atoms to which it is attached, it forms a 5-6 membered heterocyclic group or is replaced by one or more R 2-1 substituted 5-6 membered heterocyclic group;
[0107] When R 2 and R 3a Together with the atoms to which it is attached, it forms a 2-1 When the 5-6 membered heterocyclic group is substituted, at least one R 2-1 It is an oxo group (=O) or a hydroxyl group.
[0108] In one plan, In the example, the C atom marked with * can be a chiral carbon atom or an achiral carbon atom; when the C atom marked with * is a chiral carbon atom, the configuration of the chiral carbon atom is S configuration;
[0109] Preferably, for The configuration of the chiral carbon atom is S configuration.
[0110] In one plan, for (For example (For example ), (For example ), (For example ), (For example )or
[0111] In one scheme, Ar 1 It can be a 5-10 membered heteroaryl, or it ... 4-2 substituted 5-10 membered heteroaryl;
[0112] Each R 4-2 are independently cyano, C 1-6 Alkyl, or, by one or more R 4-1-8 Substituted C 1-6 Alkyl;
[0113] Each R 4-1-8 are independently halogen.
[0114] In one scheme, Ar 1 Can (Preferably )(Ar 1 Above Connected to the N atom, the following Connected to L (with fragment For example, according to the reading habit from top to bottom, mark position a as the top and position b as the bottom)).
[0115] In one scheme, Ar 2 Can be C 6-18 aryl, or one or more R 4-1 Substituted C 6-18 aryl groups;
[0116] Each R 4-1 Independently C 1-6 Alkyl, 1 or more deuterated C 1-6 Alkyl or halogen, or any two adjacent R 4- 1 Together with the atoms to which it is attached, it forms a 5-10 heteroaryl group or is replaced by one or more R 4-1-10 substituted 5-10 membered heteroaryl;
[0117] Each R 4-1-10 Independently C 1-6 of alkyl.
[0118] Preferably, each R 4-1 Independently C 1-6 Alkyl or halogen, or any two adjacent R 4-1 Together with the atoms to which it is attached, it forms a 5-10 heteroaryl group or is replaced by one or more R 4-1-10 substituted 5-10 membered heteroaryl.
[0119] In one scheme, Ar 2 Can (Ar 2 Above Connected to the N atom, the following connected to L).
[0120] In one plan, The number of ring atoms in the ring may be 11, 12 or 13, for example 12.
[0121] In one embodiment, the compound represented by Formula I may be any one of Formulas I-1 to I-7:
[0122] In formula I-1, n1 and n2 are independently 0, 1, 2 or 3; Z is C or N (for example, Z is C); L, R 1 、R 2 、R 3a 、R 3b 、R 4-1 and R 4-12 The definitions of are the same as above;
[0123] In formula I-2, Y is CHR 2-1 or C(R 2-1 )(R2-1 ); n2 is 0, 1 or 2; L, R 1 、R 2-1 、R 3b 、Ar 1 and Ar 2 The definitions of are the same as above;
[0124] In formula I-3, Y is N, CH or CHR 2-1 ; n3 is 0, 1 or 2; Ring A, L, R 1 、R 2-1 、R 3b 、Ar 1 and Ar 2 The definitions of are the same as above;
[0125] In formula I-4, Y is N, CH or CHR 2-1 ; n4 is 0, 1 or 2; Ring A, L, R 1 、R 2-1 、R 3b 、Ar 1 and Ar 2 The definitions of are the same as above;
[0126] In formula I-5, R 2 、R 3a and R 3b are independently H or C 1-6 Alkyl; L, R 1 、Ar 1 and Ar 2 The definitions of are the same as above;
[0127] In formula I-6, n3 is independently 0, 1, 2 or 3; L, R 1 、R 2-1 、R 3b 、Ar 1 and Ar 2 The definitions of are the same as above;
[0128] In formula I-7, n4 is independently 0, 1, 2 or 3; Ring B is a 3-8 membered heterocyclic ring (e.g., a 3-6 membered heterocyclic ring, another example is a pyrrole ring) or a 5-6 membered heteroaromatic ring (e.g., a 5 membered heteroaromatic ring, the heteroatom is N, another example is an imidazole ring), and the heteroatoms in the 3-8 membered heterocyclic ring and the 5-6 membered heteroaromatic ring are independently selected from 1, 2 or 3 of N, O and S; L, R 1 、R 2-1 、R 3b 、Ar 1 and Ar 2 The definitions are the same as above.
[0129] Preferably: In formulas I-1 to I-7, L is -(CH2) n-, n is 3, -(CH2) n - Any one or two -CH2- in - are optionally replaced by -CL 1a L 1b -、-CL 2a =CL 2b -、-NL 3 -, -C(=O)-, -S(=O)2- and -O-, or two of them, and the main chain of -L- contains 3 atoms;
[0130] -(CH2) n - Can also be
[0131] Preferably: In formulas I-2 to I-5, Ar 1 For one or more R 4-2 Substituted pyridyl (such as ), Ar 2 For one or more R 4-1 Substituted phenyl (such as
[0132] Preferably, in formulas I-6 to I-7, in L, when -(CH2) n Any one or two -CH2- in - are replaced by -O- or -CL 2a =CL 2b - When replacing, at least one R 2-1 It is a hydroxyl group or an oxo group.
[0133] In a certain embodiment, in the compound shown in Formula I:
[0134] In L, -(CH2) n - Any 1, 2 or 3 -CH2- in - are optionally replaced by -CL 1a L 1b -、-CL 2a =CL 2b -、-NL 3 -, -O-, -S(=O)-, -S(=O)2-, -C(=O)- and -S-, or two of them (may be -(CH2) n Any one or two -CH2- in - are replaced by -CL 1a L 1b -、-CL 2a =CL 2b -、-NL 3 -, -C(=O)-, -S(=O)2-, -OC(=O)- and -O-), n is 3 or 4;
[0135] R 1 H, C 1-6 The alkyl group or one or more R 1-1 Substituted C 1-6 Alkyl;
[0136] R 2 、R 3a and R 3b H or C 1-6 Alkyl, or R 2 and R 3a Together with the atoms to which it is attached, it forms a 5-6 membered heterocyclic group or is replaced by one or more R 2-1 substituted 5-6 membered heterocyclic group;
[0137] Each R 2-1 are independently hydroxy or oxo (=O), or any two adjacent R 2-1 Together with the atoms to which it is connected, it forms a ring A, wherein the ring A is a 5-10 membered heteroaryl, or, is supported by one or more R 2-1-4 Substituted 5-10 membered heteroaryl (such as each R 2-1 are independently hydroxy or oxo);
[0138] Each R 2-1-4 Independently C 1-6 Alkyl;
[0139] Ar 1 is a 5-10 membered heteroaryl, or, is substituted by one or more R 4-2 substituted 5-10 membered heteroaryl;
[0140] Each R 4-2 are independently cyano, C 1-6 Alkyl, or, by one or more R 4-1-8 Substituted C 1-6 Alkyl;
[0141] Each R 4-1-8 are independently halogen;
[0142] Ar 2 C 6-18 aryl, or one or more R 4-1 Substituted C 6-18 aryl groups;
[0143] Each R 4-1 Independently C 1-6 Alkyl or halogen, or any two adjacent R 4-1 Together with the atoms to which it is attached, it forms a 5-10 heteroaryl group or is replaced by one or more R 4-1-10 substituted 5-10 membered heteroaryl;
[0144] Each R 4-1-10 Independently C 1-6 of alkyl.
[0145] In one embodiment, the compound as shown in Formula I is preferably any of the following compounds:
[0146] Preferably, the compound as shown in Formula I is any of the following compounds:
[0147] The present invention also provides a method for preparing the compound of Formula I, its pharmaceutically acceptable salt, its isotope-labeled substance, its solvate, its pharmaceutically acceptable salt solvate, or its prodrug, wherein the method for preparing the compound of Formula I is any one of Methods 1 to 8:
[0148] When R 1 When is H, the preparation method of the compound as shown in Formula I is Method 1;
[0149] Method 1 comprises the following steps: reacting a compound represented by Formula II-1 in a solvent in the presence of a condensing agent or a base (such as lithium bis(trimethylsilyl)amide) to obtain the compound represented by Formula I;
[0150] Among them, R 5 is hydrogen or C 1-6 Alkyl; R 2 、R 3a 、R 3b 、Ar 1 、Ar 2 and L are defined as above;
[0151] When R 1 C 1-6 Alkyl, C 3-6 Cycloalkyl, one or more R 1-1 Substituted C 1-6 Alkyl, or, by one or more R 1-2 Substituted C 3-6 When the cycloalkyl group is , the preparation method of the compound as shown in Formula I is Method 2;
[0152] Method 2 comprises the following steps: in the presence of a base (such as NaH), subjecting the compound represented by Formula II-2 and Compound III to a substitution reaction in a solvent to obtain the compound represented by Formula I;
[0153] Wherein, X is a halogen (such as iodine); R 2 、R 3a 、R 3b 、Ar 1 、Ar 2 and L are defined as above;
[0154] When -L- is -(CH2) n -, the -(CH2) n When one or two -CH2- at the terminal group are replaced by -O-, the preparation method of the compound as shown in Formula I is method 3 or 4;
[0155] Method 3 comprises the following steps: subjecting the compound represented by Formula II-3 to an intramolecular Mitsunobu reaction in a solvent (e.g., in the presence of triphenylphosphine and diisopropyl azodicarboxylate) to obtain the compound represented by Formula I;
[0156] Among them, R 1 、R 2 、R 3a 、R 3b 、Ar 1 and Ar 2 The definition of is the same as above;
[0157] Method 4 comprises the following steps: subjecting the compound represented by Formula II-4 to an intramolecular Mitsunobu reaction in a solvent (e.g., in the presence of triphenylphosphine and diisopropyl azodicarboxylate) to obtain the compound represented by Formula I;
[0158] Among them, R 1 、R 2 、R 3a 、R 3b 、Ar 1 and Ar 2 The definition of is the same as above;
[0159] When -L- is -(CH2) n -, the -(CH2) n Any one, two or three -CH2- in - are replaced by -CL 2a =CL 2b - When substituted, the preparation method of the compound as shown in Formula I is method 5;
[0160] Method 5 comprises the following steps: in the presence of a catalyst (e.g., Grubbs third-generation catalyst), subjecting the compound represented by Formula II-5 to an intramolecular olefin metathesis reaction in a solvent to obtain the compound represented by Formula I;
[0161] wherein n5 and n6 are independently 0, 1, 2, 3 or 4, and the sum of n5 and n6 is less than or equal to 5; R 1 、R 2 、R 3a 、R 3b 、Ar 1 and Ar 2 The definition of is the same as above;
[0162] When -L- is -(CH2) n -, the -(CH2) n When - is unsubstituted, the preparation method of the compound as shown in Formula I is Method 6;
[0163] Method 6 comprises the following steps: in the presence of a catalyst (such as Pd / C) and hydrogen, subjecting the compound represented by Formula II-6 to a reduction reaction in a solvent to obtain the compound represented by Formula I;
[0164] Among them, L 4 C 2-6 Alkenyl (eg, propenyl); R 1 、R 2 、R 3a 、R 3b 、Ar 1 and Ar 2 The definition of is the same as above;
[0165] When there is at least one R 2-1 When is an oxo group, the preparation method of the compound shown in Formula I is Method 7;
[0166] Method 7 comprises the following steps: in the presence of an oxidizing agent (such as ruthenium trichloride hydrate and sodium periodate), subjecting the compound represented by Formula II-7 to an oxidation reaction in a solvent to obtain the compound represented by Formula I;
[0167] Wherein, n7 is 1, 2 or 3; R 3a 、R 3b 、Ar 1 and Ar 2 The definition of is the same as above;
[0168] When there are 1 or 2 R 2-1 When is hydroxyl, the preparation method of the compound as shown in Formula I is Method 8;
[0169] Method 8 comprises the following steps: in the presence of an acid (hydrochloric acid), subjecting the compound represented by Formula II-8 to a deprotection reaction in a solvent to obtain the compound represented by Formula I;
[0170] Wherein, M is a hydroxyl protecting group (such as tert-butyldimethylsilyl (-TBS)); R 2-1 、R 3a 、R 3b 、Ar 1 and Ar 2 The definition of is the same as above.
[0171] The present invention also provides a compound as shown in Formula II-1 to Formula II-7, II-8-1 to II-8-2 (the compounds as shown in Formula II-1 to Formula II-7, II-8-1 to II-8-2 can be used to prepare the compound as shown in Formula I above):
[0172] In each general formula, n5, n6, n7, R 1 、R 2 、R 2-1 、R 3a 、R 3b 、Ar 1 、Ar 2 ,L,L 4 and M are defined as above.
[0173] The formula II-1 is preferably
[0174] The formula II-2 is preferably
[0175] The compound of formula II-3 is preferably any one of the following:
[0176] The formula II-5 is preferably:
[0177] The formula II-6 is preferably
[0178] The formula II-7 is preferably
[0179] The formula II-8 is preferably
[0180] The present invention also provides a compound:
[0181] The present invention also provides a pharmaceutical composition comprising the compound of Formula I, a pharmaceutically acceptable salt thereof, an isotope-labeled substance thereof, a solvate thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof, and a pharmaceutical excipient.
[0182] In the composition, the amount of the compound of Formula I, its pharmaceutically acceptable salt, its isotope-labeled substance, its solvate, its pharmaceutically acceptable salt solvate or its prodrug can be an effective therapeutic amount.
[0183] The present invention also provides the use of the compound as shown in Formula I, its pharmaceutically acceptable salt, its isotope-labeled substance, its solvate, its pharmaceutically acceptable salt solvate or its prodrug in the preparation of DNA polymerase θ (Pol θ) inhibitors (in vivo or in vitro (for example, for laboratory experiments)).
[0184] The present invention also provides a use of the compound of Formula I, a pharmaceutically acceptable salt thereof, an isotope-labeled substance thereof, a solvate thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof in the preparation of a drug.
[0185] Preferably, the medicament is used for preventing or treating cancers selected from the group consisting of ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, lung cancer and cervical cancer.
[0186] The present invention also provides the use of the above-mentioned compound as shown in Formula I, its pharmaceutically acceptable salt, its isotope-labeled product, its solvate, its pharmaceutically acceptable salt solvate or its prodrug in the preparation of a drug for treating or preventing diseases related to DNA repair defects.
[0187] The disease associated with DNA repair deficiency may be the aforementioned cancer.
[0188] The present invention also provides the use of the compound of Formula I, its pharmaceutically acceptable salt, its isotope-labeled product, its solvate, its pharmaceutically acceptable salt solvate or its prodrug in the preparation of a drug for treating or preventing the above-mentioned cancer.
[0189] The present invention also provides a method for treating and / or preventing a disease characterized by overexpression of DNA polymerase θ in a patient, comprising administering to the patient a therapeutically effective amount of the compound of Formula I, a pharmaceutically acceptable salt thereof, an isotope-labeled substance thereof, a solvate thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof.
[0190] The present invention also provides a method for treating and / or preventing diseases associated with DNA repair defects, which comprises administering to a patient a therapeutically effective amount of the compound of Formula I, a pharmaceutically acceptable salt thereof, an isotope-labeled substance thereof, a solvate thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof.
[0191] The disease associated with DNA repair deficiency may be the aforementioned cancer.
[0192] The present invention also provides a method for treating and / or preventing the above-mentioned cancer, which comprises administering to a patient a therapeutically effective amount of the above-mentioned compound as shown in Formula I, a pharmaceutically acceptable salt thereof, an isotope-labeled substance thereof, a solvate thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof.
[0193] The phrase "a group B substituted by one or more groups A" means two, three, four or five groups. The phrase "a group B substituted by one or more groups A" means that one, two, three, four or five hydrogen atoms in the group B are independently replaced by groups A. When multiple A groups appear at the same time, unless otherwise specified, their definitions are independent of each other and do not affect each other. For example, "a C6-C substituted by three halogens" means that 10 "Aryl" refers to C6-C 10 The aryl group may be substituted by three halogens, the definitions of which are independent of each other and do not affect each other, including but not limited to: wait.
[0194] The term "pharmaceutically acceptable" means relatively non-toxic, safe, and suitable for use by patients.
[0195] The term "pharmaceutically acceptable salt" refers to a salt obtained by reacting a compound with a pharmaceutically acceptable acid or base. When the compound contains a relatively acidic functional group, a base addition salt can be obtained by contacting the compound with a sufficient amount of a pharmaceutically acceptable base in a suitable inert solvent. When the compound contains a relatively basic functional group, an acid addition salt can be obtained by contacting the compound with a sufficient amount of a pharmaceutically acceptable acid in a suitable inert solvent. For details, see Handbook of Pharmaceutical Salts: Properties, Selection, and Use (P. Heinrich Stahl, Camille G. Wermuth, 2011, 2nd Revised Edition).
[0196] The term "solvate" refers to a substance formed by the combination of a compound and a solvent (including but not limited to water, methanol, ethanol, etc.). Solvates are divided into stoichiometric solvates and non-stoichiometric solvates.
[0197] The term "pharmaceutically acceptable salt solvate" refers to a compound formed by combining with a pharmaceutically acceptable acid or base and a solvent (including but not limited to water, methanol, ethanol, etc.). The amount of solvent may be stoichiometric or non-stoichiometric.
[0198] In the structure fragment It means that the structural fragment is connected to the rest of the molecule through this site. For example, It refers to cyclohexyl.
[0199] A "-" at the end of a group means that the group is attached to the rest of the molecule through that site. For example, CH3-C(=O)- means an acetyl group.
[0200] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0201] The term "oxo" refers to =0, an oxygen atom replacing two hydrogens on the same carbon atom, ie, a carbonyl replacing a methylene group.
[0202] The term "alkyl" refers to a linear or branched, saturated, monovalent hydrocarbon group having a specified number of carbon atoms (e.g., C1-C6). Alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, and the like.
[0203] The term "alkoxy" refers to a group R X -O-, R X The same definition as the term "alkyl". Alkoxy includes, but is not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and the like.
[0204] The term "alkenylene" is a divalent group that is connected to the rest of the molecule by two single bonds, and the rest of the definition is the same as the term "alkenyl". The term "alkenyl" refers to a linear or branched, unsaturated, monovalent hydrocarbon group with a specified number of carbon atoms (e.g., C2-C6) having one or more (e.g., 1, 2, or 3) carbon-carbon sp 2 Double bond. Alkenyl groups include but are not limited to: vinyl, wait.
[0205] The term "cycloalkyl" refers to a cyclic, saturated, monovalent hydrocarbon radical having a specified number of carbon atoms (e.g., C3-C6) that is a single ring. Cycloalkyl groups include, but are not limited to: wait.
[0206] The term "aryl" refers to a group having the specified number of carbon atoms (e.g., C6-C 10) is a cyclic, unsaturated, monovalent hydrocarbon group, which may be monocyclic or polycyclic (e.g., 2 or 3). In the case of polycyclic rings, the monocyclic rings share two atoms and one bond, and each ring is aromatic. Aryl groups include, but are not limited to, phenyl, naphthyl, and the like.
[0207] The term "heterocycloalkyl" refers to a cyclic, saturated, monovalent group having a specified number of ring atoms (e.g., 5-10 members), a specified number of heteroatoms (e.g., 1, 2, or 3), a specified heteroatom type (one or more of P, N, O, and S), which is monocyclic or polycyclic (e.g., 2 or 3 rings, bridged, spiro, or fused rings). A bridged ring refers to a monocyclic ring that shares three or more carbon atoms and / or heteroatoms. A spirocyclic ring refers to a monocyclic ring that shares one carbon atom. A fused ring refers to a monocyclic ring that shares two carbon atoms and / or heteroatoms. A heterocycloalkyl group is connected to the rest of the molecule through a carbon atom or heteroatom. Heterocycloalkyl groups include, but are not limited to: wait.
[0208] The term "heteroaryl" refers to a cyclic, unsaturated, monovalent group having a specified number of ring atoms (e.g., 5-10 members), a specified number of heteroatoms (e.g., 1, 2, or 3), a specified type of heteroatom (one or more of P, N, O, and S), which is a single ring or multiple rings (e.g., 2 or 3), with the single rings sharing two atoms and one bond, and each ring having aromatic properties. A heteroaryl group is attached to the rest of the molecule through a carbon atom or a heteroatom; a heteroaryl group is attached to the rest of the molecule through a ring with heteroatoms or a ring without heteroatoms. Heteroaryl groups include, but are not limited to: wait.
[0209] The term "heteroaromatic ring" satisfies at least one of the following conditions, and the rest of the definition is the same as the term "heteroaryl": 1. It is connected to the rest of the molecule through two or more single bonds; 2. It shares two atoms and one bond with the rest of the molecule.
[0210] The term "isotopically labeled" refers to an isotopically labeled compound in which one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number normally found in nature, compared to the nitrogen-containing compound of Formula I. Examples of isotopes that can be incorporated into the compounds of the present invention include isotopes of H, C, N, O, S, F, and Cl, such as 2 H. 3 H. 13 C. 11 C. 14 C. 15 N. 18 O. 17 O. 32 P. 35 S. 18 F and 36Cl. Compounds of the present invention, pharmaceutically acceptable salts thereof, solvates thereof, solvates of pharmaceutically acceptable salts thereof, or prodrugs thereof containing the aforementioned isotopes and / or other isotopes of other atoms are within the scope of the present invention. Certain isotopically labeled compounds of the present invention, for example, those incorporating radioactive isotopes (such as 3 H and 14 C) compounds can be used in drug and / or substrate tissue distribution assays. 3 H) and carbon 14 (i.e. 14 C) isotopes are particularly preferred due to their ease of preparation and detectability. 2 Substitution with hydrogen (H or D) may provide certain therapeutic advantages (e.g., increased in vivo half-life or reduced dosage requirements) derived from greater metabolic stability and may therefore be preferred in certain circumstances. The compounds of the present invention as claimed in the claims may be specifically limited to substitution with deuterium or tritium. Furthermore, the absence of separate listing of the term deuterium or tritium for hydrogen present in a substituent does not exclude deuterium or tritium, but rather may also include deuterium or tritium.
[0211] The term "therapeutically effective amount" refers to an amount administered to a patient that is sufficient to effectively treat a disease. The therapeutically effective amount will vary depending on the type of compound, the type of disease, the severity of the disease, the age of the patient, etc., but can be adjusted by those skilled in the art as appropriate.
[0212] The term "pharmaceutical excipients" refers to all substances contained in pharmaceutical preparations other than the active pharmaceutical ingredient (API). These substances are generally classified into two categories: excipients and additives. For details, see the Pharmacopoeia of the People's Republic of China (2020 Edition) and the Handbook of Pharmaceutical Excipients (Paul J Sheskey, Bruno C Hancock, Gary P Moss, David J Goldfarb, 2020, 9th Edition).
[0213] The term "treat" refers to eliminating the cause or alleviating the symptoms of a disease.
[0214] The term "prevent" refers to reducing the risk of developing a disease.
[0215] The term "patient" refers to any animal, typically a mammal, such as a human, that needs to be treated or prevented. Mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, and the like.
[0216] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain preferred embodiments of the present invention.
[0217] The reagents and raw materials used in the present invention are all commercially available, among which It is commercially available with a CAS number of 15761-39-4.
[0218] The positive improvement effect of the present invention is that the compounds of the present invention have good inhibitory activity on DNA polymerase θ. BRIEF DESCRIPTION OF THE DRAWINGS
[0219] Figure 1 is an ellipsoid diagram of the molecular structure of compound I-60 under single crystal diffraction.
[0220] Figure 2 is an ellipsoid diagram of the molecular structure of compound I-64 under single crystal diffraction. DETAILED DESCRIPTION
[0221] The present invention is further illustrated by way of examples below, but the present invention is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.
[0222] In each embodiment, 1 HNMR was recorded by a BRUKER AVANCE NEO 400 MHz, JNM-ECZ400s nuclear magnetic resonance instrument, and chemical shifts are expressed in δ (ppm); liquid chromatography-mass spectrometry (LCMS) was recorded by a Shimadzu LC-20AD, Agilent 1260 mass spectrometer; preparative HPLC separations were performed using a WATERS 2545, Shimadzu LP-20AP liquid chromatograph.
[0223] In the following experimental descriptions, the following abbreviations may be used:
[0224] Single crystal diffraction test method and conditions:
[0225] Testing instrument: D8 Venture: Instrument model: D8 Venture
[0226] Instrument parameters:
[0227] Structural analysis and refinement process:
[0228] The diffraction data were integrated and reduced using the SAINT program, and then empirical absorption correction was performed on the data using the SADABS program. The single crystal structure was directly solved using SHELXT2014, and the structure was refined using the least squares method. The hydrogen atom refinement process was obtained using isotropic calculations. The hydrogen atoms on N and O were obtained through residual electron density, and the hydrogen atoms on CH were obtained through computational hydrogenation, and were refined using the riding model.
[0229] Example 1 Preparation of Compound I-1
[0230] Step 1: 2-methoxy-5-methylaniline
[0231] To a solution of 1-methoxy-4-methyl-2-nitrobenzene (3.0 g, 18.0 mmol) in ethanol (15 mL) was added 10% wet palladium on carbon (containing approximately 50% water) (190 mg) at room temperature. The reaction mixture was stirred under hydrogen at room temperature for 18 hours. After completion of the reaction, the reaction mixture was filtered and concentrated to afford the crude product, 2-methoxy-5-methylaniline (2.0 g, 81.2% yield). LCMS calc. for C8H 12 NO[M+H] + :m / z=138.1;Found:138.2.
[0232] Step 2: tert-Butyl (S)-2-((2-methoxy-5-methylphenyl)carbamoyl)pyrrolidine-1-carboxylate
[0233] To a solution of 2-methoxy-5-methylaniline (1.2 g, 5.58 mmol) and (tert-butyloxycarbonyl)-L-proline (764 mg, 5.58 mmol) in acetonitrile (20 mL) was added N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (TCFH) (3.7 g, 11.8 mmol) and 1-methylimidazole (0.53 mL, 6.69 mmol) at room temperature. The reaction mixture was stirred at room temperature for 1 hour. Water (10 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 10% to 30%) to obtain tert-butyl (S)-2-((2-methoxy-5-methylphenyl)carbamoyl)pyrrolidine-1-carboxylate (1.7 g, 91.1% yield). LCMS calc.for C 18 H 27 N2O4[M+H] + :m / z=335.2;Found:335.2.
[0234] Step 3: tert-Butyl (S)-2-((2-methoxy-5-methylphenyl)(methyl)carbamoyl)pyrrolidine-1-carboxylate
[0235] To a solution of tert-butyl (S)-2-((2-methoxy-5-methylphenyl)carbamoyl)pyrrolidine-1-carboxylate (1.7 g, 5.08 mmol) in tetrahydrofuran (10 mL) at 0°C was added sodium hydride (60% in mineral oil, 223 mg, 5.59 mmol). The reaction mixture was stirred at 0°C for 1 hour, then iodomethane (0.35 mL, 5.59 mmol) was added, the mixture was warmed to room temperature, and stirring was continued for 1 hour. Water (30 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 10% to 30%) to obtain tert-butyl (S)-2-((2-methoxy-5-methylphenyl)(methyl)carbamoyl)pyrrolidine-1-carboxylate (1.5 g, 84.6% yield). LCMS calc.for C 19 H 29 N2O4[M+H] + :m / z=349.2;Found:349.2.
[0236] Step 4: (S)-N-(2-methoxy-5-methylphenyl)-N-methylpyrrolidine-2-carboxamide
[0237] To tert-butyl (S)-2-((2-methoxy-5-methylphenyl)(methyl)carbamoyl)pyrrolidine-1-carboxylate (1.5 g, 4.3 mmol) was added a 4 M solution of dioxane hydrochloride (5 mL), and the reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was concentrated and dried to give (S)-N-(2-methoxy-5-methylphenyl)-N-methylpyrrolidine-2-carboxamide (1.0 g, yield 93.5%). LCMS calculation for C 14 H 21 N2O2[M+H] + :m / z=249.2;Found:249.2.
[0238] Step 5: (S)-1-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N-(2-methoxy-5-methylphenyl)-N-methylpyrrolidine-2-carboxamide
[0239] To a solution of (S)-N-(2-methoxy-5-methylphenyl)-N-methylpyrrolidine-2-carboxamide (900 mg, 3.62 mmol) and 2,6-dichloro-4-(trifluoromethyl)pyridine (783 mg, 3.62 mmol) in 1,4-dioxane (10 mL) was added N,N-diisopropylethylamine (936 mg, 7.25 mmol) at room temperature. The reaction mixture was stirred at 90°C for 2 hours and then cooled to room temperature. Water (30 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 10% to 20%) to give (S)-1-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N-(2-methoxy-5-methylphenyl)-N-methylpyrrolidine-2-carboxamide (1.3 g, yield 83.8%) as a white solid. LCMS calc. for C 20 H 22 ClF3N3O2[M+H] + :m / z=428.1;Found:428.1.
[0240] Step 6: (S,E)-1-(6-(2-ethoxyvinyl)-4-(trifluoromethyl)pyridin-2-yl)-N-(2-methoxy-5-methylphenyl)-N-methylpyrrolidine-2-carboxamide
[0241] To a solution of (S)-1-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N-(2-methoxy-5-methylphenyl)-N-methylpyrrolidine-2-carboxamide (750 mg, 1.75 mmol) in 1,4-dioxane (20 mL) was added 2-[(E)-2-ethoxyvinyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (520 mg, 2.63 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (128 mg, 0.18 mmol), and potassium carbonate (726 mg, 5.26 mmol) at room temperature. The reaction mixture was stirred at 90°C for 3 hours and then cooled to room temperature. Water (20 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 10% to 30%) to give (S,E)-1-(6-(2-ethoxyvinyl)-4-(trifluoromethyl)pyridin-2-yl)-N-(2-methoxy-5-methylphenyl)-N-methylpyrrolidine-2-carboxamide (600 mg, yield 73.9%). LCMS calc. for C 24 H 29 F3N3O3[M+H]+ :m / z=464.2;Found:464.2.
[0242] Step 7: (S)-N-(2-hydroxy-5-methylphenyl)-N-methyl-1-(6-(2-carbonylethyl)-4-(trifluoromethyl)pyridin-2-yl)pyrrolidine-2-carboxamide
[0243] To a solution of (S,E)-1-(6-(2-ethoxyvinyl)-4-(trifluoromethyl)pyridin-2-yl)-N-(2-methoxy-5-methylphenyl)-N-methylpyrrolidine-2-carboxamide (600 mg, 1.29 mmol) in dichloromethane (20 mL) at -78°C was added boron tribromide (0.62 mL, 6.47 mmol). The reaction mixture was stirred at room temperature for 18 hours, then cooled to -78°C, quenched with methanol, and allowed to warm to room temperature. Aqueous sodium bicarbonate was added to adjust the pH to neutral, and the mixture was extracted with dichloromethane (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (methanol:dichloromethane = 5% to 10%) to give (S)-N-(2-hydroxy-5-methylphenyl)-N-methyl-1-(6-(2-carbonylethyl)-4-(trifluoromethyl)pyridin-2-yl)pyrrolidine-2-carboxamide (400 mg, purity 50%, yield 36.7%). LCMS calc. for C 21 H 23 F3N3O3[M+H] + :m / z=422.2;Found:422.2.
[0244] Step 8: (S)-N-(2-hydroxy-5-methylphenyl)-1-(6-(2-hydroxyethyl)-4-(trifluoromethyl)pyridin-2-yl)-N-methylpyrrolidine-2-carboxamide
[0245] To a solution of (S)-N-(2-hydroxy-5-methylphenyl)-N-methyl-1-(6-(2-carbonylethyl)-4-(trifluoromethyl)pyridin-2-yl)pyrrolidine-2-carboxamide (400 mg, 50% purity, 0.47 mmol) in ethanol (8 mL) at 0°C was added sodium borohydride (35 mg, 0.95 mmol). The reaction mixture was warmed to room temperature and stirred for 3 hours. The mixture was then quenched by the addition of saturated aqueous ammonium chloride (20 mL) and extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (methanol:dichloromethane = 5% to 10%) to give (S)-N-(2-hydroxy-5-methylphenyl)-1-(6-(2-hydroxyethyl)-4-(trifluoromethyl)pyridin-2-yl)-N-methylpyrrolidine-2-carboxamide (200 mg, purity 50%, yield 49.8%). LCMS calc. for C 21 H 25 F3N3O3[M+H] + :m / z=424.2;Found:424.3.
[0246] Step 9: (S)-5 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-6-oxa-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctan-3-one (I-1)
[0247] To a solution of (S)-N-(2-hydroxy-5-methylphenyl)-1-(6-(2-hydroxyethyl)-4-(trifluoromethyl)pyridin-2-yl)-N-methylpyrrolidine-2-carboxamide (200 mg, 50% purity, 0.24 mmol) in tetrahydrofuran at 0°C were added triphenylphosphine (123 mg, 0.47 mmol) and diisopropyl azodicarboxylate (95 mg, 0.47 mmol). The mixture was allowed to warm to room temperature and the reaction was continued for 3 hours. After completion of the reaction, water (20 mL) was added and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether=30%-50%) to give a crude product, which was then purified by preparative HPLC (column: XBridge Prep C18 5μm OBD 19*150mm; mobile phase: A (10mM NH4HCO3 in Water); B (ACN); elution conditions: 0-3min: 40% B, 3-7min: 40-85% B, 7-11min: 85-95% B, 11-16min: 95% B, 16-16.5min: 95-40% B, 16.5-21min: 40% B) to give (S)-5 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-6-oxa-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctan-3-one (Compound I-1) (28 mg, purity 94.3%, yield 29.2%). LCMS calc.for C 21 H 23 F3N3O2[M+H] + :m / z=406.2;Found:406.1. 1 H NMR(400MHz,DMSO-d6)δ7.23–7.06(m,3H), 6.70(s,1H),6.48(s,1H),4.60–4.51(m,1H),4.42–4.34(m,1H),4.25–4.14(m,1H),3.51–3.46(m,1H), 3.44–3.34(m,1H),3.08–3.01(m,2H),3.00(s,3H),2.28(s,3H),2.24–2.10(m,1H),2.06–1.83(m,3H).
[0248] Example 2 Preparation of Compounds I-4, I-5 and I-12
[0249] Step 1: 1-allyl-4-methyl-2-nitrobenzene
[0250] At room temperature, 1-bromo-4-methyl-2-nitrobenzene (2.0 g, 9.26 mmol) and allylboronic acid pinacol ester (2.33 g, 13.9 mmol) were dissolved in dioxane (20 mL) and water (4 mL). 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (0.68 g, 0.93 mmol) and cesium carbonate (9.05 g, 27.8 mmol) were then added to the solution. The reaction system was purged with argon three times and heated to 100°C under an argon atmosphere with stirring for 4 hours. After the reaction was completed, the reaction mixture was cooled and filtered, and the filtrate was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 10%) to obtain 1-allyl-4-methyl-2-nitrobenzene (1.5 g, yield: 91.4%). LCMS calc.for C 10 H 12 NO2[M+H] + :m / z=178.1;Found:NO.
[0251] Step 2: 2-allyl-5-methylaniline
[0252] At room temperature, 1-allyl-4-methyl-2-nitrobenzene (1.5 g, 8.46 mmol) was dissolved in ethanol (10 mL) and water (5 mL). Iron powder (2.36 g, 42.3 mmol) and ammonium chloride (2.26 g, 42.3 mmol) were then added to the solution. The temperature was raised to 80°C and stirred for 2 hours. After the reaction was completed, the temperature was lowered and filtered, and the filtrate was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to obtain 2-allyl-5-methylaniline (1.2 g, yield: 96.3%). LCMS calc. for C 10 H 14 N[M+H] + :m / z=148.1;Found:148.2.
[0253] Step 3: tert-Butyl (S)-2-((2-allyl-5-methylphenyl)carbamoyl)pyrrolidine-1-carboxylate
[0254] 2-Allyl-5-methylaniline (1.2 g, 8.15 mmol) was dissolved in acetonitrile (10 mL) at room temperature. (tert-Butoxycarbonyl)-L-proline (1.75 g, 8.15 mmol), N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (2.74 g, 9.78 mmol), and 1-methylimidazole (1.36 mL, 17.1 mmol) were then added to the reaction mixture. The reaction mixture was allowed to react at room temperature for 3 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to obtain tert-butyl (S)-2-((2-allyl-5-methylphenyl)carbamoyl)pyrrolidine-1-carboxylate (1.4 g, yield: 49.9%). LCMS calc.for C 20 H 29 N2O3[M+H] + :m / z=345.2; Found:245.3[M-Boc+H] + .
[0255] Step 4: tert-Butyl (S)-2-((2-allyl-5-methylphenyl)(methyl)carbamoyl)pyrrolidine-1-carboxylate
[0256] Dissolve tert-butyl (S)-2-((2-allyl-5-methylphenyl)carbamoyl)pyrrolidine-1-carboxylate (1.4 g, 4.06 mmol) in DMF (10 mL). The reaction mixture was cooled to 0°C and slowly added with NaH (0.24 g, 60%, 6.1 mmol). The reaction mixture was stirred at 0°C for 0.5 hours, followed by the addition of iodomethane (0.38 mL, 6.1 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 1 hour. The reaction was quenched by the addition of saturated aqueous ammonium chloride and extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to yield a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to give tert-butyl (S)-2-((2-allyl-5-methylphenyl)(methyl)carbamoyl)pyrrolidine-1-carboxylate (1.3 g, yield: 89.2%). LCMS calc. for C 21 H 31 N2O3[M+H] + :m / z=359.2;Found:359.2.
[0257] Step 5: (S)-N-(2-allyl-5-methylphenyl)-N-methylpyrrolidine-2-carboxamide
[0258] Tert-butyl (S)-2-((2-allyl-5-methylphenyl)(methyl)carbamoyl)pyrrolidine-1-carboxylate (1.30 g, 3.63 mmol) was dissolved in DCM (15 mL). Zinc bromide (1.63 g, 7.25 mmol) was added to the reaction solution, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, the mixture was concentrated to obtain a residue, which was purified by silica gel column chromatography (methanol:dichloromethane = 0% to 5%) to obtain (S)-N-(2-allyl-5-methylphenyl)-N-methylpyrrolidine-2-carboxamide (0.9 g, yield: 96.1%). LCMS calculation for C 16 H 23 N2O[M+H] + :m / z=259.2;Found:259.2.
[0259] Step 6: (S)-N-(2-allyl-5-methylphenyl)-1-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N-methylpyrrolidine-2-carboxamide
[0260] (S)-N-(2-allyl-5-methylphenyl)-N-methylpyrrolidine-2-carboxamide (0.9 g, 3.48 mmol) was dissolved in DMF (10 mL). 2,6-dichloro-4-(trifluoromethyl)pyridine (0.9 g, 4.18 mmol) and N,N-diisopropylethylamine (1.35 g, 10.5 mmol) were then added to the reaction mixture. The reaction mixture was heated to 100°C in a microwave reactor for 1 hour. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to give (S)-N-(2-allyl-5-methylphenyl)-1-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N-methylpyrrolidine-2-carboxamide (1.1 g, yield: 72.1%). LCMS calc. for C 22 H 24 ClF3N3O[M+H] + :m / z=438.2;Found:438.2.
[0261] Step 7: (S)-N-(2-allyl-5-methylphenyl)-N-methyl-1-(4-(trifluoromethyl)-6-vinylpyridin-2-yl)pyrrolidine-2-carboxamide
[0262] (S)-N-(2-allyl-5-methylphenyl)-1-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N-methylpyrrolidine-2-carboxamide (1.1 g, 2.51 mmol) was dissolved in tetrahydrofuran (10 mL) and water (1 mL). Potassium ethylene trifluoroborate (0.5 g, 3.77 mmol), palladium dichloride (40 mg, 0.25 mmol), triphenylphosphine (200 mg, 0.75 mmol), and cesium carbonate (2.46 g, 7.54 mmol) were added to the reaction solution. The reaction mixture was purged with argon three times and heated to 80°C under an argon atmosphere with stirring for 4 hours. After the reaction was completed, the reaction solution was cooled to room temperature, filtered, and the filtrate was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to give (S)-N-(2-allyl-5-methylphenyl)-N-methyl-1-(4-(trifluoromethyl)-6-vinylpyridin-2-yl)pyrrolidine-2-carboxamide (0.79 g, yield: 73.2%). LCMS calc. for C 24 H 27 F3N3O[M+H] + :m / z=430.3;Found:430.2.
[0263] Step 8: (S,Z)-5 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-7-ene-3-one (I-5)
[0264] (S)-N-(2-allyl-5-methylphenyl)-N-methyl-1-(4-(trifluoromethyl)-6-vinylpyridin-2-yl)pyrrolidine-2-carboxamide (0.79 g, 1.84 mmol) was dissolved in toluene (80 mL), and Grubbs' third-generation catalyst (0.65 g, 0.74 mmol) was added to the reaction solution. The reaction solution was allowed to react at 80°C for 1 hour. After the reaction, the reaction solution was cooled to room temperature and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to obtain (S,Z)-5,5,4-dimethyl-14-(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-7-ene-3-one (I-5) (0.35 g, yield: 47.4%). 50 mg of the product was purified by preparative HPLC (chromatographic column: XBridge Prep C18 5μm OBD 19*150mm; mobile phase: ACN-H2O (10mMNH4CO3) gradient: 30%-90%) to obtain (S,Z)-5 5 ,4-dimethyl-14-(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-7-ene-3-one (I-5) (8.9 mg, yield: 17.8%). LCMS calc.for C 22 H 23 F3N3O[M+H] + :m / z=402.2;Found:402.3. 1 H NMR(400MHz, DMSO-d6)δ7.32(d,J=7.7Hz,1H),7.16–7.11(m,2H),6.79(s,1H),6.55-6.50(m,3H),4.39(dd,J=8.3,2.9Hz,1H),4.29–4.21(m, 1H),3.59(td,J=8.9,2.8Hz,1H),3.31-3.26(m,1H),3.18–3.10(m,1H) ,3.02(s,3H),2.33–2.26(m,4H),2.07–2.01(m,1H),1.99–1.88(m,2H).
[0265] Step 9: (S)-5 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctan-3-one (I-4)
[0266] (S,Z)-55,4-dimethyl-14-(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-7-ene-3-one (0.25 g, 0.62 mmol) was dissolved in methanol (5 mL) and 10% wet palladium on carbon (75 mg) was added. The reaction solution was replaced with hydrogen three times and reacted at room temperature under a hydrogen atmosphere (15 psi) for 3 hours. After the reaction was completed, the mixture was filtered and concentrated to obtain the crude product (S)-5 5 ,4-dimethyl-1 4 -(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctan-3-one (I-4) (0.25 g, 100%). 40 mg of the crude product was purified by preparative HPLC (column: XBridge Prep C18 5μm OBD 19*150mm; mobile phase: ACN-H2O (10mM NH4CO3) gradient: 60%-95%) to obtain (S)-55,4-dimethyl-14-(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctan-3-one (I-4) (4.3 mg, yield: 10.4%). LCMS calc. for C 22 H 25 F3N3O[M+H] + :m / z=404.2;Found:404.2. 1 H NMR(400MHz,DMSO-d6)δ7.37(d,J=7.9Hz,1H),7.20(dd,J=7.8,1.8Hz,1H),7 .13–7.08(m,1H),6.66(s,1H),6.44(s,1H),4.61(dd,J=7.9,3.2Hz,1H),3.55 (td,J=9.0,3.6Hz,1H),3.38–3.35(m,1H),2.95(s,3H),2.87–2.80(m,1H),2. 71(t,J=5.8Hz,2H),2.63–2.54(m,1H),2.32–2.27(m,4H),2.16–1.95(m,5H).
[0267] Step 10: (S)-5 5 ,4-dimethyl-1 4 -(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone (I-12)
[0268] (S)-5,5,4-dimethyl-14-(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctan-3-one (I-4) (210 mg, 0.52 mmol) was dissolved in ethyl acetate (2 mL) and water (2 mL). Ruthenium trichloride hydrate (30 mg, 0.16 mmol) and sodium periodate (560 mg, 2.6 mmol) were added to the reaction solution and stirred at room temperature for 1 hour. After completion of the reaction, the reaction was filtered and the filtrate was extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. Purification by preparative HPLC (chromatographic column: Durashell C18 10 μm 21.2*250 mm; mobile phase: ACN-H2O (10 mM NH4HCO3 + 0.05% NH3H2O) gradient: 60%-100%) gave (S)-5 5 ,4-dimethyl-1 4 -(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone (I-12) (70 mg, yield: 33.6%). LCMS calc.for C 22 H 23 F3N3O2[M+H] + :m / z=418.2;Found:418.4. 1 H NMR (400MHz, DMSO-d6) δ8.39(s,1H),7.44–7.37(m,2H),7.26(dd,J=8.0,1.8Hz,1H),7.21(d,J=1.8Hz,1H),5. 09(dd,J=8.1,2.9Hz,1H),2.98(s,3H),2.94–2.77(m,3H),2.64–2.51(m,3H),2.35(s,3H),2.21–2.08(m,4H).
[0269] Example 3 Preparation of Compound I-8
[0270] Step 1: tert-Butyl (6-chloro-4-(trifluoromethyl)pyridin-2-yl)carbamate
[0271] 2,6-Dichloro-4-(trifluoromethyl)pyridine (1.0 g, 4.63 mmol) and tert-butyl carbamate (814 mg, 6.94 mmol) were dissolved in dioxane (10 mL). 2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (288 mg, 0.46 mmol), palladium acetate (52 mg, 0.23 mmol), and cesium carbonate (2.26 g, 6.94 mmol) were added at 20°C. The mixture was stirred at 80°C for 2 hours. After cooling, the reaction solution was filtered and the filtrate was concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 10%) to obtain tert-butyl (6-chloro-4-(trifluoromethyl)pyridin-2-yl)carbamate (1.0 g, 76.9%). LCMS calc. for C 11 H 13 ClF3N2O2[M+H] + :m / z=297.1;Found:297.0.
[0272] Step 2: tert-Butyl (E)-(6-(2-ethoxyvinyl)-4-(trifluoromethyl)pyridin-2-yl)carbamate
[0273] Under nitrogen, tert-butyl (6-chloro-4-(trifluoromethyl)pyridin-2-yl)carbamate (900 mg, 3.03 mmol) was dissolved in acetonitrile (10 mL), followed by the addition of (E)-2-(2-ethoxyvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.21 g, 6.11 mmol), 1,1-bis(diphenylphosphino)ferrocenepalladium dichloride (222 mg, 0.3 mmol), and potassium carbonate (836 mg, 6.06 mmol). The reaction mixture was purged with nitrogen three times and then stirred at 80°C under nitrogen for 1 hour. The reaction solution was filtered, and the filtrate was concentrated to obtain a crude product which was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 10%) to obtain tert-butyl (E)-(6-(2-ethoxyvinyl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (150 mg, yield: 50.3%). LCMS calc. for C 15 H 20 F3N2O3[M+H] + :m / z=333.1;Found:333.1.
[0274] Step 3: 2-Bromo-N-(2-methoxy-5-methylphenyl)-N-methylacetamide
[0275] 2-Methoxy-N, 5-dimethylaniline (200 mg, 1.32 mmol) and N, N-dimethylpyridin-4-amine (162 mg, 1.32 mmol) were dissolved in dichloromethane (5 mL) and 2-bromoacetyl chloride (208 mg, 1.32 mmol) was added. The mixture was stirred at 20°C for 1 hour. The reaction mixture was concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 30%) to obtain 2-bromo-N-(2-methoxy-5-methylphenyl)-N-methylacetamide (300 mg, 83.3%). LCMS calc. for C 11 H 15 BrNO2[M+H] + :m / z=272.0;Found:272.0.
[0276] Step 4: tert-Butyl (E)-(6-(2-ethoxyvinyl)-4-(trifluoromethyl)pyridin-2-yl)(2-((2-methoxy-5-methylphenyl)(methyl)amino)-2-oxoethyl)carbamate
[0277] To a solution of tert-butyl (E)-(6-(2-ethoxyvinyl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (440 mg, 1.32 mmol) in N,N-dimethylformamide (10 mL) was added sodium hydride (66.1 mg, 60% purity, 1.65 mmol). The reaction mixture was stirred at 0°C for 0.5 hours, followed by the addition of 2-bromo-N-(2-methoxy-4-methylphenyl)-N-methylacetamide (300 mg, 1.1 mmol), and stirring continued for 1 hour. The mixture was quenched by the addition of water (20 mL), and the aqueous phase was extracted twice with ethyl acetate (30 mL). The combined organic phases were washed sequentially with water (20 mL) and saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether=0% to 30%) to give tert-butyl (E)-(6-(2-ethoxyvinyl)-4-(trifluoromethyl)pyridin-2-yl)(2-((2-methoxy-4-methylphenyl)(methyl)amino)-2-oxoethyl)carbamate (200 mg, 34.6%). LCMS calc. for C 26 H 33 F3N3O5[M+H] + :m / z=524.2;Found:524.3.
[0278] Step 5: N-(2-hydroxy-5-methylphenyl)-N-methyl-2-((6-(2-oxoethyl)-4-(trifluoromethyl)pyridin-2-yl)amino)acetamide
[0279] Boron tribromide (191 mg, 0.76 mmol) was added to tert-butyl (E)-(6-(2-ethoxyvinyl)-4-(trifluoromethyl)pyridin-2-yl)(2-((2-methoxy-5-methylphenyl)(methyl)amino)-2-oxoethyl)carbamate (200 mg, 0.38 mmol) in dichloromethane (5 mL), and the mixture was stirred at 20°C for 12 hours. After the reaction was cooled, methanol (1 mL) was added to quench the mixture, and the mixture was concentrated under reduced pressure to obtain a residue. The residue was dissolved in tetrahydrofuran (7 mL) and 4N dilute hydrochloric acid (7 mL), and the reaction was stirred at 60°C for 4 hours. The reaction solution was cooled and concentrated to obtain a residue. The residue, N-(2-hydroxy-5-methylphenyl)-N-methyl-2-((6-(2-oxoethyl)-4-(trifluoromethyl)pyridin-2-yl)amino)acetamide (150 mg, the crude product was used directly in the next reaction). LCMS calc.for C 18 H 19 F3N3O3[M+H] + :m / z=382.1;Found:382.1.
[0280] Step 6: N-(2-hydroxy-5-methylphenyl)-2-((6-(2-hydroxyethyl)-4-(trifluoromethyl)pyridin-2-yl)amino)-N-methylacetamide
[0281] To a solution of N-(2-hydroxy-5-methylphenyl)-N-methyl-2-((6-(2-oxoethyl)-4-(trifluoromethyl)pyridin-2-yl)amino)acetamide (150 mg, 0.39 mmol) in tetrahydrofuran (5 mL) was slowly added dropwise lithium borohydride (0.2 mL, 2 mol / L, 0.39 mmol) in tetrahydrofuran at -50°C, and then the temperature was raised to 20°C and stirred for 0.5 h. The reaction solution was quenched with saturated ammonium chloride (5 mL) and extracted with ethyl acetate (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude compound N-(2-hydroxy-5-methylphenyl)-2-((6-(2-hydroxyethyl)-4-(trifluoromethyl)pyridin-2-yl)amino)-N-methylacetamide (150 mg). LCMS calc. for C 18 H 21 F3N3O3[M+H] + :m / z=384.2;Found:384.1。
[0282] Step 7: 5 4 ,6-dimethyl-1 4 -(Trifluoromethyl)-4-oxa-6,9-diaza-1(2,6)-pyridin-5(1,2)-benzocyclononan-7-one (I-8)
[0283] To a solution of N-(2-hydroxy-5-methylphenyl)-2-((6-(2-hydroxyethyl)-4-(trifluoromethyl)pyridin-2-yl)amino)-N-methylacetamide (150 mg, 0.39 mmol) and triphenylphosphine (154 mg, 0.59 mmol) in tetrahydrofuran (10 mL) was added isopropyl azodicarboxylate (119 mg, 0.59 mmol) at 0°C, and the reaction mixture was stirred at 20°C for 1 hour. The reaction solution was concentrated under reduced pressure, and the crude product was purified by prep-HPLC (column: SHIMADZU Prep C18 10 μm 20*250 mm, mobile phase: A (0.1% FA aqueous solution) B (ACN); elution conditions: 0-2 min: 10% B, 2-6 min: 10-60% B, 6-10 min: 60-80% B, 10-14 min: 80-95% B, 14-21 min: 95% B, 21-21.5 min: 95-10% B, 21.5-23 min: 10% B, flow rate = 20 mL / min) to obtain 5 4 ,6-dimethyl-1 4 -(Trifluoromethyl)-4-oxa-6,9-diaza-1(2,6)-pyridin-5(1,2)-benzocyclononan-7-one (I-8) (1.3 mg, 0.9% yield over four steps). LCMS calc.for C 18 H 19 F3N3O2[M+H] + :m / z=366.1;Found:366.2。 1 H NMR (400MHz, DMSO-d6) δ7.46(t,J=7.2Hz,1H),7.17(s,2H),7.09(s,1H),6.69(s,1H),6.62(s,1H),4.46-4.36(m,2H),4.06(dd ,J=10.8,7.6Hz,1H),3.18(dd,J=14.8,5.2Hz,1H),3.10-3.00(m,1H),2.99(s,3H),2.85(dt,J=15.6,3.6Hz,1H),2.27(s,3H).
[0284] Example 4 Preparation of Compound I-14
[0285] Step 1: tert-Butyl (S)-2-((2-bromo-5-methylphenyl)carbamoyl)-2,5-dihydro-1H-pyrrole-1-carboxylate
[0286] At room temperature, (S)-1-(tert-Butoxycarbonyl)-2,5-dihydro-1H-pyrrole-2-carboxylic acid (4.5 g, 21.1 mmol), 3-bromo-5-methylaniline (4.32 g, 23.2 mmol), and N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (7.11 g, 25.3 mmol) were dissolved in acetonitrile (20 mL). 1-Methylimidazole (3.53 mL, 44.3 mmol) was then added dropwise to the solution. The resulting reaction mixture was stirred at room temperature for 2 hours. Water (50 mL) was added to the reaction system, and the mixture was extracted with ethyl acetate (30 mL x 2). The combined organic phases were washed sequentially with water (30 mL) and saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to give tert-butyl (S)-2-((2-bromo-5-methylphenyl)carbamoyl)-2,5-dihydro-1H-pyrrole-1-carboxylate (8.0 g, yield: 99.0%). LCMS calc. for C 17 H 22 BrN2O3[M+H] + :m / z=381.1;Found:381.2.
[0287] Step 2: tert-Butyl (2S,3S,4R)-2-((2-bromo-5-methylphenyl)carbamoyl)-3,4-dihydroxypyrrolidine-1-carboxylate
[0288] Tert-butyl (S)-2-((2-bromo-5-methylphenyl)carbamoyl)-2,5-dihydro-1H-pyrrole-1-carboxylate (7.6 g, 19.9 mmol) was dissolved in acetonitrile (68 mL) and water (16 mL). N-methylmorpholine-N-oxide (3.5 g, 29.9 mmol), potassium osmate (0.37 g, 1.0 mmol), and citric acid monohydrate (3.14 g, 15.0 mmol) were then added to the solution. The reaction mixture was stirred at room temperature under nitrogen for 3 hours. After the reaction was completed, the resulting mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (methanol:dichloromethane = 0% to 5%) to obtain tert-butyl (2S,3S,4R)-2-((2-bromo-5-methylphenyl)carbamoyl)-3,4-dihydroxypyrrolidine-1-carboxylate (1.7 g, yield: 20.5%). LCMS calc. for C 17 H 24 BrN2O5[M+H] + :m / z=415.1; Found:315.2[M-Boc+H] + .
[0289] Step 3: tert-Butyl (3aS,4S,6aR)-4-((2-bromo-5-methylphenyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate
[0290] To a solution of tert-butyl (2S,3S,4R)-2-((2-bromo-5-methylphenyl)carbamoyl)-3,4-dihydroxypyrrolidine-1-carboxylate (1.7 g, 4.09 mmol) in acetone (40 mL) were added 2,2-dimethoxypropane (21.3 g, 205 mmol) and pyridine p-toluenesulfonate (1.23 g, 4.91 mmol) at room temperature. The reaction system was then heated to 60°C under a nitrogen atmosphere and stirred for 3 hours. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to obtain tert-butyl (3aS,4S,6aR)-4-((2-bromo-5-methylphenyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate (2.0 g, yield: 100%). LCMS calc. for C 20 H 28 BrN2O5[M+H] + :m / z=455.1;Found:355.1[M-Boc+H] + .
[0291] Step 4: tert-Butyl (3aS,4S,6aR)-4-((2-bromo-5-methylphenyl)(methyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate
[0292] To a solution of tert-butyl (3aS,4S,6aR)-4-((2-bromo-5-methylphenyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate (1.70 g, 3.73 mmol) in N,N-dimethylformamide (20 mL) at 0°C was added sodium hydride (0.19 g, 60% purity, 4.85 mmol). The reaction was stirred at 0°C for 0.5 hour, followed by the addition of iodomethane (0.46 mL, 7.47 mmol) and continued stirring for 1 hour. The reaction was quenched by the addition of water (30 mL), and the aqueous phase was extracted three times with ethyl acetate (30 mL). The combined organic phases were washed sequentially with water (30 mL) and saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 50%) to give tert-butyl (3aS,4S,6aR)-4-((2-bromo-5-methylphenyl)(methyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate (1.6 g, 91.3%). LCMS calc. for C 21 H 30 BrN2O5[M+H] + :m / z=469.1;Found:469.2.
[0293] Step 5: tert-Butyl (3aS, 4S, 6aR)-4-((2-allyl-5-methylphenyl)(methyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate
[0294] Tert-butyl (3aS,4S,6aR)-4-((2-bromo-5-methylphenyl)(methyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate (700 mg, 1.49 mmol), 2-allyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (501 mg, 2.98 mmol) and 1,1-bis(diphenylphosphino)ferrocenepalladium dichloride (109 mg, 0.15 mmol) were dissolved in a mixed solvent of dioxane (10 mL) and water (1 mL), and potassium carbonate (618.4 mg, 4.47 mmol) was added. The mixture was stirred at 100° C. under nitrogen for 3 hours. The mixture was cooled, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to obtain tert-butyl (3aS, 4S, 6aR)-4-((2-allyl-5-methylphenyl)(methyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate (700 mg, yield: 100%). LCMS calc. for C 24 H 35 N2O5[M+H] + :m / z=431.3;Found:431.3.
[0295] Step 6: (3aS,4S,6aR)-N-(2-allyl-5-methylphenyl)-N,2,2-trimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide
[0296] Tert-butyl (3aS,4S,6aR)-4-((2-allyl-5-methylphenyl)(methyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate (700 mg, 1.63 mmol) was dissolved in dichloromethane (5 mL), and zinc bromide (1.1 g, 4.88 mmol) was added. The reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated and purified by silica gel column chromatography (methanol:dichloromethane = 0% to 5%) to obtain (3aS,4S,6aR)-N-(2-allyl-5-methylphenyl)-N,2,2-trimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (500 mg, yield: 93%). LCMS calculation for C 19 H 27 N2O3[M+H] + :m / z=331.2;Found:331.2.
[0297] Step 7: (3aS,4S,6aR)-N-(2-allyl-5-methylphenyl)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N,2,2-trimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide
[0298] To a solution of (3aS,4S,6aR)-N-(2-allyl-5-methylphenyl)-N,2,2-trimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (500 mg, 1.51 mmol) and 2,6-dichloro-4-(trifluoromethyl)pyridine (654 mg, 3.03 mmol) in DMF (10 mL) was added N,N-diisopropylethylamine (782 mg, 6.05 mmol), and the mixture was stirred at 120°C for 2 hours. After cooling, the reaction was quenched by the addition of water (30 mL), and the aqueous phase was extracted twice with ethyl acetate (30 mL). The combined organic phases were washed sequentially with water (30 mL) and saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 50%) to give (3aS,4S,6aR)-N-(2-allyl-5-methylphenyl)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N,2,2-trimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (500 mg, 64.8%). LCMS calc. for C 25 H 28 ClF3N3O3[M+H] + :m / z=510.2;Found:510.3.
[0299] Step 8: (3aS,4S,6aR)-N-(2-allyl-5-methylphenyl)-N,2,2-trimethyl-5-(4-(trifluoromethyl)-6-vinylpyridin-2-yl)tetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide
[0300] (3aS,4S,6aR)-N-(2-allyl-5-methylphenyl)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N,2,2-trimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (500 mg, 0.98 mmol) was dissolved in tetrahydrofuran (10 mL) and water (1 mL). Potassium ethylene trifluoroborate (263 mg, 1.96 mmol), palladium dichloride (17.4 mg, 0.1 mmol), triphenylphosphine (77.1 mg, 0.29 mmol), and cesium carbonate (958 mg, 2.94 mmol) were added at 20°C. The mixture was stirred at 90°C for 2 hours. After cooling, the reaction solution was concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to give (3aS,4S,6aR)-N-(2-allyl-5-methylphenyl)-N,2,2-trimethyl-5-(4-(trifluoromethyl)-6-vinylpyridin-2-yl)tetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (500 mg, 100%). LCMS calc. for C 27 H 31 F3N3O3[M+H] + :m / z=502.2; Found:502.3.
[0301] Step 9: (2 3a R,2 6 S,2 6a S,Z)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-Aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctan-7-en-3-one
[0302] Under nitrogen protection, (3aS,4S,6aR)-N-(2-allyl-5-methylphenyl)-N,2,2-trimethyl-5-(4-(trifluoromethyl)-6-vinylpyridin-2-yl)tetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (500 mg, 1 mmol) was dissolved in toluene (50 mL), Grubbs third generation catalyst (441 mg, 0.5 mmol) was added, and stirred at 80°C for 1 hour under nitrogen protection. After cooling, the reaction solution was filtered, and the filtrate was concentrated to obtain a crude product which was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 30%) to obtain (2 3a R,2 6 S,2 6a S,Z)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-Aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-7-ene-3-one (280 mg, yield: 60%). LCMS calc. for C 25 H 27 F3N3O3[M+H] + :m / z=474.2;Found:474.3.
[0303] Step 10: (2 3a R,2 6 S,2 6a S,Z)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-Aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-phenylcyclooctan-3-one
[0304] (2 3a R,2 6 S,2 6a S,Z)-2 2 ,2 2 ,55 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-7-ene-3-one (280 mg, 0.59 mmol) was dissolved in methanol (30 mL), and 10% wet palladium carbon (62.7 mg, 0.06 mmol) was added. The reaction solution was stirred under a hydrogen (15 Psi) atmosphere for 1 hour. The reaction solution was filtered, and the filtrate was concentrated to obtain a crude product which was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 30%) to obtain (2 3a R,2 6 S,2 6a S,Z)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-Aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridin-5(1,2)-benzocyclooctan-3-one (120 mg, yield: 42.7%). LCMS calc. for C 25 H 29 F3N3O3[M+H] + :m / z=476.2;Found:476.3.
[0305] Step 11: (2 3a S,2 6 S,2 6a S)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-Aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-phenylcyclooctane-2 4 ,3-diketone
[0306] (2 3a R,2 6 S,2 6a S,Z)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctan-3-one (120 mg, 0.25 mmol) was dissolved in ethyl acetate (5 mL) and water (5 mL). Ruthenium trichloride hydrate (15.7 mg, 0.08 mmol) and sodium periodate (270 mg, 1.26 mmol) were added at 20°C. The mixture was stirred at 20°C for 1 hour. The reaction solution was diluted with water (10 mL), and the aqueous phase was extracted twice with ethyl acetate (20 mL). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 30%) to obtain (2 3a S,2 6 S,2 6a S)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-Aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 4 ,3-diketone (90 mg, 72.9%). LCMS calc. for C 25 H 27 F3N3O4[M+H] + :m / z=490.2;Found:490.3
[0307] Step 12: (2 2 S,2 3 S,2 4 S)-2 3 ,2 4 -Dihydroxy-5- 5 ,4-dimethyl-1 4-(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone (I-14)
[0308] (2 3a S,2 6 S,2 6a S)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-Aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 4 ,3-diketone (80 mg, 0.16 mmol) was dissolved in methanol (5 mL) and dilute hydrochloric acid (2 mL, 4 N) and stirred at 50 ° C for 3 hours. After cooling, the reaction solution was concentrated to obtain a residue. The residue was purified by Pre-HPLC (Column XBridge Prep C18 5μm OBD 19*150mm, Mobile phase: A (10mM NH4HCO3 aqueous solution); B (acetonitrile ACN), elution conditions: 0-3min: 40% B, 3-7min: 40-85% B, 7-11min: 85-90% B, 11-13min: 90-95% B, 13-16min: 95% B, 16-16.5min: 95-40% B, 16.5-21min: 40% B, Flow = 15mL / min) to obtain (2 2 S,2 3 S,2 4 S)-2 3 ,2 4 -Dihydroxy-5- 5 ,4-dimethyl-1 4 -(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-dione (14 mg, 19.1%). LCMS calc. for C 22 H 23 F3N3O4[M+H] + :m / z=450.2;Found:450.2; 1H NMR (400MHz, DMSO-d6) δ8.34(s,1H),7.45(s,1H),7.44(d,J=8.0Hz,1H),7.27(d,J= 8.0Hz,1H),7.26(s,1H),5.74(d,J=8.0Hz,1H),5.41(d,J=12.0Hz,1H),5.30(d,J=8. 0Hz,1H),4.38-4.43(m,1H),4.03-4.10(m,1H),3.02(s,3H),2.88-2.96(m,1H),2.59 -2.74(m,2H),2.45-2.50(m,1H),2.36(s,3H),2.25-2.32(m,1H),2.00-2.10(m,1H).
[0309] Example 5 Preparation of Compound I-13
[0310] (2 2 S,2 3 S,2 4 R)-2 3 ,2 4 -Dihydroxy-5- 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctan-3-one (I-13)
[0311] (2 3a R,2 6 S,2 6a S,Z)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4H-4-Aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridin-5(1,2)-benzocyclooctan-3-one (100 mg, 0.21 mmol) was dissolved in methanol (5 mL) and dilute hydrochloric acid (2 mL, 4 N) and stirred at 20°C for 2 hours. After cooling, the reaction solution was concentrated to obtain a residue. The residue was purified by Pre-HPLC (Column: XBridge Prep C18 5μm OBD 19*150mm, Mobile phase: A (10mM NH4HCO3 in Water) B (ACN), elution conditions: 0-3min: 60% B, 3-8min: 60-80% B, 8-12min: 80-90% B, 12-16min: 90% B, 16-16.5min: 90-60% B, 16.5-20.5min: 60% B, Flow = 15mL / min) and prep-TLC (MeOH: DCM = 1:15) to give a white solid (2 2 S,2 3 S,2 4 S)-2 3 ,2 4 -Dihydroxy-5- 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctan-3-one (3.0 mg, 3.3%). LCMS calc. for C 22 H 25 F3N3O3[M+H] + :m / z=436.2;Found:436.3; 1 H NMR (400MHz, CDCl3) δ7.34(d,J=8.0Hz,1H),7.30-7.20(m,2H),6.61(s,1H),6.33(s,1H),5.19(d,J=8.0Hz,1H),4.40-4.30(m,2H),3.79(d,J=1 2.0Hz,1H),3.62(dd,J=12.0,4.0Hz,1H),3.17(s,3H),3.00-2.90(m,1H ),2.78-2.60(m,3H),2.39(s,3H),2.32-2.25(m,1H),2.10-2.00(m,1H).
[0312] Example 6 Preparation of Compound I-32
[0313] The same synthetic route as compound I-14 was used, wherein the raw material in step 3 was replaced by deuterated iodomethane.
[0314] (2 2 S,2 3 S,2 4 S)-2 3 ,2 4 -Dihydroxy-5- 5 -methyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone (I-32)
[0315] LCMS calc.for C 22 H 20 D3F3N3O4[M+H] + :m / z=453.2;Found:452.9. 1 H NMR (400MHz, DMSO-d6) δ8.34(s,1H),7.50-7.40(m,2H),7.30-7.25(m,2H),5.74(d,J=4.0Hz,1H),5.41(d,J=8.0Hz,1H),5.30(d,J=8.0Hz,1H),4 .45-4.35(m,1H),4.10-4.00(m,1H),2.95-2.80(m,1H),2.70-2.55(m,2H ),2.45-2.40(m,1H),2.36(s,3H),2.30-2.20(m,1H),2.05-1.95(m,1H).
[0316] Example 7 Preparation of Compound I-24
[0317] Step 1: 5-Bromo-1-methyl-6-nitro-1H-indazole
[0318] 5-Bromo-6-nitro-1H-indazole (8.6 g, 35.5 mmol) and methanol (2.88 mL, 71.1 mmol) were dissolved in tetrahydrofuran (100 mL). Triphenylphosphine (18.6 g, 71.1 mmol) was then added to the solution. The reaction mixture was cooled to 0°C, and diisopropyl azodicarboxylate (14.4 g, 71.1 mmol) was added dropwise. The mixture was stirred at room temperature for 1 hour. After completion of the reaction, the mixture was extracted with ethyl acetate (100 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. Purification by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) afforded 5-bromo-1-methyl-6-nitro-1H-indazole (6.3 g, 69%). LCMS calculated for C8H7BrN3O2 [M+H] + :m / z=256.0;Found:NO.
[0319] Step 2: 5-allyl-1-methyl-6-nitro-1H-indazole
[0320] At room temperature, 5-bromo-1-methyl-6-nitro-1H-indazole (2.0 g, 7.81 mmol) and allylboronic acid pinacol ester (1.97 g, 11.7 mmol) were dissolved in dioxane (20 mL) and water (4 mL). 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (0.57 g, 0.78 mmol) and cesium carbonate (7.63 g, 23.4 mmol) were then added to the solution. The reaction system was purged with argon three times and heated to 100°C under an argon atmosphere with stirring for 5 hours. After completion of the reaction, the mixture was cooled, filtered, and the filtrate was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to yield a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether=0% to 30%) to give 5-allyl-1-methyl-6-nitro-1H-indazole (1.1 g, 65%). LCMS calc. for C 11 H 12 N3O2[M+H] + :m / z=218.1;Found:NO.
[0321] Step 3: 5-allyl-1-methyl-1H-indazol-6-amine
[0322] At room temperature, 5-allyl-1-methyl-6-nitro-1H-indazole (1.1 g, 5.06 mmol) was dissolved in ethanol (10 mL) and water (2 mL), and then iron powder (1.41 g, 25.3 mmol) and ammonium chloride (1.35 g, 25.3 mmol) were added to the solution. The temperature was raised to 80°C and stirred for 1 hour. After the reaction was completed, the temperature was lowered and filtered, and the filtrate was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 20%) to obtain 5-allyl-1-methyl-1H-indazole-6-amine (0.7 g, 73.8%). LCMS calc. for C 11 H 14 N3[M+H] + :m / z=188.1;Found:188.2.
[0323] Step 4: 1-(tert-Butyl)2-methyl(2S)-3,4-dihydroxypyrrolidine-1,2-dicarboxylate
[0324] 1-(tert-Butyl)-2-methyl-(S)-2,5-dihydro-1H-pyrrole-1,2-dicarboxylate (5.0 g, 22 mmol) was dissolved in acetonitrile (10 mL) and water (12.5 mL). To the reaction solution, citric acid monohydrate (4.62 g, 22 mmol), N-methylmorpholine-N-oxide (3.87 g, 33 mmol), and potassium osmate (0.41 g, 1.1 mmol) were slowly added. The reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, the residue was concentrated to obtain a residue, which was purified by silica gel column chromatography (methanol:dichloromethane = 0% to 10%) to obtain 1-(tert-butyl)-2-methyl (2S)-3,4-dihydroxypyrrolidine-1,2-dicarboxylate (5.7 g, 99%).
[0325] Step 5: (2S)-3,4-dihydroxypyrrolidine-2-carboxylic acid methyl ester
[0326] Dissolve 1-(tert-butyl)-2-methyl (2S)-3,4-dihydroxypyrrolidine-1,2-dicarboxylate (5.7 g, 21.8 mmol) in 4M hydrochloric acid in dioxane (20 mL). Stir the reaction mixture at room temperature for 3 hours. After completion of the reaction, concentrate to obtain the crude product, methyl (2S)-3,4-dihydroxypyrrolidine-2-carboxylate (3.5 g, 99.6%).
[0327] Step 6: (2S)-1-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroxypyrrolidine-2-carboxylic acid methyl ester
[0328] To a solution of (2S)-3,4-dihydroxypyrrolidine-2-carboxylic acid methyl ester (3.5 g, 21.7 mmol) in dioxane (40 mL) were added 2,6-dichloro-4-(trifluoromethyl)pyridine (7.04 g, 32.6 mmol) and N,N-diisopropylethylamine (15.1 mL, 86.9 mmol). The reaction solution was heated to 100°C for 5 hours. After the reaction was completed, water (30 mL) was added to the reaction solution and extracted with ethyl acetate (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (methanol:dichloromethane = 0% to 5%) to obtain (2S)-1-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroxypyrrolidine-2-carboxylic acid methyl ester (4.3 g, 58%). LCMS calc. for C 12 H 13 ClF3N2O4[M+H] + :m / z=341.0;Found:341.4.
[0329] Step 7: Methyl (3aS,4S,6aR)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylate: Dissolve (2S)-1-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroxypyrrolidine-2-carboxylate (4.3 g, 12.6 mmol) in acetone (30 mL). Add 2,2-dimethoxypropane (65.7 g, 631 mmol) and PPTS (3.81 g, 15.2 mmol). Heat the reaction mixture to 60°C and stir for 3 hours. Cool the reaction mixture to room temperature, add water (30 mL), and extract with ethyl acetate (50 mL x 3). Combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 10%) to give (3aS,4S,6aR)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid methyl ester (2.5 g, 52%). LCMS calc. for C 15 H 17 ClF3N2O4[M+H] + :m / z=381.0;Found:381.2.
[0330] Step 8: (3aS,4S,6aR)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid
[0331] Methyl (3aS,4S,6aR)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylate (1.0 g, 2.63 mmol) was dissolved in methanol (10 mL) and water (2 mL). Lithium hydroxide (90 mg, 3.94 mmol) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the pH was adjusted to 5 with 1N hydrochloric acid and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (methanol:dichloromethane = 0% to 10%) to give (3aS,4S,6aR)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid (0.8 g, 83%). LCMS calc. for C 14 H 15 ClF3N2O4[M+H] + :m / z=367.0;Found:367.3.
[0332] Step 9: (3aS,4S,6aR)-N-(5-allyl-1-methyl-1H-indazol-6-yl)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide
[0333] (3aS,4S,6aR)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid (0.8 g, 2.18 mmol) was dissolved in acetonitrile (10 mL) at room temperature. 5-allyl-1-methyl-1H-indazol-6-amine (0.49 g, 2.62 mmol), tetramethylchlorouronium hexafluorophosphate (0.73 g, 2.62 mmol), and 1-methylimidazole (0.43 mL, 5.45 mmol) were then added to the reaction mixture. The reaction mixture was stirred at room temperature for 2 hours. Water (20 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to give (3aS,4S,6aR)-N-(5-allyl-1-methyl-1H-indazol-6-yl)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (1.1 g, 94%). LCMS calc. for C 25 H 26 ClF3N5O3[M+H] + :m / z=536.2;Found:536.5.
[0334] Step 10: (3aS,4S,6aR)-N-(5-allyl-1-methyl-1H-indazol-6-yl)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N,2,2-trimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide
[0335] (3aS,4S,6aR)-N-(5-allyl-1-methyl-1H-indazol-6-yl)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (1.1 g, 2.05 mmol) was dissolved in N,N-dimethylformamide (10 mL). The reaction mixture was cooled to 0°C. Sodium hydride (0.12 g, 60%, 3.08 mmol) was slowly added to the reaction mixture. The reaction mixture was stirred at 0°C for 0.5 hour, followed by the addition of iodomethane (0.15 mL, 2.46 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 1 hour. Saturated aqueous ammonium chloride (30 mL) was added to the solution to quench the reaction, and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to obtain (3aS,4S,6aR)-N-(5-allyl-1-methyl-1H-indazol-6-yl)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N,2,2-trimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (0.75 g, 66.4%). LCMS calc. for C 26 H 28 ClF3N5O3[M+H] + :m / z=550.2;Found:550.5.
[0336] Step 11: (3aS,4S,6aR)-N-(5-allyl-1-methyl-1H-indazol-6-yl)-N,2,2-trimethyl-5-(4-(trifluoromethyl)-6-vinylpyridin-2-yl)tetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide
[0337] (3aS,4S,6aR)-N-(5-allyl-1-methyl-1H-indazol-6-yl)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N,2,2-trimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (0.75 g, 1.36 mmol) was dissolved in tetrahydrofuran (8 mL) and water (1 mL). Potassium ethylene trifluoroborate (0.27 g, 2.05 mmol), palladium dichloride (0.02 g, 0.14 mmol), triphenylphosphine (0.11 g, 0.41 mmol), and cesium carbonate (1.33 g, 4.09 mmol) were added to the reaction mixture. The reaction mixture was purged with argon three times and heated to 80°C under an argon atmosphere with stirring for 8 hours. After the reaction was completed, the reaction solution was cooled to room temperature, filtered, and water (20 mL) and ethyl acetate (30 mL) were added to the filtrate. The aqueous phase was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 30%) to obtain (3aS, 4S, 6aR) -N- (5-allyl-1-methyl-1H-indazol-6-yl) -N, 2, 2-trimethyl-5- (4- (trifluoromethyl) -6-vinylpyridin-2-yl) tetrahydro -4H- [1, 3] dioxazolo [4, 5-c] pyrrole-4-carboxamide (0.5 g, 67.7%). LCMS calc. for C 28 H 31 F3N5O3[M+H] + :m / z=542.2;Found:542.6.
[0338] Step 12: (2 3a R,2 6 S,2 6a S,Z)-2 2 ,2 2 ,5 1 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H,5 1 H-4-Aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-5(6,5)-indazole-1(2,6)-pyridinecyclooctane-7-ene-3-one
[0339] (3aS,4S,6aR)-N-(5-allyl-1-methyl-1H-indazol-6-yl)-N,2,2-trimethyl-5-(4-(trifluoromethyl)-6-vinylpyridin-2-yl)tetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (500 mg, 0.92 mmol) was dissolved in toluene (50 mL), and Grubbs 3rd generation catalyst (240 mg, 0.28 mmol) was added to the reaction solution. The reaction solution was heated to 85°C and stirred for 1 hour. After the reaction was completed, the mixture was concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 30%) to obtain (2 3a R,2 6 S,2 6a S,Z)-2 2 ,2 2 ,5 1 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H,5 1 H-4-Aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-5(6,5)-indazole-1(2,6)-pyridinecyclooctane-7-en-3-one (200 mg, 42.2%). LCMS calc. for C 26 H 27 F3N5O3[M+H] + :m / z=514.2;Found:514.3.
[0340] Step 13: (2 3a R,2 6 S,2 6a S)-2 2 ,2 2 ,5 1 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H,5 1 H-4-Aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-5(6,5)-indazole-1(2,6)-pyridinecyclooctan-3-one
[0341] (2 3a R,2 6 S,2 6a S,Z)-22 ,2 2 ,5 1 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H,5 1 H-4-aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-5(6,5)-indazole-1(2,6)-pyridinecyclooctane-7-ene-3-one (200 mg, 0.39 mmol) was dissolved in methanol (4 mL) and 10% wet palladium carbon (62 mg) was added. The reaction solution was replaced with hydrogen three times and reacted at room temperature under a hydrogen atmosphere for 3 hours. After the reaction was completed, the mixture was filtered and concentrated to obtain a crude product (2 3a R,2 6 S,2 6a S)-2 2 ,2 2 ,5 1 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H,5 1 H-4-Aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-5(6,5)-indazole-1(2,6)-pyridinecyclooctan-3-one (180 mg, 89.6%). LCMS calc. for C 26 H 29 F3N5O3[M+H] + :m / z=516.2;Found:516.3.
[0342] Step 14: (2 3a S,2 6 S,2 6a S)-2 2 ,2 2 ,5 1 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H,5 1 H-4-Aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-5(6,5)-indazole-1(2,6)-pyridinecyclooctane-24 ,3-diketone
[0343] (2 3a R,2 6 S,2 6a S)-2 2 ,2 2 ,5 1 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H,5 1 H-4-aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-5(6,5)-indazole-1(2,6)-pyridinecyclooctane-3-one (180 mg, 0.35 mmol) was dissolved in ethyl acetate (5 mL) and water (5 mL). Ruthenium trichloride hydrate (21.7 mg, 0.1 mmol) and sodium periodate (373 mg, 1.75 mmol) were added to the reaction solution and stirred at room temperature for 1 hour. After the reaction was completed, the mixture was filtered and the filtrate was extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 30%) to obtain (2 3a S,2 6 S,2 6a S)-2 2 ,2 2 ,5 1 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H,5 1 H-4-Aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-5(6,5)-indazole-1(2,6)-pyridinecyclooctane-2 4 ,3-dione (40 mg, 21.6%). LCMS calc. for C 26 H 27 F3N5O4[M+H] + :m / z=530.2;Found:530.5.
[0344] Step 15: (2 2 S,2 3 S,2 4 S)-2 3 ,24 -Dihydroxy-5- 1 ,4-dimethyl-1 4 -(trifluoromethyl)-5-( 1 H-4-Aza-5(6,5)-indazole-1(2,6)-pyridine-2(1,2)-pyrrolecyclooctane-2 5 ,3-diketone (I-24)
[0345] (2 3a S,2 6 S,2 6a S)-2 2 ,2 2 ,5 1 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H,5 1 H-4-Aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-5(6,5)-indazole-1(2,6)-pyridinecyclooctane-2 4 ,3-diketone (40 mg, 0.08 mmol) was dissolved in methanol (3 mL) and 4N dilute hydrochloric acid (2 mL) and stirred at 50°C for 5 hours. After cooling, the reaction solution was concentrated to obtain a residue. The residue was purified by preparative HPLC (column: XBridge Prep C18 5μm OBD 19*150mm; mobile phase: ACN-H2O (10mM NH4HCO3+0.2% NH3H2O) gradient: 0%-40%) to obtain (2 2 S,2 3 S,2 4 S)-2 3 ,2 4 -Dihydroxy-5- 1 ,4-dimethyl-1 4 -(trifluoromethyl)-5-( 1 H-4-Aza-5(6,5)-indazole-1(2,6)-pyridine-2(1,2)-pyrrolecyclooctane-2 5 ,3-dione (4.1 mg, 11.1%). LCMS calc. for C 23 H 23 F3N5O4[M+H] + :m / z=490.2;Found:489.9. 1H NMR (400MHz, DMSO-d6) δ8.38(s,1H),8.09(d,J=1.0Hz,1H),7.91(s,1H),7.86(s,1H),7.43(d,J=1.3Hz,1H),5.82(d,J=7. 9Hz,1H),5.60(d,J=4.4Hz,1H),4.95(s,1H),4.68-4.60(m,2H),4.07(s,3H),3.08(s,3H),2.95-2.69(m,4H),2.25(s,2H).
[0346] Example 8 Preparation of Compound I-33
[0347] Step 1: 4-Methyl-2-nitrobenzyl alcohol
[0348] 4-Methyl-2-nitro-benzoic acid (5 g, 27.6 mmol) was dissolved in tetrahydrofuran (30 mL) and 1 M borane tetrahydrofuran solution (36 mL, 36 mmol) was added. The reaction solution was stirred at 70 ° C for 2 hours. After the reaction was completed, it was poured into water and extracted with ethyl acetate (50 mL). The combined organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain 4-methyl-2-nitrobenzyl alcohol (4.33 g, 94%). LCMS calc. for C8H 10 NO3[M+H] + :m / z=168.1;Found:NO.
[0349] Step 2: 1-(Iodomethyl)-4-methyl-2-nitrobenzene
[0350] Imidazole (5.29 g, 77.7 mmol) was dissolved in dichloromethane (30 mL) and triphenylphosphine (8.15 g, 31.1 mmol) was added. The reaction solution was stirred at room temperature for 1 hour. Iodine (7.89 g, 31.1 mmol) was added in batches. Stirring was carried out at room temperature for 1 hour. 4-Methyl-2-nitrobenzyl alcohol (4.33 g, 25.9 mmol) was added in batches. Stirring was continued at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated and purified by silica gel column chromatography (ethyl acetate: petroleum ether = 5% to 20%) to give 1-(iodomethyl)-4-methyl-2-nitrobenzene (3.6 g, 50%). LCMS calc. for C8H9INO2[M+H] + :m / z=278.0;Found:NO。
[0351] Step 3: (3aS,4S,6aR)-5-(6-hydroxymethyl-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid methyl ester
[0352] Methyl (3aS,4S,6aR)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylate (3.0 g, 7.88 mmol) was dissolved in toluene (50 mL). 1,1-bis(diphenylphosphino)ferrocenepalladium dichloride (577 mg, 0.79 mmol) and triethylamine (2.28 mL, 15.8 mmol) were added to the reaction solution, and the reaction solution was stirred at 100°C for 16 hours. After the reaction is complete, a saturated potassium fluoride solution (30 mL) is added to the reaction solution and stirred for 1 hour. The reaction solution is filtered, and the filter cake is washed with ethyl acetate solution. The filtrate is washed twice with water. The organic phase is dried and concentrated, and purified by silica gel column chromatography (ethyl acetate:petroleum ether = 10% to 30%) to obtain (3aS,4S,6aR)-5-(6-hydroxymethyl-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid methyl ester (1.28 g, 43%). LCMS calc. for C 16 H 20 F3N2O5[M+H] + :m / z=377.1;Found:376.9.
[0353] Step 4: (3aS,4S,6aR)-2,2-dimethyl-5-(6-(((4-methyl-2-nitrobenzyl-)oxy)methyl)-4-(trifluoromethyl)pyridin-2-yl)-tetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid methyl ester
[0354] Methyl (3aS,4S,6aR)-5-(6-(hydroxymethyl)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylate (1.28 g, 3.4 mmol) was dissolved in toluene (20 mL). 1-(iodomethyl)-4-methyl-2-nitrobenzene (1.41 g, 5.1 mmol) and silver oxide (3.94 g, 17 mmol) were added to the reaction mixture. The reaction mixture was stirred at 80°C for 16 hours. After the reaction is completed, the reaction solution is filtered and concentrated, and purified by silica gel column chromatography (ethyl acetate:petroleum ether = 10% to 20%) to obtain (3aS,4S,6aR)-2,2-dimethyl-5-(6-(((4-methyl-2-nitrobenzyl-)oxy)methyl)-4-(trifluoromethyl)pyridin-2-yl)-tetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid methyl ester (1.36 g, 76%). LCMS calc. for C 24 H 27 F3N3O7[M+H] + :m / z=526.2;Found:525.9.
[0355] Step 5: (3aS,4S,6aR)-5-(6-(((2-amino-4-methylbenzyl)oxy)methyl)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid methyl ester
[0356] At room temperature, (3aS,4S,6aR)-2,2-dimethyl-5-(6-(((4-methyl-2-nitrobenzyl-)oxy)methyl)-4-(trifluoromethyl)pyridin-2-yl)-tetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid methyl ester (1.36 g, 2.58 mmol) was dissolved in methanol (15 mL). 10% wet palladium on carbon (0.14 g) was added to the reaction solution, and the reaction solution was stirred under a hydrogen atmosphere for 2 hours. After the reaction was completed, the mixture was filtered and concentrated to give (3aS,4S,6aR)-5-(6-(((2-amino-4-methylbenzyl)oxy)methyl)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid methyl ester (1.13 g, 88%). LCMS calc. for C 24 H 29 F3N3O5[M+H] + :m / z=496.2;Found:495.9.
[0357] Step 6: (3aS,4S,6aR)-5-(6-(((2-amino-4-methylbenzyl)oxy)methyl)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid
[0358] Methyl (3aS,4S,6aR)-5-(6-(((2-amino-4-methylbenzyl)oxy)methyl)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylate (1.13 g, 2.28 mmol) was dissolved in methanol (10 mL), and lithium hydroxide (0.11 g, 4.56 mmol) and water (2.5 mL) were added. The reaction solution was stirred at 40°C for 3 hours. After the reaction is completed, the reaction solution is concentrated and diluted with water, the pH is adjusted to 4-5 with 1M dilute hydrochloric acid, and extracted with ethyl acetate (30 mL). The organic phase is washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and purified by silica gel column chromatography (methanol:dichloromethane = 0% to 10%) to give (3aS,4S,6aR)-5-(6-(((2-amino-4-methylbenzyl)oxy)methyl)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid (1.01 g, 92%). LCMS calc. for C 23 H 27 F3N3O5[M+H] + :m / z=482.2;Found:481.9.
[0359] Step 7: (2 3a R,2 6 S,2 6a S)-2 2 ,2 2 ,2 5 -Trimethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-7-oxa-4-aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctan-3-one
[0360] (3aS,4S,6aR)-5-(6-(((2-amino-4-methylbenzyl)oxy)methyl)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid (1.01 g, 2.1 mmol) was dissolved in acetonitrile (20 mL), and tetramethylchlorouronium hexafluorophosphate (0.71 g, 2.52 mmol) and 1-methylimidazole (0.35 mL, 4.41 mmol) were added. The reaction solution was stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was poured into water and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (ethyl acetate: petroleum ether = 10% to 30%) to obtain (2 3a R,2 6 S,2 6a S)-2 2 ,2 2 ,2 5 -Trimethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-7-oxa-4-aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole 1(2,6)-pyridin-5(1,2)-benzocyclooctan-3-one (0.68 g, 70%). LCMS calc. for C 23 H 25 F3N3O4[M+H] + :m / z=464.2;Found:464.0.
[0361] Step 8: (2 3a R,2 6 S,2 6a S)-2 2 ,2 2 ,2 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-7-oxa-4-aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctan-3-one
[0362] (2 3a R,2 6 S,26a S)-2 2 ,2 2 ,2 5 -Trimethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-7-oxa-4-aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole 1(2,6)-pyridine-5(1,2)-benzocyclooctan-3-one (680 mg, 1.47 mmol) was dissolved in DMF (5 mL). After the reaction solution was cooled to 0°C, sodium hydride (60%, 45.8 mg, 1.91 mmol) was added. The reaction solution was stirred at 0°C for 30 minutes, and iodomethane (0.1 mL, 1.61 mmol) was added. The reaction solution was stirred at 25°C for 1 hour. After the reaction was completed, the reaction solution was poured into water and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and purified by silica gel column chromatography (ethyl acetate: petroleum ether = 10% to 30%) to obtain (2 3a R,2 6 S,2 6a S)-2 2 ,2 2 ,2 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-7-oxa-4-aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridin-5(1,2)-benzocyclooctan-3-one (499 mg, 71%). LCMS calc. for C 24 H 27 F3N3O4[M+H] + :m / z=478.2;Found:478.0.
[0363] Step 9: (2 3a S,2 6 S,2 6a S)-2 2 ,2 2 ,2 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,26a -Tetrahydro-2 4 H-7-oxa-4-aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 4 ,3-diketone
[0364] (2 3a R,2 6 S,2 6a S)-2 2 ,2 2 ,2 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-7-oxa-4-aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole 1(2,6)-pyridine-5(1,2)-benzocyclooctan-3-one (499 mg, 1.05 mmol) was dissolved in ethyl acetate (30 mL), and ruthenium trichloride hydrate (65 mg, 0.31 mmol), sodium periodate (1.12 g, 5.23 mmol) and water (30 mL) were added. The reaction solution was stirred at room temperature for 3 hours. After the reaction was completed, the reaction solution was filtered and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and purified by silica gel column chromatography (ethyl acetate: petroleum ether = 10% to 30%) to obtain (2 3a S,2 6 S,2 6a S)-2 2 ,2 2 ,2 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-7-oxa-4-aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 4 ,3-diketone (233 mg, 45%). LCMS calc. for C 24 H 25 F3N3O5[M+H] + :m / z=492.2;Found:492.1.
[0365] Step 10: (22 S, 2 3 S, 2 4 S)-2 3 ,2 4 -Dihydroxy-5- 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-7-oxa-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone (I-33)
[0366] (2 3a S,2 6 S,2 6a S)-2 2 ,2 2 ,2 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-7-oxa-4-aza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 4 ,3-diketone (233 mg, 0.47 mmol) was dissolved in methanol (3 mL), 4 M hydrochloric acid (3.00 mL) was added, and the reaction solution was stirred at 50 ° C for 3 hours. After the reaction was completed, the reaction solution was concentrated and subjected to preparative HPLC (XBridge Prep C18 5μm OBD 19*150mm; mobile phase: ACN-H2O (0.1% NH4HCO3) gradient: 40%-95%) and supercritical fluid chromatography IC-H (0.46cm ID×15cm L) ((CO2:MeOH (0.05% DEA)=70:30) to obtain (2 2 S, 2 3 S, 2 4 S)-2 3 ,2 4 -Dihydroxy-5- 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-7-oxa-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-dione (10 mg, 5%). LCMS calc. for C 21 H 21 F3N3O5[M+H] + :m / z=452.1;Found:451.9;1 H NMR (400MHz, DMSO-d6) δ8.45 (s, 1H), 7.53 (d, J = 7.9Hz, 1H), 7.42 (s, 1H), 7. 34(s,1H),7.31(d,J=8.0Hz,1H),5.89(d,J=7.8Hz,1H),5.49(d,J=4.9Hz,1 H),4.91-4.78(m,2H),4.75(d,J=10.8Hz,1H),4.70(s,1H),4.59(d,J=10.8 Hz,1H),4.57-4.53(m,1H),4.46(t,J=5.1Hz,1H),3.01(s,3H),2.36(s,3H).
[0367] Example 9 Preparation of Compound I-36
[0368] Step 1: 1-allyl-4-methyl-2-nitrobenzene
[0369] 1-Bromo-4-methyl-2-nitrobenzene (6.0 g, 27.8 mmol) was dissolved in tetrahydrofuran (20 mL), and water (2 mL), 4,4,5,5-tetramethyl-2-prop-2-enyl-1,3,2-dioxaborolane (7.0 g, 41.7 mmol), palladium dichloride (1.02 g, 1.39 mmol), triphenylphosphine (0.99 g, 3.78 mmol), and potassium carbonate (11.5 g, 83.3 mmol) were added. The reaction mixture was stirred at 100°C for 16 hours. After the reaction was complete, the reaction mixture was concentrated and purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 5%) to obtain 1-allyl-4-methyl-2-nitrobenzene (4.8 g, 83%). LCMS calculation for C 10 H 12 NO2[M+H] + :m / z=178.1;Found:NO.
[0370] Step 2: 2-allyl-5-methylaniline
[0371] 1-Allyl-4-methyl-2-nitrobenzene (4.8 g, 27.1 mmol) was dissolved in ethanol (20 mL), and water (25 mL), iron powder (7.6 g, 136 mmol), and ammonium chloride (7.3 g, 136 mmol) were added. The reaction solution was stirred at 80°C for 1 hour. After the reaction was completed, the reaction solution was diluted with ethyl acetate, filtered, and washed with water. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. 2-allyl-5-methylaniline (2.18 g, 54%) was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 10%). LCMS calculation for C 10 H 14 N[M+H] + :m / z=148.1;Found:148.2.
[0372] Step 3: (2S,3R)-2-((2-allyl-5-methylphenyl)carbamoyl)-3-hydroxypyrrolidine-1-carboxylic acid tert-butyl ester
[0373] 2-Allyl-5-methylaniline (0.6 g, 4.08 mmol) was dissolved in acetonitrile (10 mL), and (2S,3R)-1-(tert-butoxycarbonyl)-3-hydroxypyrrolidine-2-carboxylic acid (0.94 g, 4.08 mol), tetramethylchlorouronium hexafluorophosphate (1.72 g, 6.11 mmol), and 1-methylimidazole (1.0 g, 12.2 mmol) were added. The reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was poured into water and extracted with ethyl acetate (30 mL). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (ethyl acetate:petroleum ether = 10% to 50%) to obtain tert-butyl (2S,3R)-2-((2-allyl-5-methylphenyl)carbamoyl)-3-hydroxypyrrolidine-1-carboxylate (1.03 g, 70%). LCMS calc.for C 20 H 29 N2O4[M+H]+:m / z=361.2; Found: 361.3;
[0374] Step 4: (tert-Butyl(2S,3R)-2-((2-allyl-5-methylphenyl)carbamoyl)-3-((tert-butyldimethylsilyl)oxy)pyrrolidine-1-carboxylate
[0375] Dissolve tert-butyl (2S,3R)-2-((2-allyl-5-methylphenyl)carbamoyl)-3-hydroxypyrrolidine-1-carboxylate (1.03 g, 2.87 mmol) in dichloromethane (15 mL), add tert-butyldimethylsilyl chloride (0.6 mL, 3.44 mmol) and imidazole (0.59 g, 8.61 mmol). Stir the reaction mixture at room temperature for 1 hour. After the reaction was completed, the reaction solution was poured into water (30 mL) and extracted with ethyl acetate (50 mL). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (ethyl acetate: petroleum ether = 10% to 30%) to give (tert-butyl (2S, 3R)-2-((2-allyl-5-methylphenyl)carbamoyl)-3-((tert-butyldimethylsilyl)oxy)pyrrolidine-1-carboxylate (1.25 g, 92%). LCMS calc. for C 26 H 43 N2O4Si[M+H] + :m / z=475.3;Found:475.3.
[0376] Step 5: tert-Butyl (2S, 3R)-2-((2-allyl-5-methylphenyl)(methyl)carbamoyl)-3-((tert-butyldimethylsilyl)oxy)pyrrolidine-1-carboxylate
[0377] (tert-Butyl (2S, 3R)-2-((2-allyl-5-methylphenyl)carbamoyl)-3-((tert-butyldimethylsilyl)oxy)pyrrolidine-1-carboxylate (1.18 g, 2.49 mmol) was dissolved in DMF (10 mL). The reaction solution was cooled to 0°C, and sodium hydride (60%, 90 mg, 3.37 mmol) was added. After stirring for 30 minutes, iodomethane (390 mg, 3.73 mmol) was added, and the reaction solution was stirred at room temperature for 1 hour. After the reaction was completed, it was poured into a saturated aqueous ammonium chloride solution (100 mL) and extracted with ethyl acetate (30 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (ethyl acetate: petroleum ether = 10% to 30%) to obtain tert-butyl (2S, 3R)- 2-((2-allyl-5-methylphenyl)(methyl)carbamoyl)-3-((tert-butyldimethylsilyl)oxy)pyrrolidine-1-carboxylate (1.16 g, 95%). LCMS calc. for C 27 H 45 N2O4Si[M+H] + :m / z=489.3;Found:489.5.
[0378] Step 6: (2S,3R)-N-(2-allyl-5-methylphenyl)-3-((tert-butyldimethylsilyl)oxy)-N-methylpyrrolidine-2-carboxamide
[0379] Tert-butyl (2S,3R)-2-((2-allyl-5-methylphenyl)(methyl)carbamoyl)-3-((tert-butyldimethylsilyl)oxy)pyrrolidine-1-carboxylate (1.16 g, 2.37 mmol) was dissolved in dichloromethane (20 mL), zinc bromide (1.6 g, 7.12 mmol) was added, and the reaction solution was stirred at room temperature for 1 hour. The reaction solution was purified by silica gel column chromatography (methanol:dichloromethane = 0% to 10%) to give (2S,3R)-N-(2-allyl-5-methylphenyl)-3-((tert-butyldimethylsilyl)oxy)-N-methylpyrrolidine-2-carboxamide (0.91 g, 98%). LCMS calc. for C 22 H 37 N2O2Si[M+H] + :m / z=389.3;Found:389.5;
[0380] Step 7: (2S,3R)-N-(2-allyl-5-methylphenyl)-3-((tert-butyldimethylsilyl)oxy)-1-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N-methylpyrrolidine-2-carboxamide
[0381] To a solution of (2S,3R)-N-(2-allyl-5-methylphenyl)-3-((tert-butyldimethylsilyl)oxy)-N-methylpyrrolidine-2-carboxamide (0.91 g, 2.34 mmol) in N,N-dimethylformamide (5 mL) was added N,N-diisopropylethylamine (0.91 g, 7.02 mmol) and 2,6-dichloro-4-(trifluoromethyl)pyridine (0.61 g, 2.81 mmol). The reaction solution was stirred at 80°C for 1 hour. After the reaction was completed, the reaction solution was poured into water (30 mL) and extracted with ethyl acetate (30 mL x 3). The organic phases were combined and washed with saturated brine. The organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. Then, the mixture was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 10% to 50%) to obtain (2S,3R)-N-(2-allyl-5-methylphenyl)-3-((tert-butyldimethylsilyl)oxy)-1-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N-methylpyrrolidine-2-carboxamide (1.06 g, 80%). LCMS calc. for C 28 H 38 ClF3N3O2Si[M+H] +:m / z=568.2;Found:568.3.
[0382] Step 8: (2S,3R)-N-(2-allyl-5-methylphenyl)-3-((tert-butyldimethylsilyl)oxy)-N-methyl-1-(4-(trifluoromethyl)-6-vinylpyridin-2-yl)pyrrolidine-2-carboxamide
[0383] (2S,3R)-N-(2-allyl-5-methylphenyl)-3-((tert-butyldimethylsilyl)oxy)-1-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N-methylpyrrolidine-2-carboxamide (1.06 g, 1.87 mmol) was dissolved in tetrahydrofuran (10 mL), and water (1 mL), palladium dichloride (0.03 g, 0.19 mmol), triphenylphosphine (0.15 g, 0.56 mmol), cesium carbonate (1.83 g, 5.61 mmol) and potassium ethylene trifluoroborate (0.38 g, 2.8 mmol) were added, and the reaction solution was stirred at 80 ° C for 6 hours. After the reaction is completed, the mixture is concentrated and purified by silica gel column chromatography (ethyl acetate:petroleum ether = 10% to 30%) to obtain (2S,3R)-N-(2-allyl-5-methylphenyl)-3-((tert-butyldimethylsilyl)oxy)-N-methyl-1-(4-(trifluoromethyl)-6-vinylpyridin-2-yl)pyrrolidine-2-carboxamide (0.9 g, 86%). LCMS calc. for C 30 H 41 F3N3O2Si[M+H]+:m / z=560.3; Found:560.6.
[0384] Step 9: (2 2 S,2 3 R,Z)-2 3 -((tert-Butyldimethylsilyl)oxy)-5-(tert-butyldimethylsilyl)oxy)- 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-7-en-3-one
[0385] (2S,3R)-N-(2-allyl-5-methylphenyl)-3-((tert-butyldimethylsilyl)oxy)-N-methyl-1-(4-(trifluoromethyl)-6-vinylpyridin-2-yl)pyrrolidine-2-carboxamide (0.9 g, 1.61 mmol) was dissolved in toluene (90 mL), and Grubbs third-generation catalyst (0.53 g, 0.6 mmol) was added. The reaction solution was stirred at 80°C for 1 hour. After the reaction was completed, the mixture was concentrated and purified by silica gel column chromatography (ethyl acetate: petroleum ether = 10% to 30%) to obtain (2 2 S,2 3 R,Z)-2 3 -((tert-Butyldimethylsilyl)oxy)-5-(tert-butyldimethylsilyl)oxy)- 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-7-en-3-one (0.53 g, 83%). LCMS calc.for C 28 H 37 F3N3O2Si[M+H] + :m / z=532.3;Found:532.6.
[0386] Step 10: (2 2 S,2 3 R)-2 3 -((tert-Butyldimethylsilyl)oxy)-5-(tert-butyldimethylsilyl)oxy)- 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidino-5(1,2)-benzocyclooctan-3-one
[0387] (2 2 S,2 3 R,Z)-2 3 -((tert-Butyldimethylsilyl)oxy)-5-(tert-butyldimethylsilyl)oxy)- 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-7-ene-3-one (0.53 g, 1 mmol) was dissolved in methanol (15 mL) and 10% wet palladium carbon (0.05 g, 0.5 mmol) was added. The reaction solution was stirred at room temperature under a hydrogen atmosphere for 1 hour. After the reaction was completed, it was filtered and concentrated to obtain (2 2 S,2 3 R)-2 3 -((tert-Butyldimethylsilyl)oxy)-5-(tert-butyldimethylsilyl)oxy)- 5 ,4-dimethyl-14 -(Trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctan-3-one (0.5 g, 94%). LCMS calc. for C 28 H 39 F3N3O2Si[M+H] + :m / z=534.3;Found:534.4.
[0388] Step 11: (2 2 S,2 3 R)-2 3 -Hydroxy-5 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctan-3-one (I-36)
[0389] (2 2 S,2 3 R)-2 3 -((tert-Butyldimethylsilyl)oxy)-5-(tert-butyldimethylsilyl)oxy)- 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctan-3-one (0.2 g, 0.37 mmol) was dissolved in 4N hydrochloric acid dioxane (5 mL) solution and stirred at room temperature for 1 hour. After the reaction was completed, it was purified by preparative HPLC (XBridge Prep C18 5μm OBD 19*150mm; mobile phase: ACN-H2O (0.1% NH4HCO3) gradient: 40%-95%) to obtain (2 2 S,2 3 R)-2 3 -Hydroxy-5 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctan-3-one (45 mg, 29%). LCMS calc. for C 22 H 25 F3N3O2[M+H] + :m / z=420.2;Found:420.0; 1H NMR (400MHz, DMSO-d6) δ7.35(d,J=7.8Hz,1H),7.24(d,J=1.8Hz,1H),7.18(d,J=8.0,1.8Hz,1 H),6.67(d,J=1.2Hz,1H),6.39(s,1H),5.51(d,J=5.6Hz,1H),4.75(d,J=7.6Hz,1H),4.39-4.2 6(m,1H),3.62-3.50(m,1H),3.28-3.20(m,1H),2.94(s,3H),2.85-2.75(m,1H),2.72-2.60(m, 2H),2.59-2.52(m,1H),2.48-2.40(m,1H),2.32(s,3H),2.22-2.12(m,2H),2.07-1.97(m,1H).
[0390] Example 10 Preparation of Compound I-34
[0391] Step 1: (2 2 S,2 3 R)-2 3 -((tert-Butyldimethylsilyl)oxy)-5-(tert-butyldimethylsilyl)oxy)- 5 ,4-dimethyl-1 4 -(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone
[0392] (2 2 S,2 3 R)-2 3 -((tert-Butyldimethylsilyl)oxy)-5-(tert-butyldimethylsilyl)oxy)- 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-3-one (0.38 g, 0.71 mmol) was dissolved in ethyl acetate (5 mL), and ruthenium trichloride hydrate (0.01 g, 0.07 mmol), sodium periodate (0.3 g, 1.42 mmol) and water (5 mL) were added. The reaction solution was stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was diluted with ethyl acetate (50 mL) and filtered. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and then purified by silica gel column chromatography (ethyl acetate: petroleum ether = 5% to 10%) to obtain (2 2 S,2 3 R)-2 3 -((tert-Butyldimethylsilyl)oxy)-5-(tert-butyldimethylsilyl)oxy)- 5,4-dimethyl-1 4 -(Trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone (0.38 g, 97%). LCMS calc. for C 28 H 37 F3N3O3Si[M+H] + :m / z=548.3;Found:548.6.
[0393] Step 2: (2 2 S,2 3 R)-2 3 -Hydroxy-5 5 ,4-dimethyl-1 4 -(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone (I-34)
[0394] (2 2 S,2 3 R)-2 3 -((tert-Butyldimethylsilyl)oxy)-5-(tert-butyldimethylsilyl)oxy)- 5 ,4-dimethyl-1 4 -(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone (0.38 g, 0.69 mmol) was dissolved in 4 M dioxane hydrochloride (20 mL), and the reaction solution was stirred at 50°C for 8 hours. After the reaction was completed, it was purified by preparative HPLC (XBridge Prep C18 5μm OBD 19*150mm; mobile phase: ACN-H2O (0.1% NH4HCO3) gradient: 40%-95%) to obtain (2 2 S,2 3 R)-2 3 -Hydroxy-5 5 ,4-dimethyl-1 4 -(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone (70 mg, 24%). LCMS calc. for C 22 H 23 F3N3O3[M+H] + :m / z=434.2;Found:434.0; 1H NMR(400MHz,DMSO-d6)δ8.40(s,1H),7.41(d,J=7.8Hz,1H),7.38(s,1H),7.3 2(d,J=1.9Hz,1H),7.24(d,J=7.8,1.9Hz,1H),5.96(d,J=5.7Hz,1H),5.24(d, J=8.1Hz,1H),4.63-4.50(m,1H),2.98(s,3H),2.99-2.82(m,2H),2.76-2.60( m,2H),2.62-2.50(m,2H),2.36(s,3H),2.34-2.25(m,1H),2.10-1.97(m,1H).
[0395] Example 11 Preparation of Compound I-37
[0396] The same synthetic route as compound I-36 was used, wherein the raw material in step three was replaced by (2S,3S)-1-(tert-butoxycarbonyl)-3-hydroxypyrrolidine-2-carboxylic acid instead of the original (2S,3R)-1-(tert-butoxycarbonyl)-3-hydroxypyrrolidine-2-carboxylic acid.
[0397] (2 2 S,2 3 S)-2 3 -Hydroxy-5 5 ,4-dimethyl-1 4 -(Trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctan-3-one (I-37)
[0398] LCMS calc.for C 22 H 25 F3N3O2[M+H] + :m / z=420.1;Found:420.1; 1H NMR(400MHz,DMSO-d6)δ7.37(d,J=7.9Hz,1H),7.20(dd,J=7.8,1.8Hz,1H),7.16–7.11(m,1H ),6.66(d,J=1.2Hz,1H),6.44(s,1H),5.15(d,J=4.9Hz,1H),4.54(s,1H),4.36(t,J=4.8Hz, 1H),3.61-3.51(m,1H),3.48-3.41(m,1H),2.95(s,3H),2.87-2.77(m,1H),2.74-2.64(m,2H ),2.62-2.55(m,1H),2.49-2.44(m,1H),2.32(s,3H),2.16-2.03(m,2H),1.97-1.86(m,1H).
[0399] Example 12 Preparation of Compound I-35
[0400] The same synthetic route as compound I-34 was used, and the starting intermediate was (2 2 S,2 3 S)-2 3 -((tert-Butyldimethylsilyl)oxy)-5-(tert-butyldimethylsilyl)oxy)- 5 ,4-dimethyl-1 4 -(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctan-3-one replaced the original (2 2 S,2 3 R)-2 3 -((tert-Butyldimethylsilyl)oxy)-5-(tert-butyldimethylsilyl)oxy)- 5 ,4-dimethyl-1 4 -(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidino-5(1,2)-benzocyclooctan-3-one.
[0401] (2 2 S,2 3 S)-2 3 -Hydroxy-5 5 ,4-dimethyl-1 4 -(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone (I-35)
[0402] LCMS calc.for C 22 H 23 F3N3O3[M+H] +:m / z=434.1;Found:434.3; 1 H NMR (400MHz, DMSO-d6) δ8.42(d,J=1.4Hz,1H),7.46-7.40(m,2H),7.29-7.24(m,2H),5.70(d,J=5.2Hz,1H),5.03(s,1H),4.44(t,J=5.5Hz,1H),3.1 4(dd,J=17.4,5.9Hz,1H),2.99(s,3H),2.93-2.87(m,1H),2.79-2.71(m,1 H),2.63-2.54(m,2H),2.39-2.33(m,4H),2.22(s,1H),2.16-2.06(m,1H).
[0403] Example 13 Preparation of Compound I-38
[0404] Step 1: tert-Butyl (2S,3R,4S)-2-((2-bromo-5-methylphenyl)carbamoyl)-3,4-dihydroxypyrrolidine-1-carboxylate
[0405] Tert-butyl (S)-2-((2-bromo-5-methylphenyl)carbamoyl)-2,5-dihydro-1H-pyrrole-1-carboxylate (7.6 g, 19.9 mmol) was dissolved in acetonitrile (68 mL) and water (16 mL). N-methylmorpholine-N-oxide (3.5 g, 29.9 mmol), potassium osmate (0.37 g, 1.0 mmol), and citric acid monohydrate (3.14 g, 15 mmol) were then added to the solution. The reaction mixture was stirred at room temperature under nitrogen for 3 hours. After completion of the reaction, the resulting mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (methanol:dichloromethane = 0% to 4%) to yield tert-butyl (2S,3R,4S)-2-((2-bromo-5-methylphenyl)carbamoyl)-3,4-dihydroxypyrrolidine-1-carboxylate (6.2 g, 47.4%). LCMS calc.for C 17 H 24 BrN2O5[M+H] + :m / z=415.1; Found:315.0[M-Boc+H] + .
[0406] Step 2: tert-Butyl (3aR, 4S, 6aS)-4-((2-bromo-5-methylphenyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate
[0407] At room temperature, 2,2-dimethoxypropane (94.1 g, 903 mmol) and pyridine p-toluenesulfonate (5.45 g, 21.7 mmol) were added to a solution of (tert-butyl (2S, 3R, 4S)-2-((2-bromo-5-methylphenyl)carbamoyl)-3,4-dihydroxypyrrolidine-1-carboxylate (7.5 g, 18.6 mmol) in acetone (200 mL). The reaction mixture was stirred under nitrogen atmosphere. The temperature was raised to 60°C and stirred for 3 hours. After the reaction was completed, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 0% to 30%) to obtain tert-butyl (3aR,4S,6aS)-4-((2-bromo-5-methylphenyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate (6.0 g, 73%). LCMS calc. for C 20 H 28 BrN2O5[M+H] + :m / z=455.1; Found:354.9[M-Boc+H] + .
[0408] Step 3: tert-Butyl (3aR, 4S, 6aS)-4-((2-bromo-5-methylphenyl)(methyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate
[0409] To a solution of tert-butyl (3aR,4S,6aS)-4-((2-bromo-5-methylphenyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate (3.2 g, 7.03 mmol) in N,N-dimethylformamide (30 mL) at 0°C was added sodium hydride (0.37 g, 60%, 9.14 mmol). The reaction mixture was stirred at 0°C for 0.5 hour, followed by the addition of iodomethane (2.0 g, 14.1 mmol) and continued stirring for 1 hour. The mixture was quenched by the addition of water (50 mL) and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed sequentially with water (30 mL) and saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 40%) to give tert-butyl (3aR,4S,6aS)-4-((2-bromo-5-methylphenyl)(methyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate (2.7 g, 81.8%). LCMS calc. for C 21 H 30 BrN2O5[M+H] +:m / z=469.1;Found:468.9.
[0410] Step 4: tert-Butyl (3aR, 4S, 6aS)-4-((2-allyl-5-methylphenyl)(methyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate
[0411] Tert-butyl (3aR, 4S, 6aS)-4-((2-bromo-5-methylphenyl)(methyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate (3.5 g, 7.46 mmol), 2-allyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.5 g, 14.9 mmol), and 1,1-bis(diphenylphosphino)ferrocenepalladium dichloride (546 mg, 0.75 mmol) were dissolved in a mixed solvent of dioxane (40 mL) and water (4 mL), and potassium carbonate (3.1 g, 22.4 mmol) was added. The mixture was stirred at 100 ° C for 3 hours under nitrogen protection. The mixture was cooled, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to obtain the compound tert-butyl (3aR, 4S, 6aS)-4-((2-allyl-5-methylphenyl)(methyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate (3.1 g, 96.6%). LCMS calc. for C 24 H 35 N2O5[M+H] + :m / z=431.3;Found:431.0.
[0412] Step 5: (3aR,4S,6aS)-N-(2-allyl-5-methylphenyl)-N,2,2-trimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide
[0413] Tert-butyl (3aR,4S,6aS)-4-((2-allyl-4-methylphenyl)(methyl)carbamoyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-5-carboxylate (3.0 g, 6.97 mmol) was dissolved in dichloromethane (20 mL), and zinc bromide (4.71 g, 20.9 mmol) was added. The reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated and purified by silica gel column chromatography (methanol:dichloromethane = 0% to 10%) to obtain (3aR,4S,6aS)-N-(2-allyl-5-methylphenyl)-N,2,2-trimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (3.2 g, crude product). LCMS calc. for C 19 H 27 N2O3[M+H] + :m / z=331.2;Found:331.1.
[0414] Step 6: (3aR,4S,6aS)-N-(2-allyl-4-methylphenyl)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N,2,2-trimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide
[0415] (3aR,4S,6aS)-N-(2-allyl-5-methylphenyl)-N,2,2-trimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (3.2 g, 9.68 mmol) and 2,6-dichloro-4-(trifluoromethyl)pyridine (4.18 g, 19.4 mmol) were dissolved in DMF (20 mL), and N,N-diisopropylethylamine (5.0 g, 38.7 mmol) was added. The mixture was stirred at 120°C for 2 hours. After cooling, the reaction was quenched by the addition of water (30 mL). The aqueous phase was extracted twice with ethyl acetate (30 mL). The combined organic phases were washed sequentially with water (30 mL) and saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 40%) to give a yellow oily product (3aR,4S,6aS)-N-(2-allyl-5-methylphenyl)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N,2,2-trimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (3.05 g, 60.7%). LCMS calc. for C 25 H 28 ClF3N3O3[M+H] + :m / z=510.2;Found:510.4.
[0416] Step 7: (3aR,4S,6aS)-N-(2-allyl-4-methylphenyl)-N,2,2-trimethyl-5-(4-(trifluoromethyl)-6-vinylpyridin-2-yl)tetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide
[0417] (3aR,4S,6aS)-N-(2-allyl-5-methylphenyl)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-N,2,2-trimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (1.8 g, 3.53 mmol) was dissolved in tetrahydrofuran (25 mL) and water (3 mL). Potassium ethylene trifluoroborate (946 mg, 7.06 mmol), palladium dichloride (62.6 mg, 0.35 mmol), triphenylphosphine (278 mg, 1.06 mmol), and cesium carbonate (3.45 g, 10.6 mmol) were added at 20°C. The mixture was stirred at 90°C for 2 hours. After cooling, the reaction solution was concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to give (3aR,4S,6aS)-N-(2-allyl-5-methylphenyl)-N,2,2-trimethyl-5-(4-(trifluoromethyl)-6-vinylpyridin-2-yl)tetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (1.6 g, 90.4%). LCMS calc. for C 27 H 31 F3N3O3[M+H] + :m / z=502.2;Found:502.0.
[0418] Step 8: (2 3a R,2 4 S,2 6a S,Z)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-Aza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-phenylcyclooctane-7-ene-3-one
[0419] Under nitrogen protection, (3aR, 4S, 6aS) -N- (2-allyl-5-methylphenyl) -N, 2, 2-trimethyl-5- (4- (trifluoromethyl) -6-vinylpyridin-2-yl) tetrahydro -4H- [1, 3] dioxazolo [4, 5-c] pyrrole -4-carboxamide (1.6g, 3.19mmol) was dissolved in toluene (150mL), and then Grubbs third generation catalyst (0.85g, 0.96mmol) was added, and then stirred at 80 ° C for 1 hour under nitrogen protection. After cooling, the reaction solution was filtered, and the filtrate was concentrated to obtain a crude product, which was subjected to silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 30%) to obtain (2 3a R,2 4 S,2 6a S,Z)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-Aza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-7-en-3-one (800 mg, 52.9%). LCMS calc. for C 25 H 27 F3N3O3[M+H] + :m / z=474.2;Found:474.4.
[0420] Step 9: (2 3a R,2 4 S,2 6a S)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-Aza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridin-5(1,2)-benzocyclooctan-3-one
[0421] (2 3a R,2 4 S,2 6a S,Z)-2 2 ,2 2 ,55 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-aza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-7-ene-3-one (800 mg, 1.69 mmol) was dissolved in methanol (50 mL), and 10% wet palladium carbon (538 mg, 0.51 mmol) was added. The reaction solution was stirred under a hydrogen (15 Psi) atmosphere for 1 hour. The reaction solution was filtered, and the filtrate was concentrated to obtain a crude product which was subjected to column chromatography (ethyl acetate: petroleum ether = 0% to 30%) to obtain (2 3a R,2 4 S,2 6a S)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-Aza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridin-5(1,2)-benzocyclooctan-3-one (800 mg, 99.6%). LCMS calc. for C 25 H 29 F3N3O3[M+H] + :m / z=476.2;Found:476.4.
[0422] Step 10: (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-Aza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-phenylcyclooctane-2 6 ,3-diketone
[0423] (23a R,2 4 S,2 6a S)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-aza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctan-3-one (800 mg, 1.68 mmol) was dissolved in ethyl acetate (50 mL) and water (50 mL). Ruthenium trichloride hydrate (105 mg, 0.5 mmol) and sodium periodate (1.8 g, 8.41 mmol) were added at 20°C. The mixture was stirred at 20°C for 1 hour. The reaction solution was diluted with water (50 mL), the aqueous phase was extracted with ethyl acetate (50 mL x 2), the combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 30%) to obtain a yellow oil (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(Trifluoromethyl)-2- 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-Aza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-phenylcyclooctane-2 6 ,3-dione (350 mg, 42.5%). LCMS calc. for C 25 H 26 F3N3O4[M+H] + :m / z=490.2;Found:490.3.
[0424] Step 11: (2 2 S,2 3 R,2 4 R)-2 3 ,2 4 -Dihydroxy-5- 5 ,4-dimethyl-1 4-(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone (I-38)
[0425] (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 ,4-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4-Aza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 6 ,3-diketone (350 mg, 0.71 mmol) was dissolved in methanol (10 mL) and 4N dilute hydrochloric acid (3 mL) and stirred at 50 ° C for 3 hours. After cooling, the reaction solution was concentrated to obtain a residue. The residue was purified by preparative HPLC (Column: XBridge Prep C18 5μm OBD 19*150mm, Mobile phase: A (10mM NH4HCO3 in Water) B (ACN), 0-3min: 40% B, 3-7min: 40-85% B, 7-11min: 85-90% B, 11-13min: 90-95% B, 13-16min: 95% B, 16-16.5min: 95-40% B, 16.5-21min: 40% B, Flow = 15mL / min) to obtain (2 2 S,2 3 R,2 4 R)-2 3 ,2 4 -Dihydroxy-5- 5 ,4-dimethyl-1 4 -(trifluoromethyl)-4-aza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-dione (70 mg, 21.7%). LCMS calc. for C 22 H 23 F3N3O4[M+H] + :m / z=450.2;Found:450.0. 1H NMR (400MHz, DMSO-d6) δ8.39(s,1H),7.50-7.40(m,2H),7.35-7.25(m,2H),5.84(d,J=8.0Hz,1H),5.51(d,J=8.8Hz,1H),4.95(s,1H),4.6 5-4.60(m,1H),4.50-4.40(m,1H),3.02(s,3H),2.90-2.80(m,1H),2.80-2.70(m,2H),2.65-2.55(m,1H),2.35(s,3H),2.25-2.10(m,2H).
[0426] Example 14 Preparation of Compound I-59
[0427] Step 1: 1-(tert-butyl) 2-methyl (2S)-3,4-dihydroxypyrrolidine-1,2-dicarboxylate
[0428] 1-(tert-Butyl)-2-methyl-(S)-2,5-dihydro-1H-pyrrole-1,2-dicarboxylate (5.0 g, 22 mmol) was dissolved in acetonitrile (10 mL) and water (12.5 mL). To the reaction solution, citric acid monohydrate (4.62 g, 22 mmol), N-methylmorpholine-N-oxide (3.87 g, 33 mmol), and potassium osmate (0.41 g, 1.1 mmol) were slowly added. The reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, the residue was concentrated to obtain a residue, which was purified by silica gel column chromatography (methanol:dichloromethane = 0% to 10%) to obtain 1-(tert-butyl)-2-methyl (2S)-3,4-dihydroxypyrrolidine-1,2-dicarboxylate (5.7 g, 99%).
[0429] Step 2: (2S)-3,4-dihydroxypyrrolidine-2-carboxylic acid methyl ester
[0430] Dissolve 1-(tert-butyl)-2-methyl (2S)-3,4-dihydroxypyrrolidine-1,2-dicarboxylate (5.7 g, 21.8 mmol) in 4M hydrochloric acid in dioxane (20 mL). Stir the reaction mixture at room temperature for 3 hours. After completion of the reaction, concentrate to obtain the crude product, methyl (2S)-3,4-dihydroxypyrrolidine-2-carboxylate (3.5 g, 99.6%).
[0431] Step 3: (2S)-1-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroxypyrrolidine-2-carboxylic acid methyl ester
[0432] To a solution of (2S)-3,4-dihydroxypyrrolidine-2-carboxylic acid methyl ester (3.5 g, 21.7 mmol) in dioxane (40 mL) were added 2,6-dichloro-4-(trifluoromethyl)pyridine (7.04 g, 32.6 mmol) and N,N-diisopropylethylamine (15.1 mL, 86.9 mmol). The reaction solution was heated to 100°C for 5 hours. After completion of the reaction, water (30 mL) was added to the reaction solution and extracted with ethyl acetate (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (methanol:dichloromethane = 0% to 5%) to obtain (2S)-1-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroxypyrrolidine-2-carboxylic acid methyl ester (4.3 g, 58%). LCMS calc. for C 12 H 13 ClF3N2O4[M+H] + :m / z=341.0;Found:341.4.
[0433] Step 4: Methyl (3aR,4S,6aS)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylate: Dissolve (2S)-1-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroxypyrrolidine-2-carboxylate (4.3 g, 12.6 mmol) in acetone (30 mL). Add 2,2-dimethoxypropane (65.7 g, 631 mmol) and pyridine p-toluenesulfonate (3.81 g, 15.2 mmol). Heat the reaction mixture to 60°C and stir for 3 hours. Cool the reaction mixture to room temperature, add water (30 mL), and extract with ethyl acetate (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 10%) to obtain (3aR,4S,6aS)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid methyl ester (2.1 g, 44%). LCMS calc. for C 15 H 17 ClF3N2O4[M+H] + :m / z=381.0;Found:381.2.
[0434] Step 5: (3aR,4S,6aS)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid
[0435] Methyl (3aR,4S,6aS)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylate (1.0 g, 2.63 mmol) was dissolved in methanol (10 mL) and water (2 mL). Lithium hydroxide (90 mg, 3.94 mmol) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, the pH was adjusted to 5 with 1N hydrochloric acid and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (methanol:dichloromethane = 0% to 10%) to give (3aR,4S,6aS)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid (0.8 g, 83%). LCMS calc. for C 14 H 15 ClF3N2O4[M+H] + :m / z=367.0; Found:367.3.
[0436] Step 6: (3aR,4S,6aS)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid benzyl ester
[0437] (3aR,4S,6aS)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid (10.6 g, 28.9 mmol) was dissolved in N,N-dimethylformamide (80 mL). Potassium carbonate (7.99 g, 57.8 mmol) was then added to the solution. The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was quenched with water (200 mL) and extracted with ethyl acetate (150 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to give (3aR,4S,6aS)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid benzyl ester (11.0 g, 83%). LCMS calc. for C21 H 21 ClF3N2O4[M+H] + :m / z=457.1;Found:457.2.
[0438] Step 7: (3aR,4S,6aS)-5-(6-((tert-butoxycarbonyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid benzyl ester
[0439] Benzyl (3aR,4S,6aS)-5-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylate (11.0 g, 24.1 mmol) was dissolved in dioxane (100 mL). T-butyl carbamate (4.23 g, 36.1 mmol), Sphos (1.98 g, 4.82 mmol), palladium acetate (0.54 g, 2.41 mmol), and cesium carbonate (23.5 g, 72.2 mmol) were then added to the solution. The argon atmosphere was replaced three times, and the temperature was raised to 90°C with stirring for 1 hour. After completion of the reaction, the reaction was quenched by the addition of water (100 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was slurried with petroleum ether to give benzyl (3aR,4S,6aS)-5-(6-((tert-butoxycarbonyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylate (8.9 g, 69%). LCMS calc. for C 26 H 31 F3N3O6[M+H] + :m / z=538.2; Found:482.4[M+H-56] + .
[0440] Step 8: (3aR,4S,6aR)-5-(6-((tert-butoxycarbonyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid benzyl ester
[0441] Benzyl (3aR,4S,6aS)-5-(6-((tert-butoxycarbonyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylate (8.9 g, 16.6 mmol) was dissolved in ethyl acetate (90 mL) and water (80 mL). Sodium periodate (17.7 g, 82.8 mmol) was added to the reaction solution. The reaction solution was cooled to 0°C. Ruthenium trichloride (1.03 g, 22.0 mmol) dissolved in water (10 mL) was then slowly added to the reaction solution. The reaction solution was warmed to room temperature and stirred for 3 hours. After completion of the reaction, the reaction solution was filtered, and the filtrate was extracted with ethyl acetate (100 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to give (3aR,4S,6aR)-5-(6-((tert-butoxycarbonyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid benzyl ester (4.0 g, 44%). LCMS calc. for C 26 H 29 F3N3O7[M+H] + :m / z=552.2; Found:496.2[M+H-56] + .
[0442] Step 9: (3aR,4S,6aR)-5-(6-amino-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid benzyl ester
[0443] Benzyl (3aR,4S,6aR)-5-(6-((tert-butoxycarbonyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylate (4.0 g, 7.25 mmol) was dissolved in dichloromethane (20 mL). Zinc bromide (4.9 g, 21.8 mmol) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, water (30 mL) was added to quench the reaction and the mixture was extracted with ethyl acetate (100 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to give (3aR,4S,6aR)-5-(6-amino-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid benzyl ester (2.5 g, 76%). LCMS calc. for C 21H 21 F3N3O5[M+H] + :m / z=452.1;Found:452.2.
[0444] Step 10: (3aR,4S,6aR)-2,2-dimethyl-5-(6-((4-methyl-2-nitrophenylethyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid benzyl ester
[0445] Benzyl (3aR,4S,6aR)-5-(6-amino-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylate (2.5 g, 5.54 mmol) was dissolved in methanol (20 mL) and acetic acid (5 mL). 2-(4-methyl-2-nitrophenyl)acetaldehyde (1.49 g, 8.31 mmol) was added to the reaction solution. The reaction solution was stirred at room temperature for 10 minutes. Sodium cyanoborohydride (0.75 g, 11.1 mmol) was added to the reaction solution, and the reaction solution was stirred at room temperature for 0.5 hours. After completion of the reaction, the reaction was quenched with saturated sodium bicarbonate solution and extracted with ethyl acetate (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to give (3aR,4S,6aR)-2,2-dimethyl-5-(6-((4-methyl-2-nitrophenylethyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid benzyl ester (2.0 g, 58%). LCMS calc. for C 30 H 30 F3N4O7[M+H] + :m / z=615.2;Found:615.1.
[0446] Step 11: (3aR,4S,6aR)-5-(6-((2-amino-4-methylphenethyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid
[0447] Benzyl (3aR,4S,6aR)-2,2-dimethyl-5-(6-((4-methyl-2-nitrophenylethyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylate (1.2 g, 1.95 mmol) was dissolved in ethyl acetate (10 mL) and tetrahydrofuran (5 mL). 10% wet palladium on carbon (0.6 g) was added to the reaction solution. The reaction solution was replaced with hydrogen three times and stirred at room temperature under a hydrogen atmosphere for 3 hours. After the reaction was completed, the mixture was filtered and the filtrate was concentrated to give (3aR,4S,6aR)-5-(6-((2-amino-4-methylphenethyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid (0.8 g, 83%). LCMS calc. for C 23 H 26 F3N4O5[M+H] + :m / z=495.2;Found:495.1.
[0448] Step 12: (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5-trimethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 6 ,3-diketone
[0449] (3aR,4S,6aR)-5-(6-((2-amino-4-methylphenethyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid (0.8 g, 1.62 mmol) was dissolved in acetonitrile (8 mL), and tetramethylchlorouronium hexafluorophosphate (0.54 g, 1.94 mmol) and 1-methylimidazole (0.39 mL, 4.85 mmol) were added. The reaction solution was stirred at room temperature for 1 hour. After the reaction was completed, water (20 mL) was added to the reaction solution and extracted with ethyl acetate (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 50%) to obtain (23a R,2 4 S,2 6a R)-2 2 ,2 2 ,5-trimethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 6 ,3-diketone (0.6 g, 78%). LCMS calc. for C 23 H 24 F3N4O4[M+H] + :m / z=477.2;Found:477.2.
[0450] Step 13: (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 ,4,8-pentamethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctanone-2 6 ,3-diketone
[0451] (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5-trimethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 6,3-diketone (0.60g, 1.26mmol) was dissolved in N,N-dimethylformamide (5mL), the reaction solution was cooled to 0°C, sodium hydride (0.11g, 60%, 2.64mmol) was slowly added to the reaction solution, the reaction solution was stirred at 0°C for 0.5 hours, and then iodomethane (0.2mL, 3.15mmol) was added to the solution. The reaction solution was warmed to room temperature and stirred for 2 hours. Saturated aqueous ammonium chloride solution was added to the solution to quench the reaction, and extracted with ethyl acetate (30mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 30%) to obtain (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 ,4,8-pentamethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctanone-2 6 ,3-diketone (0.5 g, 78.7%). LCMS calc. for C 25 H 28 F3N4O4[M+H] + :m / z=505.2;Found:505.2.
[0452] Step 14: (2 2 S,2 3 R,2 4 R)-2 3 ,2 4 -Dihydroxy-5- 5 ,4,8-trimethyl-1 4 -(trifluoromethyl)-4,8-diaza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone
[0453] (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 ,4,8-pentamethyl-1 4 -(trifluoromethyl)-23a , 2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctanone-2 6 ,3-diketone (0.5 g, 0.99 mmol) was dissolved in methanol (3 mL) and 4N dilute hydrochloric acid (2 mL) and stirred at 50 ° C for 3 hours. After cooling, the reaction solution was concentrated to obtain a residue. The residue was purified by preparative HPLC (Column: Durashell C18 10 μm 21.2*250 mm Mobile phase: A (10 mM NH4HCO3 in Water) B (ACN) Initial: 40% B, 1-3 min: 60% B, 3-7 min: 60% B, 7-11 min: 60-95% B, 11-15 min: 95% B, 15-15.01 min: 95-40% B, 15.01-18 min: 40% B (Flow = 30 mL / min) to obtain (2 2 S,2 3 R,2 4 R)-2 3 ,2 4 -Dihydroxy-5- 5 ,4,8-trimethyl-1 4 -(trifluoromethyl)-4,8-diaza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone (220 mg, 47.8%). LCMS calc. for C 22 H 24 F3N4O4[M+H] + :m / z=465.2;Found:464.9. 1 H NMR (400MHz, DMSO-d6) δ7.74(s,1H),7.34-7.24(m,3H),6.60(s,1H),5.80(d,J=7.4Hz,1H),5.41(d,J=4.3Hz,1H),4.88(s,1H),4.47-4 .35(m,2H),3.70(dd,J=13.3,9.3Hz,1H),3.41(dd,J=13.3,9.4Hz,1H),3.14(s,3H),3.02-2.92(m,4H),2.58-2.53(m,1H),2.33(s,3H).
[0454] Example 15 Preparation of Compound I-60
[0455] Step 1: (3aR,4S,6aR)-5-(6-((tert-butoxycarbonyl)(4-methyl-2-nitrophenylethyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid benzyl ester
[0456] To a solution of benzyl (3aR,4S,6aR)-5-(6-((tert-butoxycarbonyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylate (2.9 g, 5.26 mmol) and 2-(4-methyl-2-nitrophenyl)ethan-1-ol (1.9 g, 10.5 mmol) in toluene (20 mL) was added cyanomethylenetri-n-butylphosphine (3.8 g, 15.8 mmol), and the reaction was stirred at 100 °C for 16 hours under nitrogen protection. The reaction mixture was cooled and concentrated under reduced pressure. The residual oil was purified on a silica gel column (ethyl acetate:petroleum ether = 0-30%) to obtain (3aR,4S,6aR)-5-(6-((tert-butoxycarbonyl)(4-methyl-2-nitrophenylethyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid benzyl ester (1.0 g, 26.6%). LCMS calc. for C 35 H 38 F3N4O9[M+H] + :m / z=715.3;Found:715.0.
[0457] Step 2: (3aR,4S,6aR)-5-(6-((2-amino-4-methylphenethyl)(tert-butoxycarbonyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid
[0458] Benzyl (3aR,4S,6aR)-5-(6-((tert-butoxycarbonyl)(4-methyl-2-nitrophenylethyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylate (1.0 g, 1.4 mmol) was dissolved in ethyl acetate (20 mL), and 10% wet palladium on carbon (1.0 g, 1.4 mmol) was added successively. 0g), the reaction solution was stirred under a hydrogen atmosphere at 20°C for 2 hours, the reaction solution was filtered, and the filtrate was concentrated under reduced pressure to give (3aR,4S,6aR)-5-(6-((2-amino-4-methylphenethyl)(tert-butoxycarbonyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid (850mg). LCMS calc. for C 28 H 34 F3N4O7[M+H] + :m / z=595.2;Found:595.1.
[0459] Step 3: tert-butyl (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 -Trimethyl-2 6 ,3-dicarbonyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-8-carboxylate
[0460] To (3aR,4S,6aR)-5-(6-((2-amino-4-methylphenethyl)(tert-butoxycarbonyl)amino)-4-(trifluoromethyl)pyridin-2-yl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid (850 mg, 1.43 mmol) was dissolved in acetonitrile (10 mL), tetramethyl chlorouronium hexafluorophosphate (602 mg, 2.14 mmol) and 1-methylimidazole (0.34 mL, 4.29 mmol) were added, and the reaction solution was stirred at 20°C for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column (ethyl acetate: petroleum ether = 0-30%) to obtain tert-butyl (2 3a R,2 4 S,26a R)-2 2 ,2 2 ,5 5 -Trimethyl-2 6 ,3-dicarbonyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-8-carboxylate (400 mg, 48.5%). LCMS calc. for C 28 H 32 F3N4O6[M+H] + :m / z=577.2;Found:577.1
[0461] Step 4: tert-butyl (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 -trimethyl-4-(methyl-d3)-2 6 ,3-dicarbonyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-8-carboxylate
[0462] To tert-butyl (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 -Trimethyl-2 6 ,3-dicarbonyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4To a solution of H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-8-carboxylate (400 mg, 0.69 mmol) in N,N-dimethylformamide (5 mL) was added sodium hydride (33.3 mg, 0.83 mmol, 60%). The reaction solution was stirred at 0°C for 0.25 hours. Deuterated iodomethane (151 mg, 1.04 mmol) was added to the reaction solution and stirring continued for 1 hour. After quenching with water (20 mL), the aqueous phase was extracted three times with ethyl acetate (15 mL). The combined organic phases were washed sequentially with water (30 mL) and saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 40%) to give tert-butyl (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 -trimethyl-4-(methyl-d3)-2 6 ,3-dicarbonyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-8-carboxylate (400 mg, 97.1%) LCMS calc.for C 29 H 31 D3F3N4O6[M+H] + :m / z=594.3;Found:594.1.
[0463] Step 5: (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 -trimethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctanone-26 ,3-diketone
[0464] To tert-butyl (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 -trimethyl-4-(methyl-d3)-2 6 ,3-dicarbonyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 To a solution of H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-8-carboxylate (400 mg, 0.67 mmol) in dichloromethane (5 mL) was added zinc bromide (455 mg, 2.02 mmol), and the reaction solution was stirred at 20°C for 1 hour. After quenching with water (30 mL), the aqueous phase was extracted three times with dichloromethane (20 mL), and the combined organic phases were washed with water (30 mL) and saturated brine (30 mL) in sequence, dried over anhydrous sodium sulfate, filtered and concentrated to obtain (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 -trimethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctanone-2 6 ,3-dione (250 mg, 75.2%), LCMS calc. for C 24 H 23 D3F3N4O4[M+H] + :m / z=494.2;Found:494.1
[0465] Step 6: (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5-8-Tetramethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctanone-2 6 ,3-diketone
[0466] To (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 -trimethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctanone-2 6 ,3-diketone (250mg, 0.11mmol) in N,N-dimethylformamide (5mL) was added with sodium hydride (30.4mg, 0.76mmol, 60%), and the reaction solution was stirred at 0°C for 0.25 hours. Iodomethane (141mg, 1.04mmol) was added to the reaction solution, and stirring was continued at 20°C for 3 hours. After quenching with water (20mL), the aqueous phase was extracted three times with ethyl acetate (30mL), and the combined organic phases were washed with water (30mL) and saturated brine (30mL) in turn, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 40%) to obtain (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 -8-Tetramethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctanone-2 6 ,3-dione (200 mg, 77.8%) LCMS calc.for C 25 H 25 D3F3N4O4[M+H] + :m / z=508.2;Found:508.1
[0467] Step 7: (2 2 S,2 3 R,2 4 R)-2 3 ,2 4 -Dihydroxy-5- 5 ,8-dimethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-4,8-diaza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone
[0468] To (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,5 5 -8-Tetramethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctanone-2 6, 3-diketone (200 mg, 0.39 mmol) in methanol (8 mL) was added with 4N dilute hydrochloric acid (4 mL), and the reaction solution was stirred at 50 ° C for 3 hours. After cooling, the reaction solution was concentrated to obtain a residue. The crude product was purified by preparative high performance liquid chromatography (Column: Durashell C18 10μm 21.2*250mm Mobile phase: A (10mM NH4HCO3 in Water) B (ACN) Initial: 40% B, 1-3min: 60% B, 3-7min: 60% B, 7-11min: 60-95% B, 11-15min: 95% B, 15-15.01min: 95-40% B, 15.01-18min: 40% B (Flow = 30mL / min) to obtain (2 2 S,2 3 R,2 4 R)-2 3 ,2 4 -Dihydroxy-5- 5 ,8-dimethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-4,8-diaza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-dione (80 mg, 43.4%) LCMS calc. for C 22 H 21 D3F3N4O4[M+H] + :m / z=468.2; Found:468.4 1 H NMR (400MHz, DMSO) δ7.74(s,1H),7.20-7.35(m,3H),6.60(s,1H),5.80(d,J=4.0Hz,1H),5.41(s,1H),4.88(s,1H),4.3 0-4.40(m,2H),3.70-3.80(m,1H),3.40-3.50(m,1H),3.14(s,3H),2.90-3.00(m,1H),2.50-2.55(m,1H),2.33(s,3H).
[0469] In the X-ray single crystal diffraction test, the Flack constant was 0.07 (13), C18 and C19 were R configuration, and C20 was S configuration.
[0470] Example 16 Preparation of Compound I-61
[0471] The same synthetic route as compound I-60 was used, except that the starting material of step 4 was replaced by deuterated iodomethane instead of iodomethane, and the starting material of step 6 was replaced by deuterated iodomethane instead of iodomethane.
[0472] (2 2 S,2 3 R,2 4 R)-2 3 ,2 4 -Dihydroxy-5- 5 ,4-dimethyl-8-(methyl-d3)-1 4 -(trifluoromethyl)-4,8-diaza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone
[0473] LCMS calc.for C 22 H 21 D3F3N4O4[M+H] + :m / z=468.2; Found:468.1;. 1 H NMR (400MHz, DMSO-d6) δ7.73 (s, 1H), 7.33-7.21 (m, 3H), 6.59 (s, 1H), 5.80 (d, J = 7.5Hz, 1H), 5.41 (d, J = 4.4Hz, 1H), 4.88(s,1H),4.48-4.30(m,2H),3.83-3.63(m,1H),3.47-3.36(m,1H),2.98(s,4H),2.59-2.52(m,1H),2.33(s,3H).
[0474] In the X-ray single crystal diffraction test, the Flack constant was 0.05(8), and the chirality of C3, C4 and C17 was S configuration.
[0475] Example 17 Preparation of Compound I-62
[0476] The same synthetic route as compound I-59 was used, except that the starting material in step 13 was replaced by deuterated iodomethane.
[0477] (2 2 S,2 3 R,2 4 R)-2 3 ,2 4 -Dihydroxy-5- 5 -methyl-4,8-di(methyl-d3)-1 4-(trifluoromethyl)-4,8-diaza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone
[0478] LCMS calc.for C 22 H 18 D6F3N4O4[M+H] + :m / z=471.2;Found:471.3. 1 H NMR (400MHz, DMSO-d6) δ7.73(d,J=1.1Hz,1H),7.34-7.22(m,3H),6.59(s,1H),5.80(d,J=7.5Hz,1H),5.41(d,J=4.4Hz,1H),4.88( s,1H),4.45-4.35(m,2H),3.71(dt,J=13.4,9.4Hz,1H),3.40(d,J=3.8Hz,1H),3.02-2.90(m,1H),2.58-2.53(m,1H),2.33(s,3H).
[0479] Example 18 Preparation of Compound I-63
[0480] The same synthetic route as compound I-59 was used, and the starting material in step 10 was replaced by 2-(4-(methyl-d3)-2-nitrophenyl)acetaldehyde.
[0481] (2 2 S,2 3 R,2 4 R)-2 3 ,2 4 -dihydroxy-4,8-dimethyl-5 5 -(methyl-d3)-1 4 -(trifluoromethyl)-4,8-diaza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone
[0482] LCMS calc.for for C 22 H 21 D3F3N4O4[M+H] + :m / z=468.2;Found:468.1; 1H NMR (400MHz, DMSO-d6) δ7.74(s,1H),7.39-7.17(m,3H),6.60(s,1H),5.80(d,J=7.5Hz,1H),5.42(d,J=4.4Hz,1H),4.8 8(s,1H),4.48-4.27(m,2H),3.79-3.61(m,1H),3.42-3.40(m,1H),3.14(s,3H),3.04-2.90(m,4H),2.57-2.53(m,1H).
[0483] Example 19 Preparation of Compound I-64
[0484] Step 1: tert-Butyl N-(6-bromo-4-(trifluoromethyl)pyridin-2-yl)carbamate
[0485] At room temperature, 2,6-dibromo-4-(trifluoromethyl)pyridine (9.6 g, 31.5 mmol) was dissolved in 2-methyltetrahydrofuran (40 mL). To this solution were added tert-butyl carbamate (5.5 g, 47.2 mmol), 1,1'-bis(di-tert-butylphosphino)ferrocenepalladium dichloride (2.1 g, 3.2 mmol), and sodium tert-butoxide (9.1 g, 94.5 mmol). The reaction mixture was stirred at 80°C under a nitrogen atmosphere for 2 hours. After completion, the reaction mixture was poured into water and extracted twice with ethyl acetate (100 mL). The organic phases were combined and washed twice with saturated brine (200 mL). The organic phases were dried, concentrated, and purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 10%) to yield tert-butyl N-(6-bromo-4-(trifluoromethyl)pyridin-2-yl)carbamate (7.0 g, 65.2%). LCMS calc.for C 11 H 13 BrF3N2O2[M+H] + :m / z=341.0; Found:285.0[M+H-56].
[0486] Step 2: 6-Bromo-4-(trifluoromethyl)pyridin-2-amine
[0487] At room temperature, tert-butyl N-(6-bromo-4-(trifluoromethyl)pyridin-2-yl)carbamate (7.0 g, 20.5 mmol) was dissolved in dichloromethane (10 mL) solution, and trifluoroacetic acid (5 mL) was added to the reaction solution, and the reaction solution was stirred at room temperature for 30 minutes. After the reaction was completed, a saturated aqueous sodium bicarbonate solution (100 mL) was poured into the reaction solution and extracted with ethyl acetate (50 mL x 2). The organic phases were combined, dried, concentrated, and purified by silica gel column chromatography (ethyl acetate: petroleum ether = 10% to 30%) to give 6-bromo-4-(trifluoromethyl)pyridin-2-amine (4.7 g, 95.0%). LCMS calc. for C6H5BrF3N2[M+H] + :m / z=241.0;Found:241.0.
[0488] Step 3: 6-Bromo-N-(4-methyl-2-nitro-phenyl)ethyl)-4-(trifluoromethyl)pyridin-2-amine
[0489] At room temperature, 6-bromo-4-(trifluoromethyl)pyridin-2-amine (4.7 g, 19.5 mmol) was dissolved in methanol (20 mL). 2-(4-methyl-2-nitro-phenyl)acetaldehyde (4.2 g, 23.4 mmol) and acetic acid (5 mL) were added to the solution. The reaction solution was stirred at room temperature for 1 hour, and sodium cyanoborohydride (1.6 g, 25.4 mmol) was added to the reaction solution in batches. After the reaction was completed, the reaction solution was poured into a saturated aqueous sodium bicarbonate solution (100 mL) and extracted with ethyl acetate (50 mL x 2). The organic phases were combined and washed with saturated brine (100 mL). The organic phases were dried and concentrated, and then purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 10%) to give 6-bromo-N-(4-methyl-2-nitro-phenyl)ethyl)-4-(trifluoromethyl)pyridin-2-amine (5.2 g, 65.5%). LCMS calc.for C 15 H 14 BrF3N3O2[M+H] + :m / z=404.0;Found:404.1;
[0490] Step 4: 6-Bromo-N-methyl-N-(4-methyl-2-nitrophenylethyl)-4-(trifluoromethyl)pyridin-2-amine
[0491] At room temperature, 6-bromo-N-(2-4-methyl-2-nitro-phenyl)ethyl)-4-(trifluoromethyl)pyridin-2-amine (3.7 g, 9.1 mmol) was dissolved in N,N-dimethylformamide (30 mL). After the reaction solution was cooled to 0°C, sodium hydride (0.26 g, 10.9 mmol) was added to the reaction solution. After the reaction solution was stirred at 0°C for 10 minutes, iodomethane (0.56 mL, 9.1 mmol) was added to the reaction solution, and the reaction solution was continued to stir at 0°C for 30 minutes. After the reaction was completed, the reaction solution was poured into a saturated aqueous ammonium chloride solution (100 mL) and extracted with ethyl acetate (50 mL x 2). The organic phases were combined and washed with saturated brine (100 mL). The organic phase was dried and concentrated to give 6-bromo-N-methyl-N-(4-methyl-2-nitrophenylethyl)-4-(trifluoromethyl)pyridin-2-amine (3.7 g, 96.7%). LCMS calc. for C 16 H 16 BrF3N3O2[M+H] + :m / z=418.0;Found:418.1
[0492] Step 5: N-(2-amino-4-methylphenethyl)-6-bromo-N-methyl-4-(trifluoromethyl)pyridin-2-amine
[0493] At room temperature, 6-bromo-N-methyl-N-(4-methyl-2-nitrophenylethyl)-4-(trifluoromethyl)pyridin-2-amine (3.66 g, 8.75 mmol) was dissolved in ethanol (40 mL), and iron powder (2.44 g, 43.8 mmol), ammonium chloride (2.34 g, 43.8 mmol) and water (10 mL) were added to the reaction solution. The reaction solution was stirred at 60°C for 1 hour. After the reaction was completed, the reaction solution was cooled to room temperature and ethyl acetate (200 mL) was added to the reaction solution. The reaction solution was filtered through celite, and the filtrate was washed once with saturated brine (300 mL). The organic phase was dried and concentrated, and then purified by silica gel column chromatography (petroleum ether:ethyl acetate = 5-20%) to obtain N-(2-amino-4-methylphenethyl)-6-bromo-N-methyl-4-(trifluoromethyl)pyridin-2-amine (3.28 g, 96.5%). LCMS calc.for C 16 H 18 BrF3N3[M+H] + :m / z=388.1;Found:388.1;
[0494] Step 6: (3aS,4S,6aS)-N-(2-(2-((6-bromo-4-(trifluoromethyl)pyridin-2-yl)(methyl)amino)ethyl)-5-methylphenyl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide
[0495] N-(2-amino-4-methylphenethyl)-6-bromo-N-methyl-4-(trifluoromethyl)pyridin-2-amine (3.28 g, 8.45 mmol), (3aS,4S,6aS)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid (1.7 g, 8.45 mmol), and 1-methylimidazole (2.02 mL, 25.4 mmol) were dissolved in N,N-dimethylformamide (30 mL), and the reaction solution was cooled to 0°C. Tetramethylchlorouronium hexafluorophosphate (2.84 g, 10.1 mmol) was dissolved in N,N-dimethylformamide (10 mL) and added dropwise to the reaction solution, which was stirred at 0°C for 2 hours. After the reaction was completed, the reaction solution was poured into water and extracted twice with ethyl acetate (30 mL). The organic phases were combined and washed twice with half-saturated brine (100 mL). The organic phase was dried and concentrated, and then purified by silica gel column chromatography (methanol: dichloromethane = 0-3%) to obtain (3aS, 4S, 6aS)-N-(2-(2-((6-bromo-4-(trifluoromethyl)pyridin-2-yl)(methyl)amino)ethyl)-5-methylphenyl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (2.35 g, 48.7%). LCMS calc. for C 24 H 27 BrF3N4O4[M+H] + :m / z=571.1; Found:571.4;.
[0496] Step 7: (2 3a S,2 6 S,2 6a S)-2 2 ,2 2 ,5 5 ,8-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 4,3-diketone (3aS,4S,6aS)-N-(2-(2-((6-bromo-4-(trifluoromethyl)pyridin-2-yl)(methyl)amino)ethyl)-5-methylphenyl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (2.35 g, 4.11 mmol) was dissolved in toluene (25 mL) at room temperature, and cuprous iodide (0.39 g, 2.06 mmol), N,N'-dimethylethylenediamine (0.36 g, 4.11 mmol) and potassium carbonate (1.14 g, 8.23 mmol) were added to the reaction solution. The reaction solution was stirred at 100° C. for 6 hours. After the reaction was completed, the reaction solution was poured into water, and aqueous ammonia (2 mL) was added to the water. The reaction solution was fully stirred and extracted twice with ethyl acetate (100 mL). The organic phases were combined and washed twice with semi-saturated brine (200 mL). The organic phase was dried and concentrated and then purified by silica gel column chromatography (methanol: dichloromethane = 3%) to obtain (2 3a S,2 6 S,2 6a S)-2 2 ,2 2 ,5 5 ,8-tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 4 ,3-diketone (1.15 g, 57%). LCMS calc. for C 24 H 26 F3N4O4[M+H] + :m / z=491.2;Found:491.4;
[0497] Step 8: (2 3a S,2 6 S,2 6a S)-2 2 ,2 2 ,5 5 ,8-tetramethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4H-4,8-diaza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 4 ,3-diketone
[0498] At room temperature, (2 3a S,2 6 S,2 6a S)-2 2 ,2 2 ,5 5 -8-Tetramethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 4 ,3-diketone (1.15g, 2.34mmol) was dissolved in N,N-dimethylformamide (5mL). After the reaction solution was cooled to 0°C, sodium hydride (0.07g, 2.8mmol, 60%) was added to the reaction solution, and the reaction solution was stirred at 0°C for 10 minutes. Deuterated iodomethane (0.34g, 2.34mmol) was added to the reaction solution, and the reaction solution was continued to stir at 0°C for 30 minutes. After the reaction was completed, the reaction solution was poured into a saturated aqueous ammonium chloride solution (100mL) and extracted twice with ethyl acetate (50mL). The organic phases were combined and washed twice with semi-saturated brine (100mL). The organic phase was dried and concentrated to obtain (2 3a S,2 6 S,2 6a S)-2 2 ,2 2 ,5 5 ,8-tetramethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 4 ,3-dione (1.1 g, 92.4%). LCMS calc. for C 25 H 25 D3F3N4O4[M+H] + :m / z=508.2;Found:508.3.
[0499] Step 9: (2 2 S,2 3 S,2 4 S)-2 3 ,2 4 -Dihydroxy-5- 5 ,8-dimethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-4,8-diaza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone
[0500] At room temperature, (2 3a S,2 6 S,2 6a S)-2 2 ,2 2 ,5 5 -8-Tetramethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 4 ,3-diketone (1.1 g, 2.17 mmol) was dissolved in methanol (10 mL), and 4N hydrochloric acid solution (2.0 mL) was added to the reaction solution, and the reaction solution was stirred at 50°C for 6 hours. After the reaction was complete, the reaction solution was poured into a saturated sodium bicarbonate aqueous solution (100 mL) and extracted twice with ethyl acetate (50 mL). The organic phases were combined, dried, concentrated, and purified by silica gel column chromatography (methanol: dichloromethane = 3%) to obtain a crude product. The crude product was purified by preparative high performance liquid chromatography (XBridge Prep C18 5μm OBD 19*150mm; mobile phase: ACN-H2O (0.1% NH4HCO3) gradient: 40%-95%) to obtain (2 2 S,2 3 S,2 4 S)-2 3 ,2 4 -Dihydroxy-5- 5 ,8-dimethyl-4-(methyl-d3)-1 4 -(Trifluoromethyl)-4,8-diaza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5,3-diketone (450 mg, 44%). LCMS calc. for C 22 H 21 D3F3N4O4[M+H] + :m / z=468.2;Found:468.3 1 H NMR (400MHz, DMSO-d6) δ7.56(d,J=1.0Hz,1H),7.30(d,J=1.7Hz,1H),7.28-7.21(m,2H),6.62(s,1H),5.38-5.27(m,2H),5.09(d,J=6.7Hz,1H),4. 28(t,J=6.7Hz,1H),4.14(d,J=6.7Hz,1H),3.73-3.61(m,1H),3.47-3.40 (m,1H),3.14(s,3H),3.02-2.91(m,1H),2.49-2.44(m,1H),2.34(s,3H).
[0501] Example 20 Preparation of Compound I-65
[0502] The same synthetic route as compound I-64 was used, except that the starting material in step 4 was replaced by deuterated iodomethane.
[0503] (2 2 S,2 3 S,2 4 S)-2 3 ,2 4 -Dihydroxy-5- 5 -methyl-4,8-di(methyl-d3)-1 4 -(trifluoromethyl)-4,8-diaza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone
[0504] LCMS calc.for for C 22 H 18 D6F3N4O4[M+H] + :m / z=471.2;Found:471.0; 1H NMR(400MHz, DMSO-d6)δ7.56(s,1H),7.30(s,1H),7.28-7.21(m,2H),6.61(s,1H),5.34-5.29(m,2H),5.09(d,J=6.7Hz,1H),4 .31-4.25(m,1H),4.18-4.11(m,1H),3.72-3.61(m,1H),3.47-3.40(m,1H),3.02-2.92(m,1H),2.49-2.45(m,1H),2.34(s,3H).
[0505] Example 21 Preparation of Compound I-66
[0506] Step 1: (S)-4-methyl-2,5-dihydro-1H-pyrrole-1,2-dicarboxylic acid di-tert-butyl ester
[0507] At room temperature, (S)-1-(tert-Butyloxycarbonyl)-4-methyl-2,5-dihydro-1H-pyrrole-2-carboxylic acid (13.2 g, 58.1 mmol) and 4-dimethylaminopyridine (7.09 g, 58.0 mmol) were dissolved in tert-butyl alcohol (100 mL). Di-tert-butyl dicarbonate (25.3 g, 116 mmol) was then added dropwise to the solution. The resulting reaction mixture was stirred at 50°C for 2 hours. The reaction mixture was concentrated under reduced pressure, water (50 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 2). The combined organic phases were washed sequentially with water (30 mL) and saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 10%) to give (S)-4-methyl-2,5-dihydro-1H-pyrrole-1,2-dicarboxylic acid di-tert-butyl ester (12.0 g, 73.0%). LCMS calc. for C 15 H 26 NO4[M+H] + :m / z=284.2;Found:284.3.
[0508] Step 2: (2S,3R,4S)-3,4-dihydroxy-4-methylpyrrolidine-1,2-dicarboxylic acid di-tert-butyl ester
[0509] (S)-di-tert-butyl 4-methyl-2,5-dihydro-1H-pyrrole-1,2-dicarboxylate (15 g, 52.9 mmol) was dissolved in tert-butanol (80 mL) and water (80 mL). Potassium carbonate (22.0 g, 159 mmol), potassium ferricyanide (52.3 g, 159 mmol), methanesulfonamide (5.03 g, 52.9 mmol), hydroquinine (4.13 g, 5.29 mmol), and potassium osmate (0.98 g, 2.65 mmol) were then added to the solution. The reaction mixture was stirred at room temperature under nitrogen for 3 hours. Water (100 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (100 mL x 2). The combined organic phases were washed sequentially with water (100 mL) and saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. After the reaction was completed, the resulting mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (methanol:dichloromethane = 0% to 4%) to obtain (2S,3R,4S)-3,4-dihydroxy-4-methylpyrrolidine-1,2-dicarboxylic acid di-tert-butyl ester (8.0 g, 47.6%). LCMS calc. for C 15 H 28 NO6[M+H] + :m / z=318.2;Found:318.2。
[0510] Step 3: (3aR,4S,6aS)-2,2,6a-trimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-4,5-dicarboxylic acid di-tert-butyl ester
[0511] To a solution of di-tert-butyl (2S,3R,4S)-3,4-dihydroxy-4-methylpyrrolidine-1,2-dicarboxylate (8.0 g, 25.2 mmol) in acetone (100 mL) at room temperature were added 2,2-dimethoxypropane (131 g, 126 mmol) and pyridine p-toluenesulfonate (3.2 g, 12.6 mmol). The reaction system was then heated to 60°C and stirred for 3 hours under a nitrogen atmosphere. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 0% to 30%) to obtain di-tert-butyl (3aR,4S,6aS)-2,2,6a-trimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-4,5-dicarboxylate (8.0 g, 88.8%). LCMS calc. for C 18 H 32 NO6[M+H] + :m / z=358.2;Found:358.1.
[0512] Step 4: (3aR,4S,6aS)-2,2,6a-methyl-6-carbonyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-4,5-dicarboxylic acid di-tert-butyl ester
[0513] Dissolve di-tert-butyl (3aR,4S,6aS)-2,2,6a-trimethyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-4,5-dicarboxylate (8.0 g, 22.4 mmol) in ethyl acetate (160 mL) and water (160 mL). Add ruthenium trichloride hydrate (1.39 g, 6.71 mmol) and sodium periodate (28.7 g, 134 mmol) at 20°C, and stir for 1 hour. Dilute the reaction solution with water (200 mL), extract the aqueous phase twice with ethyl acetate (200 mL), and wash the combined organic phases with saturated brine (100 mL), dry over anhydrous sodium sulfate, filter, and concentrate to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to give (3aR,4S,6aS)-2,2,6a-methyl-6-carbonyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-4,5-dicarboxylic acid di-tert-butyl ester (5.6 g, 67.4%). LCMS calc. for C 18 H 30 NO7[M+H] + :m / z=372.2;Found:372.3.
[0514] Step 5: (3aR,4S,6aS)-2,2,6a-trimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid
[0515] Dissolve (3aR,4S,6aS)-2,2,6a-methyl-6-carbonyltetrahydro-5H-[1,3]dioxazolo[4,5-c]pyrrole-4,5-dicarboxylic acid di-tert-butyl ester (5.0 g, 13.5 mmol) in acetonitrile (20 mL), then add trifluoroacetic acid (6 mL, 65.5 mmol) and stir at 20°C under nitrogen for 10 hours. The reaction solution was concentrated under reduced pressure to give (3aR,4S,6aS)-2,2,6a-trimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid (3.0 g, crude product >99%). LCMS calc. for C9H 14 NO5[M+H] + :m / z=216.1;Found:216.1.
[0516] Step 6: (3aR,4S,6aR)-N-(2-(2-((6-bromo-4-(trifluoromethyl)pyridin-2-yl)(methyl)amino)ethyl)-5-methylphenyl)-2,2,6a-trimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide
[0517] To a solution of (3aR,4S,6aS)-2,2,6a-trimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid (580 mg, 2.70 mmol) and N-(2-amino-4-methylphenethyl)-6-bromo-N-methyl-4-(trifluoromethyl)pyridin-2-amine (837 mg, 2.16 mmol) in N,N-dimethylformamide (6.0 mL) were added tetramethylchlorouronium hexafluorophosphate (907 mg, 3.23 mmol) and 1-methylimidazole (0.43 mL, 5.39 mmol), and the reaction solution was stirred at 20°C for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0-30%) to give (3aR,4S,6aR)-N-(2-(2-((6-bromo-4-(trifluoromethyl)pyridin-2-yl)(methyl)amino)ethyl)-5-methylphenyl)-2,2,6a-trimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (500 mg, 31.7%). LCMS calc. for C 25 H 29 BrF3N4O4[M+H] + :m / z=585.1;Found:585.1
[0518] Step 7: (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,2 6a ,5 5 ,8-pentamethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrolidine-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 6 ,3-diketone
[0519] (3aR,4S,6aR)-N-(2-(2-((6-bromo-4-(trifluoromethyl)pyridin-2-yl)(methyl)amino)ethyl)-5-methylphenyl)-2,2,6a-trimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (380 mg, 0.65 mmol) was dissolved in toluene (8 mL), and then N,N-dimethylethylenediamine (57.2 mg, 0.65 mmol), cuprous iodide (61.8 mg, 0.32 mmol) and potassium carbonate (179 mg, 1.3 mmol) were added. The reaction solution was stirred at 100°C for 2 hours. After the reaction was cooled, it was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 50%) to give (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,2 6a ,5 5 ,8-pentamethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrolidine-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 6 ,3-diketone (300 mg, 91.6%). LCMS calc. for C 25 H 28 F3N4O4[M+H] + :m / z=505.2;Found:505.3.
[0520] Step 8: (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,2 6a ,5 5 ,8-pentamethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrolidine-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 6,3-diketone
[0521] To (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,2 6a ,5 5 ,8-pentamethyl-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrolidine-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 6 ,3-diketone (300mg, 0.89mmol) in N,N-dimethylformamide (5.0mL) was added with sodium hydride (35.6mg, 0.83mmol, 60%), and the reaction solution was stirred at 0°C for 0.25 hours. Deuterated iodomethane (172mg, 1.19mmol) was added to the reaction solution and continued to stir for 1 hour. After adding water (20mL) to quench, the aqueous phase was extracted three times with ethyl acetate (15mL). The combined organic phases were washed with water (30mL) and saturated brine (30mL) in turn, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 40%) to obtain (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,2 6a ,5 5 ,8-pentamethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrolidine-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 6 ,3-dione (100 mg, 32.3%) LCMS calc. for C 26 H 27 D3F3N4O4[M+H] + :m / z=522.2;Found:522.4.
[0522] Step 9: (22 S,2 3 R,2 4 R)-2 3 ,2 4 -Dihydroxy-2 4 ,5 5 ,8-trimethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-4,8-diaza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-diketone
[0523] (2 3a R,2 4 S,2 6a R)-2 2 ,2 2 ,2 6a ,5 5 ,8-pentamethyl-4-(methyl-d3)-1 4 -(trifluoromethyl)-2 3a ,2 5 ,2 6 ,2 6a -Tetrahydro-2 4 H-4,8-diaza-2(5,4)-[1,3]dioxazolo[4,5-c]pyrrolidine-1(2,6)-pyridine-5(1,2)-benzocyclooctane-2 6 ,3-diketone (100 mg, 0.19 mmol) was dissolved in methanol (30 mL) and 4N dilute hydrochloric acid (20 mL) and stirred at 60 ° C for 3 hours. After cooling, the reaction solution was concentrated to obtain a residue. The residue was purified by preparative high performance liquid chromatography (Column: XBridge Prep C18 5μm OBD 19*150mm, Mobile phase: A (10mM NH4HCO3 in Water) B (ACN), 0-3min: 40% B, 3-7min: 40-85% B, 7-11min: 85-90% B, 11-13min: 90-95% B, 13-16min: 95% B, 16-16.5min: 95-40% B, 16.5-21min: 40% B, Flow = 15mL / min) to obtain (2 2 S,2 3 R,2 4 R)-2 3 ,2 4 -Dihydroxy-2 4 ,5 5 ,8-trimethyl-4-(methyl-d3)-1 4-(trifluoromethyl)-4,8-diaza-1(2,6)-pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocyclooctane-2 5 ,3-dione (30 mg, 32.5%). LCMS calc. for C 23 H 23 D3F3N4O4[M+H] + :m / z=482.2;Found:482.2 1 H NMR (400MHz, DMSO-d6) δ7.58(s,1H),7.29(s,1H),7.27-7.21(m,2H),6.22(s,1H),5.54(s,1H),5.45(d,J=6.0Hz,1H),4.81(d,J=2.8Hz,1H),3 .93(dd,J=6.4,2.8Hz,1H),3.75-3.60(m,1H),3.50-3.40(m,1H),3.14( s,3H),3.05-2.90(m,1H),2.50-2.45(m,1H),2.32(s,3H),1.37(s,3H).
[0524] [Corrected 23.10.2024 according to Rule 91] Example 22 Preparation of Compound I-67 and Compound I-68
[0525] Step 1: 4-iodo-1-tosyl-1H-pyrrolo[2,3-b]pyridine
[0526] 4-iodo-1H-pyrrolo[2,3-b]pyridine (7.0 g, 28.7 mmol) was dissolved in tetrahydrofuran (100 mL) and water (10 mL). Sodium hydroxide (5.74 g, 143 mmol) and p-toluenesulfonyl chloride (6.56 g, 34.4 mmol) were then added to the solution. The reaction mixture was stirred at room temperature for 5 hours. After the reaction was completed, water (200 mL) was added to the reaction mixture to quench the reaction mixture and the mixture was extracted with ethyl acetate (200 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 30%) to obtain 4-iodo-1-toluenesulfonyl-1H-pyrrolo[2,3-b]pyridine (8.0 g, 70.2%). LCMS calc. for C 14 H 12 IN2O2S[M+H] + :m / z=399.0;Found:399.3.
[0527] Step 2: 1-Tosyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine
[0528] Dissolve 4-iodo-1-tosyl-1H-pyrrolo[2,3-b]pyridine (8.0 g, 20.1 mmol) in N,N-dimethylformamide (100 mL). Add cuprous iodide (3.83 g, 20.1 mmol), potassium fluoride (0.12 g, 2.01 mmol), and (trifluoromethyl)trimethylsilane (8.57 g, 60.3 mmol). Replace the argon atmosphere three times, raise the temperature to 80°C, and stir for 16 hours. After completion, quench the reaction with water (100 mL) and extract with ethyl acetate (200 mL x 3). Combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to give 1-tosyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine (5.0 g, yield: 73%). LCMS calc. for C 15 H 12 F3N2O2S[M+H] + :m / z=341.0;Found:341.0.
[0529] Step 3: 4-(Trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine
[0530] 1-Tosyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine (5.0 g, 14.7 mmol) was dissolved in N,N-dimethylformamide (50 mL), and potassium tert-butoxide (44.1 mL, 1.0 mol / L, 44.1 mmol) was added to the solution. The reaction mixture was stirred at room temperature for 5 hours. After completion of the reaction, the mixture was quenched with water (200 mL) and extracted with ethyl acetate (200 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to obtain 4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine (2.0 g, 73.0%). LCMS calc. for C8H6F3N2[M+H] + :m / z=187.0;Found:187.0.
[0531] Step 4: 4-(Trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine 7-nitroxide
[0532] 4-(Trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine (2.0 g, 10.7 mmol) was dissolved in dichloromethane (20 mL), and m-chloroperbenzoic acid (3.71 g, 21.5 mmol) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 16 hours. After completion, saturated sodium bicarbonate (50 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (100 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 100%) to obtain 4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine 7-nitroxide (2.0 g, 91.6%). LCMS calculated for C8H6F3N2O [M+H] + :m / z=203.0;Found:203.1.
[0533] Step 5: (6-Bromo-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)(phenyl)methanone
[0534] 4-(Trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine 7-oxide (2.0 g, 9.85 mmol) was dissolved in toluene (20 mL). Benzoyl bromide (2.73 g, 14.8 mmol) and hexamethyldisilazane (4.1 mL, 19.7 mmol) were added to the reaction solution, and the reaction solution was stirred at room temperature for 3 hours. After the reaction was completed, water (50 mL) was added to quench the reaction and the mixture was extracted with ethyl acetate (100 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 50%) to obtain (6-bromo-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)(phenyl)methanone (2.0 g, 55.0%). LCMS calc. for C 15 H9BrF3N2O[M+H] + :m / z=369.0;Found:369.0.
[0535] Step 6: 6-Bromo-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine
[0536] (6-Bromo-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)(phenyl)methanone (2.0 g, 5.42 mmol) was dissolved in methanol (20 mL). Sodium hydroxide (13.6 mL, 2.0 mol / L, 27.2 mmol) was then added to the reaction mixture, and the reaction mixture was stirred at room temperature for 0.5 hours. After completion, the reaction was quenched by the addition of water (30 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 50%) to obtain 6-bromo-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine (0.6 g, 41.8%). LCMS calc. for C8H5BrF3N2[M+H] + :m / z=265.0;Found:265.0.
[0537] Step 7: 6-Bromo-1-(4-methyl-2-nitrophenylethyl)-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine
[0538] 6-Bromo-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine (0.6 g, 2.26 mmol) was dissolved in tetrahydrofuran (10 mL). Triphenylphosphine (1.18 g, 4.53 mmol), 2-(4-methyl-2-nitrophenyl)ethane-1-ol (0.61 g, 3.4 mmol), and diisopropyl azodicarboxylate (0.96 g, 4.75 mmol) were added to the reaction solution. The reaction solution was stirred at room temperature for 1 hour. After the reaction was completed, water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 30%) to give 6-bromo-1-(4-methyl-2-nitrophenylethyl)-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine (0.7 g, 72.2%). LCMS calc. for C 17 H 14 BrF3N3O2[M+H] + :m / z=428.0;Found:427.7.
[0539] Step 8: 2-(2-(6-bromo-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)ethyl)-5-methylaniline
[0540] 6-Bromo-1-(4-methyl-2-nitrophenylethyl)-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine (0.7 g, 1.63 mmol) was dissolved in ethanol (6 mL) and water (2 mL). Iron powder (0.46 g, 8.17 mmol) and ammonium chloride (0.44 g, 8.17 mmol) were added to the reaction mixture, and the mixture was stirred at 80°C for 1 hour. After completion of the reaction, the mixture was filtered, and the filtrate was extracted with ethyl acetate (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 50%) to obtain 2-(2-(6-bromo-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)ethyl)-5-methylaniline (0.65 g, 99.9%). LCMS calc.for C 17 H 16 BrF3N3[M+H] + :m / z=398.0;Found:397.7.
[0541] Step 9: (3aS,4S,6aS)-N-(2-(2-(6-bromo-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)ethyl)-5-methylphenyl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide
[0542] 2-(2-(6-bromo-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)ethyl)-5-methylaniline (0.65 g, 1.63 mmol) was dissolved in acetonitrile (8 mL). Tetramethylchlorouronium hexafluorophosphate (0.54 g, 1.94 mmol), 1-methylimidazole (0.39 mL, 4.85 mmol), and (3aS,4S,6aS)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxylic acid (0.36 g, 1.8 mmol) were added. The reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, water (20 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether = 0% to 100%) to give (3aS,4S,6aS)-N-(2-(2-(6-bromo-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)ethyl)-5-methylphenyl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (0.8 g, 84.3%). LCMS calc. for C25 H 25 BrF3N4O4[M+H] + :m / z=581.1;Found:580.6.
[0543] Step 10: (1 3a S,1 6 S,1 6a S)-1 2 ,1 2 ,5 4 -Trimethyl-2 4 -(trifluoromethyl)-1 3a ,1 5 ,1 6 ,1 6a -Tetrahydro-1 4 H,2 1 H-6-Aza-1(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-2(6,1)-pyrrolo[2,3-b]pyridine-5(1,2)-benzocycloheptane-1 4 ,7-dione
[0544] (3aS,4S,6aS)-N-(2-(2-(6-bromo-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)ethyl)-5-methylphenyl)-2,2-dimethyl-6-carbonyltetrahydro-4H-[1,3]dioxazolo[4,5-c]pyrrole-4-carboxamide (0.8 g, 1.38 mmol) was dissolved in toluene (20 mL). To the reaction solution were added cuprous iodide (0.05 g, 0.28 mmol), N,N-dimethylethylenediamine (0.04 g, 0.41 mmol), and potassium carbonate (0.57 g, 4.13 mmol). The atmosphere was replaced with argon three times, and the reaction was stirred at 100°C for 3 hours. After completion of the reaction, water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (methanol: dichloromethane = 0% to 10%) to obtain (1 3a S,1 6 S,1 6a S)-1 2 ,1 2 ,5 4 -Trimethyl-2 4 -(trifluoromethyl)-1 3a ,1 5 ,1 6 ,1 6a -Tetrahydro-1 4 H,2 1H-6-Aza-1(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-2(6,1)-pyrrolo[2,3-b]pyridine-5(1,2)-benzocycloheptane-1 4 ,7-dione (0.4 g, 58.1%). LCMS calc. for C 25 H 24 F3N4O4[M+H] + :m / z=501.1;Found:500.8.
[0545] Step 11: (1 3a S,1 6 S,1 6a S)-1 2 ,1 2 ,5 4 ,6-tetramethyl-2 4 -(trifluoromethyl)-1 3a ,1 5 ,1 6 ,1 6a -Tetrahydro-1 4 H,2 1 H-6-Aza-1(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-2(6,1)-pyrrolo[2,3-b]pyridine-5(1,2)-benzocycloheptane-1 4 ,7-dione
[0546] (1 3a S,1 6 S,1 6a S)-1 2 ,1 2 ,5 4 -Trimethyl-2 4 -(trifluoromethyl)-1 3a ,1 5 ,1 6 ,1 6a -Tetrahydro-1 4 H,2 1 H-6-Aza-1(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-2(6,1)-pyrrolo[2,3-b]pyridine-5(1,2)-benzocycloheptane-1 4,7-diketone (0.4g, 0.8mmol) was dissolved in N,N-dimethylformamide (5mL), the reaction solution was cooled to 0°C, sodium hydride (0.03g, 1.2mmol) was added to the reaction solution, and stirred at 0°C for 15 minutes. Then, iodomethane (0.1mL, 1.6mmol) was added to the reaction solution, and the reaction was stirred at room temperature for 1 hour. After the reaction was completed, the reaction was quenched with saturated ammonium chloride solution and extracted with ethyl acetate (50mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain (1 3a S,1 6 S,1 6a S)-1 2 ,1 2 ,5 4 ,6-tetramethyl-2 4 -(trifluoromethyl)-1 3a ,1 5 ,1 6 ,1 6a -Tetrahydro-1 4 H,2 1 H-6-Aza-1(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-2(6,1)-pyrrolo[2,3-b]pyridine-5(1,2)-benzocycloheptane-1 4 ,7-dione (0.35 g, 85.1%). LCMS calc. for C 26 H 26 F3N4O4[M+H] + :m / z=515.2;Found:514.8.
[0547] Step 12: (2 2 S,2 3 S,2 4 S)-2 3 ,2 4 -Dihydroxy-5- 5 ,4-dimethyl-1 4 -(trifluoromethyl)-1 1 H-4-Aza-1(6,1)-pyrrolo[2,3-b]pyridine-2(1,2)-pyrrolidine-5(1,2)benzocycloheptane-2 5 ,3-diketone
[0548] (1 3a S,1 6 S,1 6a S)-1 2 ,1 2 ,5 4 ,6-tetramethyl-24 -(trifluoromethyl)-1 3a ,1 5 ,1 6 ,1 6a -Tetrahydro-1 4 H,2 1 H-6-Aza-1(5,6)-[1,3]dioxazolo[4,5-c]pyrrole-2(6,1)-pyrrolo[2,3-b]pyridine-5(1,2)-benzocycloheptane-1 4 ,7-dione (0.35 g, 0.68 mmol) was dissolved in methanol (3 mL) and 4N dilute hydrochloric acid (2 mL) and stirred at 50 ° C for 3 hours. After cooling, the reaction solution was concentrated. The residue was purified by preparative high performance liquid chromatography (Column: XBridge C18 5μm 19*150mm Mobile phase: A (0.1% FA in Water) B (ACN) 0-2min: 40% B, 2-4min: 40-75% B, 4-5min: 75% B, 5-9min: 75-95% B, 9-13min: 95% B, 13-13.5: 95-40% B, 13.5-18min: 40% B (Flow = 15 mL / min)) to obtain (2 2 S,2 3 S,2 4 S)-2 3 ,2 4 -Dihydroxy-5- 5 ,4-dimethyl-1 4 -(trifluoromethyl)-1 1 H-4-Aza-1(6,1)-pyrrolo[2,3-b]pyridine-2(1,2)-pyrrolidine-5(1,2)benzocycloheptane-2 5 ,3-diketone (60 mg, 18.6%). LCMS calc. for C 23 H 22 F3N4O4[M+H] + :m / z=475.2;Found:474.7. 1H NMR (400MHz, DMSO-d6) δ8.42(s,1H),7.76(d,J=3.5Hz,1H),7.46-7.39(m,2H),7.35-7.27(m,1H),6.52(dd,J=3.4,1.7Hz,1H),5.63(d,J=5. 9Hz,1H),5.36-5.19(m,2H),5.08-4.94(m,1H),4.49(q,J=6.7Hz,1H), 4.16-4.06(m,2H),3.06-2.97(m,4H),2.54-2.51(m,1H),2.38(s,3H).
[0549] Step 13: (2 2 S,2 3 S,2 4 S)-2 3 ,2 4 -Dihydroxy-5- 5 ,4-dimethyl-1 4 -(trifluoromethyl)-1 2 ,1 3 -Dihydro-1 1 H-4-Aza-1(6,1)-pyrrolo[2,3-b]pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocycloheptane-2 5 ,3-diketone
[0550] (2 2 S,2 3 S,2 4 S)-2 3 ,2 4 -Dihydroxy-5- 5 ,4-dimethyl-1 4 -(trifluoromethyl)-1 1 H-4-Aza-1(6,1)-pyrrolo[2,3-b]pyridine-2(1,2)-pyrrolidine-5(1,2)benzocycloheptane-2 5,3-diketone (50 mg, 0.11 mmol) was dissolved in methanol (5 mL), 10% palladium carbon (50 mg) was added to the reaction solution, and the reaction solution was stirred at 30 ° C under a hydrogen atmosphere for 48 hours. After the reaction was completed, it was filtered and the filtrate was concentrated. The residue was purified by preparative high performance liquid chromatography (Column: XBridge C18 5μm 19*150mm Mobile phase: A (0.1% FA in Water) B (ACN) 0-3min: 40% B, 3-5min: 40-75% B, 5-7min: 75% B, 7-10min: 75-95% B, 10-13min: 95% B, 13-13.01: 95-40% B, 13.01-16.5min: 40% B (Flow = 15 mL / min)) to obtain (2 2 S,2 3 S,2 4 S)-2 3 ,2 4 -Dihydroxy-5- 5 ,4-dimethyl-1 4 -(trifluoromethyl)-1 2 ,1 3 -Dihydro-1 1 H-4-Aza-1(6,1)-pyrrolo[2,3-b]pyridine-2(1,2)-pyrrolidine-5(1,2)-benzocycloheptane-2 5 ,3-diketone (0.54 mg, 1.1%). LCMS calc. for C 23 H 24 F3N4O4[M+H] + :m / z=477.2;Found:476.8. 1H NMR(400MHz,Chloroform-d)δ7.81(s,1H),7.35(s,1H),7.15(d,J=7.9Hz,1H),7.07(d,J=7.9Hz,1H),5. 28(t,J=4.8Hz,1H),5.23(d,J=7.4Hz,1H),4.99(d,J=11.9Hz,1H),4.23(q,J=7.2Hz,1H),4.10(dd,J=11 .8,6.3Hz,1H),3.72(td,J=9.0,3.9Hz,1H),3.66-3.55(m,1H),3.36(q,J=9.3Hz,1H),3.19-3.14(m,1H) ,3.12(s,3H),3.05-3.00(m,1H),2.95-2.91(m,1H),2.33(s,3H),2.22-2.10(m,1H),2.01-1.91(m,1H).
[0551] Biological experiments
[0552] Polθ polymerase activity assay
[0553] The inhibitory effect of the compounds on Polθ polymerase activity was evaluated by PicoGreen assay.
[0554] The compound was dissolved in 100% DMSO and added to a 384-well plate (corning Cat#4514) after serial dilution. The initial (final) concentration was 12 μM and the mixture was diluted 4-fold for a total of 10 concentration points. Purified recombinant Pol θ protein (aa1792-2590) and a 1:1.1 ratio of primer (5'-GCG GCT GTC ATA AG-3'): template (5'-GCT ACA TTG ACA ATG GCA TCA AAT CTC AGA TTG CGT CTT ATG ACA GCC GCG-3') duplex were added to the assay plate in assay reaction buffer containing 25 mM Tris (pH 7.5), 12.5 mM NaCl, 0.5 mM MgCl2, 1 mM DTT, 0.01% (v / v) Triton X-100, 0.01% (v / v) BSA, and 5% glycerol to final concentrations of 1.5 nM, 50 nM, and 55 nM, respectively. After a 30-minute preincubation at room temperature, dNTPs were added to a final concentration of 40 μM. By supplementing DMSO solution, the DMSO concentration in each well was maintained at 1%, and the cells were incubated at room temperature for 60 minutes. 10mM EDTA, 25mM Tris (pH 7.5), and a 1:200 dilution of PicoGreen dye (Invitrogen, P7581) were added and incubated in the dark for 30 minutes to stop the reaction. Fluorescence was read and analyzed using ENVISION at 485 / 520nm. The RFU values normalized to the control well values in each assay plate were used to calculate the inhibition percentage (%) of each concentration of compound, and curve fitting was performed using XLfit. The specific results are shown in Table 1.
[0555] Table 1: Inhibitory activity of compounds against Polθ polymerase
[0556] Ref.1 is Selected from WO2021028670A1.
[0557] *+ refers to IC 50 ≤2nM,++ means 2nM <IC 50 ≤10nM,+++ means 10nM <IC 50 ≤100nM,++++ means 100nM <IC 50 ≤1000nM.
[0558] The above data show that the compounds of the present invention have good inhibitory activity against Pol θ polymerase, especially some compounds (such as compounds I-12 to 14, 59 to 67) have better inhibitory activity against Pol θ polymerase than compound Ref.1.
[0559] TMEJ reporter experiments:
[0560] Compounds were evaluated for their inhibitory effects on theta-mediated end joining (TMEJ) process.
[0561] Experimental instruments:
[0562] Experimental Materials:
[0563] Experimental methods:
[0564] 1) HEK293T cells were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin (PS).
[0565] 2) Before starting, sterilize the Neon transfection system and equilibrate the E2 and R buffers to room temperature.
[0566] 3) Preheat the culture medium without antibiotics.
[0567] 4) The cells in the flask with a confluence of 80-90% were treated with trypsin, neutralized with culture medium, centrifuged, and counted.
[0568] 5) Take 2×10 6 The cells were transfected using a 100 μL electroporation pipette tip and washed with DPBS (without Mg). 2+ and Ca 2+ ) Wash once, centrifuge at 1000 rpm for 5 min, and discard the supernatant. Increase the number of cells and volume as needed.
[0569] 6) Set up the neon tube system, insert the neon tube into the neon tube pipette, and add E2 buffer.
[0570] 7) Add 10 μg of TMEJ substrate to 100 μl of R solution. Increase the volume as needed.
[0571] 8) Resuspend the cells in DNA buffer and start electroporation using the following parameters:
[0572] 9) Place the cells in culture medium without antibiotics and mix gently
[0573] 10) Repeat steps 8)-9) as needed and seed the cells into a 384-well plate at 40,000 cells / well in 40 μl of culture medium.
[0574] 11) Culture in a 37°C humidified CO2 incubator for 24 hours.
[0575] 12) Warm the NanoGlo reagent to room temperature and mix the NanoGlo buffer with the substrate at a ratio of 50:1.
[0576] 13) The cell culture plate was equilibrated at room temperature for 10 minutes.
[0577] 14) Add 40 μL of NanoGlo substrate buffer to each well and shake at 300 rpm for 3 minutes in the dark.
[0578] 15) Read the signal via BMG PHERAstar FSX.
[0579] See Table 2 for specific results.
[0580] Table 2: Inhibitory activity of compounds on theta-mediated end joining (TMEJ) process in HEK293T cells
[0581] The above data show that the example compounds of the present invention have good inhibitory activity on the Theta-mediated end-joining (TMEJ) process in HEK293T cells.
[0582] DLD-1 BRCA2 - / - DLD-1 BRCA2 WT Cell proliferation assay:
[0583] The CellTiter-Glo (CTG) method was used to evaluate the effects of compounds on the human colorectal adenocarcinoma cell line DLD-1 BRCA2 - / - DLD-1 BRCA2 WT anti-proliferative effect.
[0584] Instruments and equipment:
[0585] Reagents and consumables:
[0586] DLD-1 (purchased from ATCC, product number: CCL-221, batch number: 70033255)
[0587] RPMI1640 (purchased from Invitrogen, cat. no.: 11875-085)
[0588] 0.25% Trypsine-EDTA (purchased from Invitrogen, cat. no.: 25200-072)
[0589] Penicillin-Streptomycin solution (purchased from Hyclone, product number: SV30010)
[0590] FBS (purchased from BI, product number: 04-002-1A)
[0591] DMSO (purchased from Sigma, product number: D4540-1L)
[0592] 96-well plate (purchased from Corning, catalog number: CLS3903)
[0593] CellTiter-Glo reagent (purchased from Promega, product number: G7558)
[0594] Experimental methods:
[0595] The antiproliferative effect of the compounds on human colorectal adenocarcinoma cell lines was evaluated by ATP quantification, and the activity was well correlated with the number of viable cells. - / - The cells were cultured in RPMI 1640 (Invitrogen, 11875-085) medium supplemented with 10% (v / v) fetal bovine serum (BI, 04-002-1A). Cell lines were cultured according to the standard instructions of the American Type Culture Collection. Cell lines were authenticated by their short tandem repeat profiles.
[0596] For proliferation experiments, harvest cells and resuspend them in cell culture medium. Determine cell density using a cell counter. Pipette an appropriate amount of cell suspension from the centrifuge tube to prepare the seeding working solution (100 cells / 100 μL for DLD1 cell line and 100 μL for DLD-1 BRCA2 - / - Cell line 150 cells / 100 μL). 100 μL of cell suspension was plated in each well of a 96-well plate (Corning, 3603) and incubated overnight in an incubator. The diluted test compound solution was added to the well plate. Fresh culture medium was replaced and the compound was re-treated on the fourth and seventh days of incubation, for a total incubation time of 10 days. After the incubation, the cell culture plate was removed and equilibrated to room temperature. 100 μL CellTiter-Glo (Promega, G7558) was added to each well and incubated at room temperature for 30 minutes. The data on the plate was read using a microplate reader in 96-well Luminescence mode (Perkinelme, Enspire). The Dose-response one-site 205 model of IDBS XLfit was used for data analysis, curve fitting, and reporting. The specific results are shown in Table 3.
[0597] Table 3: Effects of compounds on DLD1 BRCA2 - / - and DLD1 BRCA2 WT Cell proliferation inhibitory activity
[0598] The above data show that the compounds of the present invention have a significant effect on DLD-1 BRCA2 - / - It has good inhibitory activity on cell proliferation and is significantly better than the reference compound Ref.1; and relative to DLD-1 BRCA2 WT The inhibition of cell proliferation has a certain selectivity.
[0599] Evaluation of drug-drug interactions involving metabolic enzymes: CYP enzyme inhibition assays
[0600] Experimental instruments and materials:
[0601] 1 Liver microsomes
[0602] 2 Preparation of buffers and solutions
[0603] 2.1 Phosphate buffer
[0604] Dissolve 8.71 g of K2HPO4 in 950 mL of water; adjust the pH to 7.4 with hydrochloric acid solution; and adjust the final volume to 1000 mL with water. Filter the buffer through a 0.45 μm filter and store in a refrigerator at 4°C for future use.
[0605] 2.2 Stop Solution
[0606] 2.2.1 Prepare terfenadine / tolbutamide (1 mg / mL each) stock solutions in DMSO.
[0607] 2.2.2 Dilute the above stock solution with acetonitrile to prepare a quenching solution containing 5 / 10 ng / mL (terfenadine / tolbutamide).
[0608] 2.3 Positive control working solution and substrate working solution
[0609] The positive control information and substrate information are shown in the following table:
[0610] 2.4 Liver microsome working solution
[0611] Before use, the liver microsomes were thawed in a 37°C water bath and the liver microsome working solution was prepared (final concentration of the system was 0.5 mg / mL).
[0612] 2.5 NADPH working solution
[0613] Prepare a 5 mM NADPH working solution in phosphate buffered saline.
[0614] 2.6 Test compound working solution
[0615] The above stock solution was prepared into a 2 mM working solution using DMSO.
[0616] 3. Incubation
[0617] Add 238.5 μL of liver microsome working solution to a 1.1 mL tube; add 1.5 μL of test compound / control working solution / DMSO and mix by pipetting several times; preincubate at 37°C in a shaking waterbath for 5 minutes. After preincubation, add 60 μL of NADPH working solution and mix by pipetting several times; incubate at 37°C in a shaking waterbath for 10 minutes. Immediately after incubation, add 500 μL of quenching solution and vortex for 1 minute. Centrifuge all samples at 4,000 rpm for 15 minutes at 4°C. Aliquot 300 μL of the supernatant for further LC-MS / MS analysis.
[0618] 4 Data Processing
[0619] The percentage inhibition (% inhibition) was calculated using the metabolite formation of the test compound or control compound compared to the matrix control. Specific results are shown in Table 4.
[0620] Table 4: Inhibitory activity of compounds against CYP-1A2 / 2C9 / 2C19 / 2D6 / 3A4 / 5 (M / T)
[0621] a: N means no inhibition;
[0622] The above data show that the example compounds of the present invention have no significant inhibitory effect on CYP mixed enzymes or the inhibition rate is low, while the reference compound Ref.1 has a 75% inhibition rate on 2D6 in the CYP mixed enzyme at a concentration of 10 μM. Further IC tests were conducted on CYP enzymes with an inhibition rate of more than 50% at a concentration of 10 μM. 50 , CYP 3A4 / 5(T)IC of compound I-60 50 =25 μM, while the CYP 2D6 IC of the reference compound Ref.1 50 =2.4 μM, which is consistent with the test results of CYP mixed enzymes, indicating that the example compounds of the present invention have lower CYP enzyme inhibition than the reference compound Ref.1.
[0623] Pharmacokinetic studies in mice:
[0624] 1. Experimental purpose: To test the pharmacokinetics of the compound in CD-1 mice.
[0625] 2. Experimental instruments and materials:
[0626] Animals: CD-1 mice (male)
[0627] instrument:
[0628] Reagents:
[0629] Solvent:
[0630] Intravenous injection: 40% HP-β-CD aqueous solution; intragastric administration: 0.2% HPC + 0.5% Tween80 aqueous solution.
[0631] 3. Experimental methods:
[0632] Six male mice were enrolled. They were fasted in the evening before administration and had free access to water. Mice were allowed to eat and drink freely during the experiment. The mice were administered intravenously or orally. After administration, the animals were observed and any abnormalities were recorded. Blood was collected from the orbital cavity at 0.0833, 0.25, 1, 2, 4, 8, and 24 hours after intravenous injection; and at 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after oral gavage. A 20 μL plasma sample was collected, and 250 μL of acetonitrile (containing dexamethasone as an internal standard) was added to precipitate the protein. The sample was centrifuged at 4000 rpm for 20 minutes at 4°C. 180 μL of the supernatant was mixed with 180 μL of an aqueous solution containing 0.1% formic acid in a 96-well plate. A 10 μL sample was then collected for LC-MS / MS analysis.
[0633] 4. Data processing methods and results:
[0634] The internal standard method was used to establish a standard curve, with the theoretical standard curve concentration as the horizontal axis and the peak area ratio as the vertical axis (test compound peak area / internal standard peak area). The linear regression method (weighting factor 1 / X2) was used, R 2 >0.9900. Unknown samples were calculated using the standard curve. Pharmacokinetic parameters were calculated using the non-compartmental analysis model of WinNonlin 8.2 software and presented in the report, including T 1 / 2 , T max , C max and AUC, etc. The specific results are shown in Table 5.
[0635] Table 5 Pharmacokinetic test results of the compounds in mice (PO)
[0636] a:PO means oral administration; b:T 1 / 2 is the drug half-life; c:AUC 0-t is the area under the plasma drug concentration-time curve from time 0 to the last selected time point; d: F% is the bioavailability.
[0637] The above data show that the example compounds of the present invention have higher oral exposure and bioavailability in CD-1 mice, and longer half-life.
Claims
1. A compound as shown in formula I, a pharmaceutically acceptable salt thereof, an isotope-labeled substance thereof, a solvate thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof: in, -L- is -(CH2) n -, n is 1, 2, 3, 4, 5 or 6; -(CH2) n Any 1, 2 or 3 -CH2- in - may be optionally replaced by -CL 1a L 1b -、-CL 2a =CL 2b -、-NL 3 -, -O-, -S(=O)-, -S(=O)2-, -C(=O)- and -S- are substituted with one or two of them; L 1a , L 1b , L 2a and L 2b are independently H, deuterium, halogen, cyano, hydroxyl, -NL 1a-1 L 1a-2 , C 1-6 Alkyl, C 1-6 Alkoxy or C 3-6 The cycloalkyl group of L 1a and L 1b Not at the same time H; Or, any adjacent L 1a Together with the atoms it is attached to form C 3-6 A cycloalkyl group or a 3-6-membered heterocyclic group, or L 1a and L 1b Together with its co-attached atoms, it forms C 3-6 The cycloalkane or 3-6 membered heterocycle; the heteroatoms in the 3-6 membered heterocyclic group and the 3-6 membered heterocycle are independently selected from 1, 2 or 3 of N, O and S; L 1a-1 , L 1a-2 and L 3 Independently H, C 1-6 Alkyl, substituted with one or more deuterated C 1-6 Alkyl or C 3-6 of a cycloalkyl group; R 1 H, C 1-6 Alkyl, C 3-6 Cycloalkyl, 1 or more R 1-1 Substituted C 1-6 Alkyl, or one or more R 1-2 Substituted C 3-6 Cycloalkyl; Each R 1-1 and each R 1-2 are independently deuterium, halogen, hydroxyl, -COOH, -NR 1-1-1 R 1-1-2 、-C(=O)NR 1-1-3 R 1-1-4 、-S(=O)2R 1- 1-5 or -S(=O)2NR 1-1-6 R 1-1-7 ; R 1-1-1 , R 1-1-2 , R 1-1-3 , R 1-1-4 , R 1-1-5 , R 1-1-6 and R 1-1-7 Independently H, C 1-6 Alkyl or C 3-6 of a cycloalkyl group; R 2 , R 3a and R 3b are independently H or C 1-6 The alkyl group Or, R 2 and R 3a Together with the atoms to which it is attached, it forms a 5-6 membered heterocyclic group or is replaced by one or more R 2-1 substituted 5-6 membered heterocyclic group; the 5-6 membered heterocyclic group and the substituted 5-6 membered heterocyclic group 2-1 The heteroatoms in the substituted 5-6 membered heterocyclic group are independently selected from 1, 2 or 3 of N, O and S, and contain at least 1 N; Each R 2-1 are independently halogen, cyano, hydroxyl, oxo, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl or -NR 2- 1-1 R 2-1-2 , Or, any two adjacent R 2-1 Together with the atoms to which it is connected, it forms a ring A, wherein the ring A is C 6-18 aryl, 5-10 membered heteroaryl, C 3-6 Cycloalkyl, 5-10 membered heterocyclic group, 1 or more R 2-1-3 Substituted C 6-18 The aromatic group, one or more R 2-1-4 Substituted 5-10 membered heteroaryl, substituted by 1 or more R 2-1-5 Substituted C 3-6 cycloalkyl, or one or more R 2-1-6 substituted 5-10 membered heterocyclic group; The 5-10 membered heteroaryl, the 5-10 membered heterocyclic group, the 2-1-4 The substituted 5-10 membered heteroaryl and the 2-1-6 The heteroatoms in the substituted 5-10 membered heterocyclyl are independently selected from 1, 2 or 3 of N, O and S; R 2-1-1 and R 2-1-2 Independently H, C 1-6 Alkyl or C 3-6 of a cycloalkyl group; Each R 2-1-3 , each R 2-1-4 , each R 2-1-5 and each R 2-1-6 are independently deuterium, halogen, cyano, hydroxyl, -NR 2-1-3-1 R 2-1-3-2 , C 1-6 of Alkyl, -C 1-6 Alkyl-C(=O)OH, C 1-6 Alkoxy or C 3-6 of a cycloalkyl group; R 2-1-1-1 and R 2-1-1-2 Independently H, C 1-6 Alkyl or C 3-6 Cycloalkyl; Ar 1 and Ar 2 Independently for C 6-18 aryl, 5-10 membered heteroaryl, 1 or more R 4-1 Substituted C 6-18 The aromatic group, one or more R 4-2 Substituted 5-10 membered heteroaryl, 5-10 membered heteroaryl and 3-8 membered heterocyclic group, substituted by one or more R 4-2 substituted 5-10 membered heteroaryl and 3-8 membered heterocyclyl; The 5-10 membered heteroaryl, the 4-2 substituted 5-10 membered heteroaryl, the 5-10 membered heteroaryl and 3-8 membered heterocyclic group and the substituted ... 4-2 The heteroatoms in the substituted 5-10-membered heteroaryl and 3-8-membered heterocyclic group are independently selected from 1, 2 or 3 of N, O and S; Each R 4-1 and each R 4-2 are independently deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-6 Alkyl, C 1-6 Alkoxy, -NR 4-1-1 R 4- 1-2 、-C(=O)NR 4-1-3 R 4-1-4 、-S(=O)2R 4-1-5 、-S(=O)2NR 4-1-6 R 4-1-7 , by one or more R 4-1-8 Substituted C 1-6 Alkyl, or one or more R 4-1-9 Substituted C 1-6 Alkoxyl groups; Or, any two adjacent R 4-1 Together with the atoms to which it is attached, it forms a 5-10 heteroaryl, C 3-6 Cycloalkyl, 5-10 membered heterocycloalkyl, 1 or more R 4-1-10 Substituted 5-10 membered heteroaryl, substituted by 1 or more R 4-1-11 Substituted C 3-6 cycloalkyl, or one or more R 4-1-12 Substituted 5-10 membered heterocycloalkyl; The 5-10 heteroaryl, 5-10 membered heterocycloalkyl, the 4-1-10 The substituted 5-10 membered heteroaryl and the 4-1-12 The heteroatoms in the substituted 5-10 membered heterocycloalkyl are independently selected from 1, 2 or 3 of N, O and S; R 4-1-1 , R 4-1-2 , R 4-1-3 , R 4-1-4 , R 4-1-5 , R 4-1-6 and R 4-1-7 Independently H, C 1-6 Alkyl or C 3-6 of a cycloalkyl group; Each R 4-1-8 , each R 4-1-9 , each R 4-1-10 and each R 4-1-11 are independently deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-6 Alkyl, C 1- 6 alkoxy, -NR 4-1-8-1 R 4-1-8-2 、-C(=O)NR 4-1-8-3 R 4-1-8-4 、-S(=O)2R 4-1-8-5 or -S(=O)2NR 4-1-8-6 R 4-1-8-7 ; R 4-1-8-1 , R 4-1-8-2 , R 4-1-8-3 , R 4-1-8-4 , R 4-1-8-5 , R 4-1-8-6 and R 4-1-8-7 Independently H, C 1-6 Alkyl or C 3-6 of a cycloalkyl group.
2. The compound of formula I according to claim 1, its pharmaceutically acceptable salt, its isotope-labeled substance, its solvate, its pharmaceutically acceptable salt solvate or its prodrug, characterized in that: It meets one or more of the following conditions: (1)L 1a , L 1b , L 2a and L 2b wherein the halogen is independently fluorine, chlorine or bromine, for example fluorine; (2)L 1a , L 1b , L 2a , L 2b , L 1a-1 , L 1a-2 and L 3 In the C 1-6 The alkyl group and the C 1- The C in the alkyl group of 6 1-6 The alkyl groups are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example methyl; (3)L 1a , L 1b , L 2a and L 2b In the C 1-6 The alkoxy groups are independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy; (4)L 1a , L 1b , L 2a , L 2b , L 1a-1 , L 1a-2 and L 3 In the C 3-6 The cycloalkyl groups are independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; (5)L 1a and L 1b Together with its co-attached atoms, it forms C 3-6 The cycloalkane may be cyclopropane, cyclobutane, cyclopentane or cyclohexane, for example cyclopropane; (6)R 1 In the C 1-6 The alkyl group and the 1-1 Substituted C 1-6 The C 1-6 Alkyl is optionally methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example methyl; (7)R 2 , R 3a and R 3b In the C 1-6 The alkyl groups are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example methyl; (8)R 2 and R 3a Together with the atoms to which it is connected, the 5-6 membered heterocyclic group and the one or more R 2-1 The substituted 5-6 membered heterocyclic groups are independently pyrrolidinyl, for example Through N and Ar 1 Connected to each other, connected to the carbonyl group through C; (9) Each R 2-1 , each R 2-1-3 , each R 2-1-4 , each R 2-1-5 and each R 2-1-6 In the C 1-6 The alkoxy groups are independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy; (10) Each R 2-1 , R 2-1-1 , R 2-1-2 , each R 2-1-3 , each R 2-1-4 , each R 2-1-5 , each R 2-1-6 , R 2-1-1-1 and R 2-1-1-2 , the C 1- The alkyl group of 6 is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example methyl; (11) Each R 2-1 , R 2-1-1 , R 2-1-2 Each R 2-1-3 , each R 2-1-4 , each R 2-1-5 , each R 2-1-6 , R 2-1-1-1 and R 2-1-1-2 In the C 3-6 Any two adjacent R 2-1 Together with the atoms to which it is attached, it forms the C 3-6 The cycloalkyl group and the 2-1-5 Substituted C 3-6 The C in the cycloalkyl 3-6 The cycloalkyl groups are independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; (12) Any two adjacent R 2-1 Together with the atoms to which it is attached, it forms the C 6-18 The aryl group and the 2-1-3 Substituted C 6-18 The aryl groups of are independently phenyl or naphthyl; (13) Any two adjacent R 2-1 Together with the atoms to which it is connected, the 5-10 membered heteroaryl and the one or more R 2-1-4 The 5-10-membered heteroaryl in the substituted 5-10-membered heteroaryl is independently a 5-6-membered heteroaryl, the heteroatom is selected from N, the number is 1 or 2, such as pyridyl, pyrazolyl or pyrimidinyl, and for example It means that a cyclic structure is formed with a 5-6-membered heterocyclic group through the bond here; (14)Ar 1 and Ar 2 In the C 6-18 The aryl group and the 4-1 Substituted C 6-18 The C in the aromatic group 6- 18 The aryl groups of are independently phenyl or naphthyl, for example phenyl; (15)Ar 1 and Ar 2 wherein the 5-10 membered heteroaryl and the 4-2 The 5-10-membered heteroaryl in the substituted 5-10-membered heteroaryl is independently a 5-10-membered heteroaryl, the heteroatom is selected from N, the number is 1 or 2, and it can be a 5-6-membered monocyclic heteroaryl or an 8-10-membered cyclic heteroaryl, such as pyridyl or (16)Ar 1 and Ar 2 wherein the 5-10 membered heteroaryl and 3-8 membered heterocyclic group and the 4-2 The 5-10-membered heteroaryl and 3-8-membered heterocyclic group in the substituted 5-10-membered heteroaryl and 3-8-membered heterocyclic group is independently a 5-6-membered heteroaryl and 3-6-membered heterocyclic group, the heteroatom is selected from N, the number is 1 or 2, and can be pyridyl and pyrrolidinyl, for example (17) Each R 4-1 and each R 4-2 In the C 1-6 The alkyl group and the 4-1-8 Substituted C 1-6 The C 1-6 The alkyl groups are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example methyl; (18) Each R 4-1 , each R 4-2 , each R 4-1-8 , each R 4-1-9 , each R 4-1-10 and each R 4-1-11 In the C 1-6 The alkoxy group and the 4-1-9 Substituted C 1-6 The alkoxy groups independently may be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy; (19) Any two adjacent R 4-1 Together with the atoms to which they are attached, they form the 5-10 heteroaryl group and the one or more R 4-1-10 The 5-10-membered heteroaryl in the substituted 5-10-membered heteroaryl is a 5-6-membered heteroaryl, the heteroatom is selected from N, the number is 1 or 2, for example, pyrazolyl, for example Indicates that the key here and C 6-18 The aromatic groups form a ring structure; (20)R 4-1-1 , R 4-1-2 , R 4-1-3 , R 4-1-4 , R 4-1-5 , R 4-1-6 , R 4-1-7 , each R 4-1-8 , each R 4-1-9 , each R 4-1-10 , each R 4-1-11 , R 4-1-8-1 , R 4-1-8-2 , R 4-1-8-3 , R 4-1-8-4 , R 4-1-8-5 , R 4-1-8-6 and R 4-1-8-7 In the C 1-6 The alkyl groups are independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example methyl; (21) Each R 4-1 , each R 4-2 , each R 4-1-8 , each R 4-1-9 , each R 4-1-10 and each R 4-1-11 wherein the halogen is independently fluorine, chlorine or bromine, such as fluorine or chlorine; (22) The number of chain atoms in the main chain of -L- is 3, 4 or 5 atoms, for example 3-4 atoms; and (23) The number of ring atoms in the ring may be 11, 12 or 13, for example 12.
3. The compound of formula I as claimed in claim 2, its pharmaceutically acceptable salt, its isotope-labeled substance, its solvate, its pharmaceutically acceptable salt solvate or its prodrug, characterized in that: It meets one or more of the following conditions: (1)L 3 wherein the C 1-6 The alkyl group is -CD3; (2)R 1 In the above, one or more R 1-1 Substituted C 1-6 The alkyl group is a C 1-6 Alkyl groups, such as -CD3; (3) Any two adjacent R 2-1 Together with the atoms to which it is attached, it forms the 2-1-4 The substituted 5-10 membered heteroaryl is 2-1-4 Substituted 5-6 membered heteroaryl, R 2-1-4 C 1-6 Alkyl or -C 1-6 Alkyl-C(=O)OH; for example For example It means that a cyclic structure is formed with a 5-6-membered heterocyclic group through the bond here; (4) Each R 4-1 and each R 4-2 In the above, one or more R 4-1-8 Substituted C 1-6 The alkyl group may be substituted by 1, 2 or 3 halogens. 1-6 An alkyl group, such as -CF3.
4. The compound of formula I according to claim 1, its pharmaceutically acceptable salt, its isotope-labeled substance, its solvate, its pharmaceutically acceptable salt solvate or its prodrug, characterized in that: It meets one or more of the following conditions: (1) In L, when the -(CH2) n Any one, two or three -CH2- in - are replaced by -CL 1a L 1b -、-CL 2a =CL 2b -、-NL 3 -, -O-, -S(=O)-, -S(=O)2-, -C(=O)- and -S- are substituted by one or two of them, the -(CH2) n - is -(CH2) n Any one or two -CH2- in - are replaced by -CL 1a L 1b -、-CL 2a =CL 2b -、-NL 3 -, -O-, -S(=O)2- and -C(=O)-, one or two of which are substituted, and n is 2, 3, 4 or 5; it can also be -(CH2) n Any one or two -CH2- in - are replaced by -CL 1a L 1b -、-CL 2a =CL 2b -、-NL 3 -、-C(=O)-、 -OC(=O)-, -S(=O)2- and -O- are substituted, n is 2, 3, 4 or 5; and -(CH2) is substituted n Any one or two -CH2- in - are replaced by -CL 1a L 1b -、-CL 2a =CL 2b - and -O- are substituted, and n is 2, 3, 4 or 5; (2)-CL 1a L 1b -Medium, L 1a and L 1b One of the groups is H and the other is halogen, hydroxyl or C 1-6 Alkyl, or L 1a and L 1b Together with its co-attached atoms, it forms C 3-6 Cycloalkane or 3-6 membered heterocycle; (3)-NL 3 -Medium, L 3 H, C 1-6 Alkyl or one or more deuterated C 1-6 The alkyl group; (4)R 1 H, C 1-6 Alkyl, or one or more R 1-1 Substituted C 1-6 The alkyl group; (5) In, R 2 , R 3a and R 3b Defined as case 1 or 2: Scenario 1: R 2 , R 3a and R 3b H or C 1-6 Alkyl, or, R 2 and R 3a Together with the atoms to which it is attached, it forms a 5-6 membered heterocyclic group or is replaced by one or more R 2-1 substituted 5-6 membered heterocyclic group; Each R 2-1 are independently hydroxyl, C 1-6 An alkyl or oxo group, Or, any two adjacent R 2-1 Together with the atoms connected thereto, they form a ring A, wherein the ring A is a 5-10 membered heteroaryl group, or is substituted by one or more R 2-1-4 substituted 5-10 membered heteroaryl; Each R 2-1-4 Independently for C 1-6 Alkyl or -C 1-6 Alkyl-C(=O)OH; Scenario 2: R 2 , R 3a and R 3b H or C 1-6 Alkyl, or, R 2 and R 3a Together with the atoms to which it is attached, it forms a 5-6 membered heterocyclic group or is replaced by one or more R 2-1 substituted 5-6 membered heterocyclic group; Each R 2-1 are independently hydroxy or oxo, Or, any two adjacent R 2-1 Together with the atoms connected thereto, they form a ring A, wherein the ring A is a 5-10 membered heteroaryl group, or is substituted by one or more R 2-1-4 substituted 5-10 membered heteroaryl; Each R 2-1-4 Independently for C 1-6 The alkyl group; Preferably, in case 1, when R 2 and R 3a Together with the atoms to which it is attached, a 5-6 membered heterocyclic group is formed by one or more R 2-1 substituted 5-6 membered heterocyclic group; When R 2 and R 3a Together with the atoms to which it is attached, it forms a 2-1 When the 5- to 6-membered heterocyclic group is substituted, at least one R 2-1 is an oxo group or a hydroxyl group; (6) In the above, the C atom marked with * can be a chiral carbon atom or an achiral carbon atom; when the C atom marked with * is a chiral carbon atom, the configuration of the chiral carbon atom is S configuration; Preferably, for The configuration of the chiral carbon atom is S configuration; (7)Ar 1 is a 5-10 membered heteroaryl group, or is substituted by one or more R 4-2 substituted 5-10 membered heteroaryl; Each R 4-2 are independently cyano, C 1-6 Alkyl, or, by one or more R 4-1-8 Substituted C 1-6 The alkyl group; Each R 4-1-8 are independently halogen; and (8)Ar 2 C 6-18 aryl, or one or more R 4-1 Substituted C 6-18 The aromatic group; Each R 4-1 Independently for C 1-6 Alkyl, substituted with one or more deuterated C 1-6 Alkyl or halogen, or any two adjacent R 4- 1 Together with the atoms to which it is attached, it forms a 5-10 heteroaryl group or is replaced by one or more R 4-1-10 substituted 5-10 membered heteroaryl; Each R 4-1-10 Independently for C 1-6 of alkyl.
5. The compound of formula I according to claim 4, its pharmaceutically acceptable salt, its isotope-labeled substance, its solvate, its pharmaceutically acceptable salt solvate or its prodrug, characterized in that: It meets one or more of the following conditions: (1) In L, when -(CH2) n When any one -CH2- in - is replaced, -(CH2) n Any one -CH2- in - is replaced by -CL 1a L 1b -、-NL 3 -, -O- and -S(=O)2-; when -(CH2) n When any two -CH2- in - are replaced, -(CH2) n Any two -CH2- in - are replaced by --CL 2a =CL 2b -or"-NL 3 - and C(=O)-"; Preferably, -(CH2) n - in which any -CH2- is replaced by -CH(CH3)-, -CH(OH)-, -CHF2-, N(CH3)-, -N(CD3)- or -S(=O)2-, or -(CH2) n - in which any two -CH2- are replaced by "-NH- and C(=O)-", "-N(CH3)- and C(=O)-", "-N(CD3)- and C(=O)-" or "-C(=O)- and -O-"; More preferably, -(CH2) n -for For example The alkyl or alkenyl group on the left side and Ar 1 connected, the right-hand alkyl, NH, C(=O) or O and Ar 2 Connected; (2)R 1 is H, methyl or -CD3; (3) for For example (4)Ar 1 for Preferably and (5)Ar 2 6. The compound of formula I, a pharmaceutically acceptable salt thereof, an isotope-labeled substance thereof, a solvate thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof according to any one of claims 1 to 5, characterized in that: The compound shown in Formula I is the following Scheme 1, Scheme 2 or Scheme 3: Scenario 1: The compound as shown in Formula I can be any one of the general formulas I-1 to I-7: In formula I-1, n1 and n2 are independently 0, 1, 2 or 3; Z is C or N; L, R 1 , R 2 , R 3a , R 3b , R 4-1 and R 4-12 The definitions are the same as those in any one of claims 1 to 5; In formula I-2, Y is CHR 2-1 or C(R 2-1 )(R 2-1 ); n2 is 0, 1 or 2; L, R 1 , R 2-1 , R 3b ,Ar 1 and Ar 2 The definitions are the same as those in any one of claims 1 to 5; In formula I-3, Y is N, CH or CHR 2-1 ; n3 is 0, 1 or 2; Ring A, L, R 1 , R 2-1 , R 3b ,Ar 1 and Ar 2 The definitions are the same as those in any one of claims 1 to 5; In formula I-4, Y is N, CH or CHR 2-1 ; n4 is 0, 1 or 2; Ring A, L, R 1 , R 2-1 , R 3b ,Ar 1 and Ar 2 The definitions are the same as those in any one of claims 1 to 5; In Formula I-5, R 2 , R 3a and R 3b are independently H or C 1-6 Alkyl; L, R 1 ,Ar 1 and Ar 2 The definitions are the same as those in any one of claims 1 to 5; In formula I-6, n3 is independently 0, 1, 2 or 3; L, R 1 , R 2-1 , R 3b ,Ar 1 and Ar 2 The definitions are the same as those in any one of claims 1 to 5; In formula I-7, n4 is independently 0, 1, 2 or 3; Ring B is a 3-8 membered heterocyclic ring or a 5-6 membered heteroaromatic ring, and the heteroatoms in the 3-8 membered heterocyclic ring and the 5-6 membered heteroaromatic ring are independently selected from 1, 2 or 3 of N, O and S; L, R 1 , R 2-1 , R 3b ,Ar 1 and Ar 2 The definitions are the same as those in any one of claims 1 to 5; Preferably: In formulas I-1 to I-7, -(CH2) n -, n is 3, -(CH2) n - Any one or two -CH2- in - are optionally replaced by -CL 1a L 1b -、-CL 2a =CL 2b -、-NL 3 -, -C(=O)-, -S(=O)2- and -O- are substituted by one or two thereof, and the main chain of -L- contains 3 atoms; -(CH2) n - Further Preferably: In formulas I-2 to I-5, Ar 1 For one or more R 4-2 Substituted pyridyl, Ar 2 For one or more R 4-1 Substituted phenyl; Ar 1 Further, it can be Ar 2 Further, it can be Preferably, in formula I-6 to I-7, in L, when -(CH2) n Any 1 or 2 -CH2- in - are replaced by -O- or -CL 2a =CL 2b - When replacing, at least one R 2-1 is a hydroxyl group or an oxo group; Scenario 2: In the compound shown in formula I: In L, -(CH2) n Any 1, 2 or 3 -CH2- in - are optionally replaced by -CL 1a L 1b -、-CL 2a =CL 2b -、-NL 3 -, -O-, -S(=O)-, -S(=O)2-, -C(=O)- and -S- are replaced by -(CH2) n Any one or two -CH2- in - are replaced by -CL 1a L 1b -、-CL 2a =CL 2b -、-NL 3 -, -C(=O)-, -OC(=O)-, -S(=O)2- and -O-, and n is 3 or 4; R 1 H, C 1-6 The alkyl group or one or more R 1-1 Substituted C 1-6 The alkyl group; R 2 , R 3a and R 3b H or C 1-6 Alkyl, or, R 2 and R 3a Together with the atoms to which it is attached, it forms a 5-6 membered heterocyclic group or is replaced by one or more R 2-1 substituted 5-6 membered heterocyclic group; Each R 2-1 are independently hydroxyl or oxo, or any two adjacent R 2-1 Together with the atoms connected thereto, they form a ring A, wherein the ring A is a 5-10 membered heteroaryl group, or is substituted by one or more R 2-1-4 substituted 5-10 membered heteroaryl; Each R 2-1-4 Independently for C 1-6 The alkyl group; Ar 1 is a 5-10 membered heteroaryl, or, is substituted by one or more R 4-2 substituted 5-10 membered heteroaryl; Each R 4-2 are independently cyano, C 1-6 Alkyl, or, by one or more R 4-1-8 Substituted C 1-6 The alkyl group; Each R 4-1-8 are independently halogen; Ar 2 C 6-18 aryl, or one or more R 4-1 Substituted C 6-18 The aromatic group; Each R 4-1 Independently for C 1-6 Alkyl or halogen, or any two adjacent R 4-1 Together with the atoms to which it is attached, it forms a 5-10 heteroaryl group or is replaced by one or more R 4-1-10 substituted 5-10 membered heteroaryl; Each R 4-1-10 Independently for C 1-6 The alkyl group; Solution 3: In the compound shown in formula I: -L- is -(CH2) n -, n is 1, 2, 3, 4, 5 or 6; -(CH2) n Any 1, 2 or 3 -CH2- in - may be optionally replaced by -CL 1a L 1b -、-CL 2a =CL 2b -、-NL 3 -, -O-, -S(=O)-, -S(=O)2- and -S- are substituted by one or two thereof; L 1a , L 1b , L 2a and L 2b are independently H, deuterium, halogen, cyano, hydroxyl, -NL 1a-1 L 1a-2 , C 1-6 Alkyl, C 1-6 Alkoxy or C 3-6 The cycloalkyl group of L 1a and L 1b Not at the same time H; Or, any adjacent L 1a Together with the atoms it is attached to form C 3-6 A cycloalkyl group or a 3-6-membered heterocyclic group, or L 1a and L 1b Together with its co-attached atoms, it forms C 3-6 The cycloalkane or 3-6 membered heterocycle; the heteroatoms in the 3-6 membered heterocyclic group and the 3-6 membered heterocycle are independently selected from 1, 2 or 3 of N, O and S; L 1a-1 , L 1a-2 and L 3 Independently H, C 1-6 Alkyl or C 3-6 Cycloalkyl; R 1 H, C 1-6 Alkyl, C 3-6 Cycloalkyl, 1 or more R 1-1 Substituted C 1-6 Alkyl, or one or more R 1-2 Substituted C 3-6 Cycloalkyl; Each R 1-1 and each R 1-2 are independently deuterium, halogen, hydroxyl, -COOH, -NR 1-1-1 R 1-1-2 、-C(=O)NR 1-1-3 R 1-1-4 、-S(=O)2R 1- 1-5 or -S(=O)2NR 1-1-6 R 1-1-7 ; R 1-1-1 , R 1-1-2 , R 1-1-3 , R 1-1-4 , R 1-1-5 , R 1-1-6 and R 1-1-7 Independently H, C 1-6 Alkyl or C 3-6 of a cycloalkyl group; R 2 , R 3a and R 3b are independently H or C 1-6 The alkyl group Or, R 2 and R 3a Together with the atoms to which it is attached, it forms a 5-6 membered heterocyclic group or is replaced by one or more R 2-1 substituted 5-6 membered heterocyclic group; the 5-6 membered heterocyclic group and the substituted 5-6 membered heterocyclic group 2-1 The heteroatoms in the substituted 5-6 membered heterocyclic group are independently selected from 1, 2 or 3 of N, O and S, and contain at least 1 N; Each R 2-1 are independently halogen, cyano, hydroxyl, oxo (=O), C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl or -NR 2-1-1 R 2-1-2 , Or, any two adjacent R 2-1 Together with the atoms to which it is connected, it forms a ring A, wherein the ring A is C 6-18 aryl, 5-10 membered heteroaryl, C 3-6 Cycloalkyl, 5-10 membered heterocyclic group, 1 or more R 2-1-3 Substituted C 6-18 The aromatic group, one or more R 2-1-4 Substituted 5-10 membered heteroaryl, substituted by 1 or more R 2-1-5 Substituted C 3-6 cycloalkyl, or one or more R 2-1-6 substituted 5-10 membered heterocyclic group; The 5-10 membered heteroaryl, the 5-10 membered heterocyclic group, the 2-1-4 The substituted 5-10 membered heteroaryl and the 2-1-6 The heteroatoms in the substituted 5-10 membered heterocyclic group are independently selected from N, O and S. 1, 2 or 3; R 2-1-1 and R 2-1-2 Independently H, C 1-6 Alkyl or C 3-6 Cycloalkyl; Each R 2-1-3 , each R 2-1-4 , each R 2-1-5 and each R 2-1-6 are independently deuterium, halogen, cyano, hydroxyl, -NR 2-1-3-1 R 2-1-3-2 , C 1-6 Alkyl, C 1-6 Alkoxy or C 3-6 of a cycloalkyl group; R 2-1-1-1 and R 2-1-1-2 Independently H, C 1-6 Alkyl or C 3-6 Cycloalkyl; Ar 1 and Ar 2 Independently for C 6-18 aryl, 5-10 membered heteroaryl, 1 or more R 4-1 Substituted C 6-18 aryl, or one or more R 4-2 substituted 5-10 membered heteroaryl; The 5-10 membered heteroaryl and the 4-2 The heteroatoms in the substituted 5-10 membered heteroaryl are independently selected from 1, 2 or 3 of N, O and S; Each R 4-1 and each R 4-2 are independently deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-6 Alkyl, C 1-6 Alkoxy, -NR 4-1-1 R 4- 1-2 、-C(=O)NR 4-1-3 R 4-1-4 、-S(=O)2R 4-1-5 、-S(=O)2NR 4-1-6 R 4-1-7 , by one or more R 4-1-8 Substituted C 1-6 Alkyl, or one or more R 4-1-9 Substituted C 1-6 Alkoxyl groups; Or, any two adjacent R 4-1 Together with the atoms to which it is attached, it forms a 5-10 heteroaryl, C 3-6 Cycloalkyl, 5-10 membered heterocycloalkyl, 1 or more R 4-1-10 Substituted 5-10 membered heteroaryl, substituted by 1 or more R 4-1-11 Substituted C 3-6 cycloalkyl, or one or more R 4-1-12 Substituted 5-10 membered heterocycloalkyl; The 5-10 heteroaryl, 5-10 membered heterocycloalkyl, the 4-1-10 The substituted 5-10 membered heteroaryl and the 4-1-12 The heteroatoms in the substituted 5-10 membered heterocycloalkyl are independently selected from 1, 2 or 3 of N, O and S; R 4-1-1 , R 4-1-2 , R 4-1-3 , R 4-1-4 , R 4-1-5 , R 4-1-6 and R 4-1-7 Independently H, C 1-6 Alkyl or C 3-6 of a cycloalkyl group; Each R 4-1-8 , each R 4-1-9 , each R 4-1-10 and each R 4-1-11 are independently deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-6 Alkyl, C 1- 6 alkoxy, -NR 4-1-8-1 R 4-1-8-2 、-C(=O)NR 4-1-8-3 R 4-1-8-4 、-S(=O)2R 4-1-8-5 or -S(=O)2NR 4-1-8-6 R 4-1-8-7 ; R 4-1-8-1 , R 4-1-8-2 , R 4-1-8-3 , R 4-1-8-4 , R 4-1-8-5 , R 4-1-8-6 and R 4-1-8-7 Independently H, C 1-6 Alkyl or C 3-6 of a cycloalkyl group.
7. The compound of formula I according to claim 1, its pharmaceutically acceptable salt, its isotope-labeled substance, its solvate, its pharmaceutically acceptable salt solvate or its prodrug, characterized in that: The compound as shown in formula I is any of the following compounds: Preferably, the compound as shown in formula I is any of the following compounds:
8. The compound of formula I, a pharmaceutically acceptable salt thereof, an isotope-labeled substance thereof, a solvate thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof according to any one of claims 1 to 7, characterized in that: The preparation method of the compound as shown in Formula I is any one of Method 1 to Method 8: When R 1 When is H, the preparation method of the compound as shown in Formula I is method 1; Method 1 comprises the following steps: reacting a compound as shown in formula II-1 in a solvent in the presence of a condensing agent or a base to obtain the compound as shown in formula I; Among them, R 5 is hydrogen or C 1-6 Alkyl; R 2 , R 3a , R 3b ,Ar 1 ,Ar 2 and L is as defined in any one of claims 1 to 7; When R 1 C 1-6 Alkyl, C 3-6 Cycloalkyl, 1 or more R 1-1 Substituted C 1-6 Alkyl, or, by one or more R 1-2 Substituted C 3-6 When the cycloalkyl group is cycloalkyl, the preparation method of the compound as shown in Formula I is method 2; Method 2 comprises the following steps: in the presence of a base, reacting the compound shown in formula II-2 with compound III in a solvent for substitution reaction; The compound shown in formula I is obtained; Wherein, X is a halogen; R 2 , R 3a , R 3b ,Ar 1 ,Ar 2 and L is as defined in any one of claims 1 to 7; When -L- is -(CH2) n -, the -(CH2) n When one or two -CH2- at the terminal group are replaced by -O-, the preparation method of the compound as shown in Formula I is method 3 or 4; Method 3 comprises the following steps: subjecting the compound represented by formula II-3 to an intramolecular Mitsunobu reaction in a solvent to obtain the compound represented by formula I; Among them, R 1 , R 2 , R 3a , R 3b ,Ar 1 and Ar 2 The same as defined in any one of claims 1 to 7; Method 4 comprises the following steps: subjecting the compound represented by formula II-4 to an intramolecular Mitsunobu reaction in a solvent to obtain the compound represented by formula I; Among them, R 1 , R 2 , R 3a , R 3b ,Ar 1 and Ar 2 The same as defined in any one of claims 1 to 7; When -L- is -(CH2) n -, the -(CH2) n Any one, two or three -CH2- in - are replaced by -CL 2a =CL 2b - when substituted, the method for preparing the compound as shown in Formula I is method 5; Method 5 comprises the following steps: in the presence of a catalyst, subjecting the compound represented by formula II-5 to an intramolecular olefin metathesis reaction in a solvent to obtain the compound represented by formula I; Wherein, n5 and n6 are independently 0, 1, 2, 3 or 4, and the sum of n5 and n6 is less than or equal to 5; R 1 , R 2 , R 3a , R 3b ,Ar 1 and Ar 2 The same as defined in any one of claims 1 to 7; When -L- is -(CH2) n -, the -(CH2) n When - is unsubstituted, the preparation method of the compound as shown in Formula I is method 6; Method 6 comprises the following steps: in the presence of a catalyst (such as Pd / C) and hydrogen, subjecting the compound shown in Formula II-6 to a reduction reaction in a solvent to obtain the compound shown in Formula I; Among them, L 4 C 2-6 Alkenyl (R 1 , R 2 , R 3a , R 3b ,Ar 1 and Ar 2 The same as defined in any one of claims 1 to 7; When there is at least one R 2-1 When is an oxo group, the preparation method of the compound as shown in Formula I is method 7; Method 7 comprises the following steps: in the presence of an oxidant, subjecting the compound represented by formula II-7 to an oxidation reaction in a solvent to obtain the compound represented by formula I; Wherein, n7 is 1, 2 or 3; R 3a , R 3b ,Ar 1 and Ar 2 The same as defined in any one of claims 1 to 7; When there are 1 or 2 R 2-1 When is hydroxyl, the preparation method of the compound as shown in Formula I is method 8; Method 8 comprises the following steps: in the presence of an acid, subjecting the compound represented by formula II-8 to a deprotection reaction in a solvent to obtain the compound represented by formula I; Wherein, M is a hydroxyl protecting group, R 2-1 , R 3a , R 3b ,Ar 1 and Ar 2 The definition is the same as that in any one of claims 1-7.
9. A compound as shown in formula II-1 to formula II-7, II-8-1 to II-8-2: In each general formula, M, n5, n6, n7, R 1 , R 2 , R 2-1 , R 3a , R 3b ,Ar 1 ,Ar 2 , L and L 4 The definition is the same as that in claim 8; The formula II-1 is preferably The formula II-2 is preferably The formula II-3 is preferably any of the following compounds: The formula II-5 is preferably: The formula II-6 is preferably The formula II-7 is preferably The formula II-8 is preferably 10. A pharmaceutical composition, characterized in that It includes a compound as shown in formula I according to any one of claims 1 to 7, a pharmaceutically acceptable salt thereof, an isotope-labeled substance thereof, a solvate thereof, a solvate of a pharmaceutically acceptable salt thereof or a prodrug thereof, and a pharmaceutical excipient.
11. Use of a compound of formula I as described in any one of claims 1 to 7, a pharmaceutically acceptable salt thereof, an isotope-labeled substance thereof, a solvate thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof in the preparation of a DNA polymerase θ inhibitor or a drug; The drug is used to treat or prevent cancer, or to prevent diseases related to DNA repair defects; The cancer is preferably selected from the group consisting of ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, lung cancer and cervical cancer.
12. A method for treating a disease, characterized in that: The treatment method comprises administering to the patient a therapeutically effective amount of a compound of formula I as described in any one of claims 1 to 7, a pharmaceutically acceptable salt thereof, an isotope-labeled substance thereof, a solvate thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof; The disease is for treating or preventing cancer, a disease characterized by overexpression of DNA polymerase θ, or a disease associated with DNA repair defects; The cancer is preferably selected from the group consisting of ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, lung cancer and cervical cancer.
